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ABSTRACT 
In recent years, self-medication products have undergone a dramatic change due 
to the advent of herbal medicines, dietary supplements, nutraceuticals and health foods 
in addition to traditional nonprescription medicines and the increasing societal 
preferences towards greater individual control over the use of medicines. Globally, the 
role and importance of nonprescription medicines in healthcare delivery is also rapidly 
increasing due to the potential cost-savings. Hence, this area is beginning to receive 
much attention from regulatory authorities, academia and professional/industry/trade 
organizations. 
This dissertation presents a comprehensive analysis of the classification of 
nonprescription medicines and Rx-to-OTC switch criteria/policy in the United States, 
United Kingdom, Canada, Japan and Australia. A new approach to investigating US 
FDA's overall switch regulatory policies through the combined application of case-
history evaluations, electronic survey questionnaire and telephone interviews has been 
utilized. 
This investigation was conducted in three phases. Phase-1 involved information 
retrieval and a critical review of existing literature, phase-2 applied switch case history 
analyses pertinent to US FDA and phase-3 measured the attitudes/opinions of the 
academic/professional community and key opinion leaders in nonprescription medicines 
across the US, Canada, UK and Australia on important questions. 
The subject matter of this dissertation is of enormous current interest in the 
global nonprescription medicines arena. The significance of the results presented in this 
dissertation is amplified as this area has received little academic attention and this is 
perhaps the first comprehensive treatment of this subject. 
Overall, inferences based on the information elicited have been summarized to 
provide data-based responses to questions of global interest in the self-medication 
arena. This information is especially valuable to the US FDA as they are currently 
seeking public comment. Data shows that the OTC regulatory model in the United 
States may be improved. Evidence indicates that principles upon which approaches for 
improvement of the US regulatory system must be based should include: an objective 
evaluation of pharmacist class of OTC medicines, development of effective consumer 
education tools, increase in regulation of non-traditional OTC medicines, acknowledge 
that not all disease conditions and drug classes are suitable for self-treatment, a 
collaborative approach by FDA towards switching that includes all stakeholders is more 
favored, decisions on switch petitions must be case-specific without a presumptive bias 
and public health benefit must be the paramount evaluation criterion. 
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PREFACE 
This document has been prepared in the format of the manuscript plan in 
accordance to section 11-3 of the Graduate Manual at the University of Rhode Island. 
This dissertation has been divided into three sections. 
Section I contains the statement of the problem and a brief introduction to the 
objectives of this research. Section II forms the central part of this dissertation and is 
composed of eight manuscripts written in the format prescribed by the scientific journal 
to which they have been or will be submitted for publication. Section III contains 
appendices that include the list of publications, methodological details and 
supplementary material useful for clearer understanding of the results described in the 
preceding manuscripts. One of the appendices presents a brief chronological list of 
some key milestones in the history of food and drug regulation in the United States to 
assist the reader in developing a historical perspective. An overall summary of 
conclusions and bibliography for the entire dissertation follows this section. 
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SECTION I 
INTRODUCTION 
In recent years, self-medication products have undergone a dramatic change due 
to the advent of herbal medicines, dietary supplements, nutraceuticals and health foods 
in addition to traditional nonprescription medicines and the increasing societal 
preferences towards greater individual control over the use of medicines (1,2). 
Conventional regulations seem inadequate to address the complex challenges and 
regulatory needs of today's self-medication arena leading to a regulatory vacuum. Some 
important discrepancies associated with the regulation of nonprescription medicines are: 
(1) Globally, there exists no uniformity in the classification of nonprescription 
medicines. For example, over-the-counter (OTC), pharmacy medicine (P) and quasi-
drugs (QD) are variations of nonprescription drug products available within the 
developed world. 
(2) Scientific methodologies to assess the risks and benefit to individuals/general 
public health associated with use of OTC drug products (in terms of pharmacological 
profile of active moieties, their dosage or disease conditions) are unclear. There exist 
inadequacies to facilitate an efficient Rx-to-OTC switch driven by science-based, data-
driven decision making processes. 
(3) The role of the US Food and Drug Administration (FDA) in the Rx-to-OTC 
switch process in the absence of support from a sponsor is unclear. 
Globally, the role and importance of nonprescription medicines in healthcare 
delivery is rapidly increasing due to the shift in societal attitudes towards self-
medication and the associated cost-savings (3). In 1999, global sales of nonprescription 
medicines grew by 4.7% to US $49.2 billion following the trend in recent years (4). The 
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growing global interest in self-medication and related economic benefits emphasize the 
importance of and necessity for a regulatory framework developed on the basis of sound 
scientific principles. Hence, this area is beginning to receive much attention from 
regulatory authorities, academia and professional/industry/trade organizations. 
Also, the US FDA recently initiated a comprehensive review of the Agency's 
approach to regulating over-the-counter (OTC) drug products, that is ongoing and 
conducted a public hearing on this subject in June, 2000 (5). The purpose of the hearing 
was to solicit information from interested persons including scientists, professional 
groups and consumers. FDA's intention is to elicit comments on general issues 
regarding the status of OTC drug products, including the criteria the Agency should 
consider in rendering decisions on OTC availability of drugs, the classes of products, if 
any, that are not currently available OTC that should or should not be available OTC, 
how FDA can be assured that consumers understand the issues relating to OTC 
availability of drug products, how rational treatment decisions are affected by 
coexisting prescription and OTC therapies for a given disease, whether the current 
structure for marketing OTC products in the United States is adequate, and FDA's role 
in switching products from prescription to OTC status. 
As per the Food and Drug Administration Modernization Act of 1997 
(FDAMA), the US FDA held a series of public meetings in the summer of 1999 to 
obtain stakeholder views on how FDA can best meet its statutory obligations (6). In 
response, the Consumer Healthcare Products Association (CHP A) representing 
producers of nonprescription medicines and dietary supplements provided comments 
emphasizing the need for science-based regulatory framework for OTC medicines and 
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especially for the OTC switch process (7). These recent developments clearly justify the 
need for a detailed investigation of the regulatory aspects of OTC medicines with an 
emphasis on the Rx-to-OTC switch process. 
This investigation addresses issues central to the regulatory aspects of OTC 
products. Considering the rapidly increasing global interest in responsible self-
medication and the recent call for proposals from all interested parties by the US FDA 
on this topic, the timing of this study is very appropriate. 
This investigation was conducted in three phases. Phase-1 involved the 
completion of: (a) a critical review of existing literature related to this investigation, and 
(b) information retrieval. During information retrieval, data describing the regulatory 
aspects of nonprescription medicines from various sources (including governmental 
regulatory authorities, trade/industry organizations, pharmaceutical companies and 
academia) were collected. Special emphasis was placed on collecting data related to the 
regulatory environments in United States, Canada, United Kingdom, The European 
Union, Japan and Australia. The completion of a critical, comparative evaluation of the 
regulatory frameworks across these countries marked the culmination of Phase-1. 
During Phase-2, case history analyses of drugs to represent a broad variety of Rx-to-
OTC switches of contemporary interest within the US FDA context were examined. A 
secondary goal was to use these switch case studies to illustrate and analyze the 
application of Rx-to-OTC switch regulatory policy by the US FDA in the recent past. 
An appropriate number of drugs that were selected and studied are: (a) successful Rx-
to-OTC switch (nicotine) (b) unsuccessful Rx-to-OTC switch (lovastatin) (c) initially 
approved Rx-to-OTC switch that was later reverted to Rx status (metaproterenol), and 
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(d) switch proposal initiated by a party other than the sponsor (non-sedating 
antihistamines). In Phase-3, the attitudes/opinions of the academic/professional 
community with expertise in nonprescription medicines across the US, Canada, UK and 
Australia on important questions posed by the US FDA were measured using an 
internet-based electronic survey questionnaire instrument. The responses of the survey 
participants were analyzed using appropriate statistical techniques. Also, the opinions of 
a small group of key opinion leaders across the previously mentioned four countries 
selected to represent the diverse viewpoints of stakeholders in this area were studied 
using telephone interviews. Overall, conclusions and inferences based on the 
comparative literature review, investigation of OTC switch case histories, analysis of 
survey questionnaire and telephone interview responses have been summarized to 
provide data-based, rational answers to questions posed by the US FDA. 
References 
1. E.E. Bachrach, Drug Inf., 11. 805-810 (1999). 
2. R.W. Soller, Clin. Ther., 20, C134-C140 (1998). 
3. K.K. Knapp, The OTC Movement, Internet address, 
http://www.medscape.com/medscape/CN0/2000/ APHN APHA-1 O.html 
4. Marketletter, NewsEdge Corporation, Burlington, MA, May, 2000. 
5. Federal Register, 65(81), 24704-24706 (2000). 
6. A Message to FDA Stakeholders: FDA's Progress in Implementing FDAMA, 
Internet address, http://www.f da. gov I oc/f dam a/ comm/message99 .html 
7. Response of CHP A, Internet address, 
http://www.fda.gov I ohrms/ dockets/ dockets/99n03 86/ c000009 .doc 
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OBJECTIVES 
The salient objectives of this study are listed below: 
1. Perform an examination of the current global regulatory environment of 
nonprescription medicines. To conduct a detailed review and comparative 
evaluation of the US OTC regulations with those in other comparable developed 
nations (Australia, United Kingdom, European Union, Canada and Japan) by 
focusing on: (a) classification of medicines (for human use) and the underlying 
scientific rationale, and (b) regulatory policies affecting prescription to 
nonprescription reclassification (Rx-to-OTC switch) of medicines. 
2. To study the application of US FDA OTC switch regulatory policy in the recent 
past to obtain learning and make inferences that may be applied to answer 
questions of current interest, using the following case history evaluations as 
illustrative examples: 
a. Nicotine: a habit-forming drug that was successfully switched to OTC 
status. 
b. Metaproterenol: a bronchodilator that was switched to OTC status by the 
FDA upon its own initiative and was later reverted back to prescription 
status. 
c. Lovastatin: a cholesterol-lowering drug for which OTC status was 
requested and was not granted by the US FDA. 
d. Second generation nonsedating antihistamines: loratadine, fexofenidine 
and cetirizine, three nonsedating antihistamines for which OTC status 
was requested by an independent party over the objections of the 
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manufacturers that are currently being considered for OTC status by the 
US FDA. 
3. To measure the attitudes and opinions of experts in the area of nonprescription 
medicines in the US, UK, Canada and Australia on regulatory aspects of OTC 
medicines on which the US FDA has requested information through the 
administration of an internet based electronic survey questionnaire instrument 
and telephone interviews. 
4. To use the observations, learning and results of the above examinations in the 
development of rational, data-based recommendations related to important 
regulatory questions on OTC medicines in the US FDA context. 
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SECTION II 
8 
MANUSCRIPT I 
EXAMINATION OF REGULATORY ASPECTS OF NONPRESCRIPTION 
MEDICINES IN THE UNITED STATES 
9 
Abstract 
Growing patient involvement in diagnosis and treatment coupled with easy 
information access has increased interest in self-care and use of nonprescription 
medicines globally. The mounting interest in self-medication and potential economic 
benefits highlight the importance of and necessity for a regulatory framework 
developed on sound scientific principles. Hence, this area is receiving attention from 
regulatory authorities, academia and industry. The US Food and Drug Administration 
(FDA) recently announced a public hearing to evaluate its approach to regulating over-
the-counter (OTC) drug products. The main objectives of this study are to review and 
compare: (a) classification of medicines, and (b) regulatory policies affecting 
prescription to nonprescription reclassification (Rx-to-OTC switch) of medicines, 
among major developed nations along with the World Health Organization (WHO) 
perspective. This paper presents an analysis of the regulatory environment in the United 
States. 
10 
Introduction 
Growing patient involvement in the diagnosis and treatment of common 
ailments coupled with easy access to reliable information is leading to increasing 
interest in self-care and the use of nonprescription medicines worldwide. 
Nonprescription medicines now account for about 60% of all medications used in the 
United States and may be used to treat or cure about 400 ailments (1). In 1999, global 
sales of nonprescription medicines grew by 4.7% to US $49.2 billion in line with the 
trend in recent years (2). The role and importance of nonprescription medicines in 
healthcare delivery all over the world is rapidly increasing due to the shift in attitude 
towards self-medication and the potential cost-savings (3). In recent years, the 
landscape of self-medication products has undergone a dramatic change due to the rapid 
advent of herbal medicines, dietary supplements, nutraceuticals and health foods in 
addition to traditional "pharmaceutical" nonprescription medicines (4). Conventional 
regulations were not designed to address the complex challenges and regulatory 
requirements of today's self-medication arena precipitating the need for concomitant 
evolution in regulatory policies. 
The growing global interest in self-medication and related economic benefits 
accentuate the importance of and necessity for a regulatory framework developed on the 
basis of sound scientific principles. Hence, this area is beginning to receive much 
attention from global regulatory authorities, academia and related industry/professional 
organizations. The US Food and Drug Administration (FDA) recently announced a 
public hearing to evaluate the Agency's approach to regulating over-the-counter (OTC) 
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drug products (5). The purpose of the hearing is to solicit information from interested 
persons including scientists, professional groups and consumers. 
Consequently, an examination of the current global regulatory environment of 
nonprescription medicines has been undertaken to review and compare the US OTC 
regulations with those in other comparable developed nations. The central focus of this 
exegesis is on: (a) classification of medicines (for human use) and the underlying 
scientific rationale, and (b) regulatory policies affecting prescription to nonprescription 
reclassification (Rx-to-OTC switch) of medicines, in the United States. 
State of nonprescription medicines 
The usual perception of nonprescription medicines as pharmaceutical medicines 
available without a prescription has undergone a dramatic change due to the rapid 
advent of complementary and alternative medicines (CAM). This shift in societal 
preferences has increased the scope of nonprescription medicines to include dietary 
supplements, herbal medicines, folk remedies and other traditional ethnic medicines (6). 
Eisenberg et.al. studied the trends in CAM use in the US between 1990 and 1997 (7). 
Their results show that CAM use and expenditures substantially increased between 
1990 and 1997 attributable primarily to an increase in the proportion of population 
seeking alternative therapies and the pertinent data is summarized in table 1. 
The significance of nonprescription medicines in public health care is also 
reaching unprecedented levels. In the US, approximately 60% of all medicine dosage 
units consumed are nonprescription medicines. Of approximately 3.5 billion health 
problems treated annually in the US, some 2 billion (57%) are treated with a 
nonprescription medicine. About a third (33%) of all nonprescription medicines are 
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consumed by the rapidly growing demographic group of older Americans. The benefit-
cost ratio of responsibly used nonprescription medicines is very favorable. 
Nonprescription medicines account for less than three cents of every dollar spent on 
healthcare in the US, yet the benefit derived is vast (8). These observations are in 
agreement with global trends in support of self-medication. In the United Kingdom, 
evidence indicates that growing numbers of general practitioners and consumers are in 
favor of increased responsible self-medication. Positive support by physicians for self-
medication is growing and research shows that more than half the general practitioners 
expect to increase their recommendations of nonprescription medicines in the next year 
(9). It is reasonable to conclude that due to the onset of the information age, change in 
consumer preferences and the availability of new nonprescription medicines that were 
previously unavailable, the significance of nonprescription medicines in overall health 
care is bound to increase in the future. 
Regulation of nonprescription medicines in the US 
In the United States, the original Food and Drugs Act was passed m 1906 
prohibiting interstate commerce in misbranded and adulterated foods, drinks and drugs 
(10,11). This law only ensured purity and did not address the important issue of 
truthfulness of health claims among other inadequacies. Following the Sulfanilamide 
tragedy, The Federal Food, Drug and Cosmetic Act (FD&C Act) was passed in 1938 as 
the foundation of present day drug laws (12). This law contained many new provisions 
such as, requiring new drugs to be shown safe before marketing (starting a new system 
of drug regulation), eliminating the earlier requirement to prove intent to defraud in 
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drug misbranding cases, requiring human drugs to bear label warnings against habit 
formation and requiring FDA to enforce the law. 
Arguably, the most important amendment to the FD&C Act in this context is the 
Durham-Humphrey Amendment of 1951. This amendment clarified the dispensing 
obligations of the pharmacist by defining the kinds of drugs that cannot be safely used 
without medical supervision and restricting their sale to prescription by a licensed 
practitioner (13). This amendment also serves as the foundational basis for the current 
classification system of drug products in the United States into, prescription medicine 
and nonprescription medicine (or OTC). Section 503(b)(l) of FD&C Act states: 
"A drug intended for use by man which -
(A) because of its toxicity or other potentiality for harmful effect, or the method 
of its use, or the collateral measures necessary to its use, is not safe for use 
except under the supervision of a practitioner licensed by law to administer such 
drug; or 
(BJ is limited by an approved application under section 505 to use under the 
professional supervision of a practitioner licensed by law to administer such 
drug; shall be dispensed only 
(i) upon a written prescription of a practitioner licensed by law to 
administer such drug, or 
(ii) upon an oral prescription of such practitioner which is reduced promptly 
to writing and filed by the pharmacist, or 
(iii) by refilling any such written or oral prescription if such refilling is 
authorized by the prescriber either in the original prescription or by oral 
order which is reduced promptly to writing and filed by the pharmacist. 
The act of dispensing a drug contrary to the provisions of this paragraph shall be 
deemed to be an act which results in the drug being misbranded while held for sale. " 
Hence, the need for medical supervision and prescription requirement for a drug 
product may arise due to: (a) the drug characteristics or the method of use necessary for 
its safe use, or, (b) the new drug application (Section 505 of FD&C Act) under which it 
received approval. An implication of section 503(b )(1) that needs emphasis is that, only 
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drugs meeting above stated conditions reqmre the additional control of medical 
supervision and prescription requirement, otherwise they may be sold without a 
prescription. Alternately stated, drug products are inherently presumed to be 
nonprescription unless otherwise required, as per FD&C Act. This assertion may be 
tersely stated as, "if it can be OTC, it must be OTC" to illustrate the inherent bias for 
"nonprescriptionness" arising from the law and is critical in the comprehension of this 
classification system ( 4). 
Another important legislative development in this context is the Kefauver-Harris 
Drug Amendments of 1962, enacted as a result of the Thalidomide disaster (14). As per 
these amendments, manufacturers were required to prove the safety and efficacy of any 
new drug before its marketing, and FDA approval of the new drug application (NDA) 
became a necessary prerequisite to marketing. These amendments required an 
unprecedented program of accountability from the manufacturers. To fulfill its 
obligations under these amendments, the FDA contracted with the National Academy of 
Sciences/National Research Council to evaluate the effectiveness of 4000 drugs 
approved only on the basis of safety between 1938 and 1962, under the so called Drug 
Efficacy Study Implementation or DESI Review in 1966 (11). 
Further the FDA in 1972, initiated rulemaking procedures to determine which 
nonprescription medicines (The OTC Drug Review) can be generally recognized among 
qualified experts as safe and effective and not misbranded under prescribed, 
recommended, or suggested conditions of use (5). Through the OTC Drug review 
process, FDA established monographs for classes of nonprescription medicines (such as 
antacids etc.) that were generally recognized as safe and effective and not misbranded 
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when the products contained the ingredients and are labeled as per the monograph. OTC 
drug monographs describe the active ingredients, amount of drug, formulation, labeling 
and other general requirements for drugs to be lawfully sold OTC. In all 722 active 
ingredients for different uses were reviewed by 17 expert advisory panels through the 
public review and comment process of OTC Review. About a third of all the drugs 
reviewed were found to be generally recognized as safe and effective for OTC use (15). 
The OTC Drug Review marked the onset of the era of rational regulation of 
nonprescription medicines on the basis of sound scientific evidence. It is generally 
agreed that the OTC Review created: (a) a claims structure based on scientific evidence 
and rational regulatory policy (b) a safety standard that is equal to or higher than that for 
prescription medicines ( c) an increase in consumer confidence by ensuring 
nonprescription medicines deliver the benefits advertised, and (d) an emphasis on 
comprehensive labeling, with clearly defined policies for OTC warnings (4). 
Considering the rapidly growmg segment of the nonprescription medicine 
market that is comprised of CAM, it is important to also discuss the state of their 
regulation in the US. Kottke has recently published an elaborate review of the scientific 
basis and the regulatory state of nutraceutical products. It is suggested that readers 
peruse that report and other references for a comprehensive study of this subject 
(16,17,18,19). FDA's concern to regulate vitamins and dietary products in a manner 
similar to drug regulation has been ongoing for many years. But, unfortunately such 
attempts have only been unsuccessful, for instance, FDA withdrew proposed regulation 
requiring minimum and maximum levels of dietary supplements in the face of severe 
consumer protest in 1962 and federal courts disallowed FDA from regulating high 
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dosage vitamins as drugs based on the toxic impacts of such products in late 1970s. An 
immensely counteracting force restraining FDA's attempts from regulating dietary 
supplements and vitamins based on scientific evidence has been the lack of 
Congressional support due to intense advocacy by the dietary supplement industry. 
Such lobbying and effective grass roots level campaigning led to the enactment of the 
Dietary Supplement Health and Education Act (DSHEA) of 1994 causing dramatic 
changes in the regulatory framework. Most importantly, DSHEA resulted in: (a) a clear, 
but very broad, definition for a "dietary supplement" (b) changing the rules surrounding 
the labeling of dietary supplements, and (c) shifting the burden of proof of product 
safety from the manufacturer to the FDA. 
As per DSHEA, a dietary supplement is a product (other than tobacco) that is 
intended to supplement the diet that bears or contains one or more of the following 
dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a 
dietary substance for use by man to supplement the diet by increasing the total daily 
intake, or a concentrate, metabolite, constituent, extract, or combinations of these 
ingredients. Further, the term is defined to include products such as an approved new 
drug, certified antibiotic, or licensed biologic that was marketed as a dietary supplement 
or food before approval, certification, or license. This very broad definition has had the 
unintended consequence of including even prescription medicines under the term 
"dietary supplements" raising public health concerns (17,18). Cholestin® is a red yeast 
rice product marketed as a dietary supplement, and is a natural source of lovastatin 
which is the active drug in the prescription medicine Mevacor® used for lowering 
cholesterol levels. Before DSHEA, FDA contended that "labeling" of dietary 
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supplements included not only the actual product label, but also any other written, 
printed or graphic matter accompanying the product. DSHEA explicitly exempted from 
"labeling", any such accompanying written matter provided that such written matter is 
truthful and not misleading, effectively preventing the FDA from regulating 
supplements as drugs based on the claims made in accompanying material about cure, 
mitigation, treatment or prevention of any disease. As a result of such promotional 
literature being permissible, studies have found that significant proportions of public 
believe, quite often wrongfully, the ability of supplements in being helpful with 
illnesses (20). 
The shifting of burden of proof of product safety from the manufacturer to the 
FDA is in stark contrast to the conventional regulatory philosophy of FDA with drugs 
(wherein a manufacturer has to demonstrate product safety and efficacy in a premarket 
review) and has left FDA with the authority only for postmarket surveillance. This 
observation is particularly important as per recent evidence showing an increasing 
number of adverse event reports associated with the use of supplements (21 ). Further, 
studies also show that frequently public fails to inform their physicians of the use of 
supplements, leading to an increase in potential for adverse events (7,21). The issue of 
claims for dietary supplements remains to be an extremely contentious one (22). 
Clearly, the rigorousness of regulatory evaluation of alternative medicines and 
supplements does not match the same for traditional prescription and nonprescription 
medicines that are preapproved on the basis of elaborate scientific data and evidence to 
prove product safety and efficacy. Further, the level of scientific advancement amongst 
traditional pharmaceutical nonprescription medicines is much greater than that of 
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supplements and alternative medicines. To strengthen the scientific foundation of 
alternative medicines, DSHEA has mandated the creation of an office within the 
National Institutes of Health (NIH) to explore the potential role of supplements to 
improve health care in the U.S. The office will also need to: (a) promote scientific study 
of supplements and their value in preventing chronic diseases (b) collect and compile 
scientific research, including data from foreign sources and the NIH-Office of 
Alternative Medicine ( c) serve as a scientific adviser to Secretary of Health and Human 
Services and FDA, and ( d) compile a database of scientific research on supplements and 
individual nutrients. These initiatives will, hopefully, help strengthen the scientific 
foundation driving regulatory policy concerning nontraditional nonprescription 
medicines. It is also hoped that as traditional pharmaceutical companies enter the arena 
of developing supplement products for economic benefits, they will extend their 
science-based and data driven product development philosophy to the supplements 
industry. 
Reclassification of medicinal products in the US 
Reclassification is the process of removing the prescription requirement and 
need for medical supervision for a marketed drug product (for human use) that was 
previously available only through a legitimate prescription and making it available 
over-the-counter. It is commonly referred to as "Rx-to-OTC switch" or simply "the 
switch". One major factor responsible for the rapid growth of responsible self-
medication via use of nonprescription medicines is the recent reclassification of 
previously prescription medicines to OTC status that have been very successful, both 
medically and commercially. It may be helpful to divide this subject into, (a) regulatory 
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mechanisms through which a marketed prescription drug product may be reclassified as 
an OTC product, and (b) scientific evidence or data required in support of the petition 
requesting such a reclassification. 
An excellent review of the Rx-to-OTC switch process, related procedures and 
the underlying statutory scheme has been presented by Wion (23). There are essentially 
four regulatory mechanisms through which reclassification may be achieved. They are: 
• filing of an NDA (NDA approach) 
• filing of a supplement to an approved NDA (sNDA approach) 
• as per section 503(b)(3) ofFD&C Act (switch regulation approach), and 
• the OTC Drug Review (monograph approach). 
In the NDA approach, either a traditional NDA (per section 505(b)(l) of FD&C 
Act) or a "paper" NDA (per section 505(b)(2) of FD&C Act) may be filed. The NDA 
route is suitable in the event where the proposed OTC product is of a lesser strength or 
for a different indication than its prescription counterpart, in which event efficacy and 
safety need to be established. The switch of Ibuprofen at the 200 mg dose to OTC status 
utilized the NDA approach for reclassification. Under the sNDA approach, a 
supplement to the original NDA under which the drug product was approved may be 
filed demonstrating the suitability of the product for OTC use to request reclassification. 
Benylin® cough syrup containing diphenhydramine hydrochloride was switched to OTC 
status using the sNDA approach. It must be noted that upon successful reclassification 
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via the NDA approach or sNDA approach, the drug product in the OTC status is 
considered to be a new drug. 
The Durham-Humphrey amendments to the FD&C Act were enacted to state clearly 
the criteria useful in limiting drug products to sale by prescription only. These 
amendments eliminated the confusion prevalent before their enactment and are 
contained in section 503 ofFD&C Act. Section 503(b)(3) of FD&C Act states: 
"The Secretary may by regulation remove drugs subject to sections 502(d) and 505 
from the requirements of paragraph (1) of this subsection when such requirements are 
not necessary for the protection of the public health. " 
This statement authorizes the Secretary of Department of Health and Human 
Services to remove the prescription requirement and need for medical supervision 
arising from NDA approval for prescription use (section 505) or for habit-forming drugs 
(section 502(d)) or the drug characteristics or method of its use necessary for its safe 
use (section 503(b)(l)) when the determination is made that such requirements are not 
needed to protect public health. Using this authority, FDA in 1956 issued the so-called 
"switch regulation" that is now codified in 21 CFR 310.200. Subsection (b) of 21 CFR 
310.200 states: 
"Prescription-exemption procedure. 
(b) Prescription-exemption procedure for drugs limited by a new drug 
application. Any drug limited to prescription use under section 503(b)(J)(C) of the act 
shall be exempted from prescription-dispensing requirements when the Commissioner 
finds such requirements are not necessary for the protection of the public health by 
reason of the drug's toxicity or other potentiality for harmful effect, or the method of its 
use, or the collateral measures necessary to its use, and he finds that the drug is safe 
and effective for use in self-medication as directed in proposed labeling. A proposal to 
exempt a drug from the prescription-dispensing requirements of section 503(b)(l)(C) of 
the act may be initiated by the Commissioner or by any interested person. Any 
interested person may file a petition seeking such exemption, which petition may be 
pursuant to part 10 of this chapter, or in the form of a supplement to an approved new 
drug application. " 
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Hence, using the switch regulation the FDA or any interested person may initiate the 
reclassification process and drugs so switched to OTC status also are considered to be 
new drugs (see 21 CFR 310.200(c)). Prior to 1971, the FDA switched 25 ingredients to 
OTC status using the switch regulation (listed in 21 CFR 310.201). The NDA or sNDA 
approaches to reclassification are useful if there exist only a few manufacturers of the 
drug product whereas broad rulemaking and promulgating a switch regulation is 
preferred if the product has a large number of manufacturers. Subsection ( e) of 21 CFR 
310.200 states: 
"Prescription-exemption procedure. 
(e) Prescription-exemption procedure of OTC drug review. A drug limited to 
prescription use under section 503(b)(l)(C) of the act may also be exempted from 
prescription-dispensing requirements by the procedure set forth in Sec. 330.13 of this 
chapter." 
21 CFR 330.13 describes the conditions for marketing ingredients 
recommended for over-the-counter (OTC) use under the OTC Drug Review 
(monograph approach). As discussed earlier, this is the mechanism that FDA used in 
1972 to initiate the OTC Drug review through the use of Expert Advisory Panels for the 
establishment of OTC monographs for classes of drugs (such as antacids). Concurrent 
to the OTC review, the FDA also invited views from interested persons on prescription 
drugs that may be suitable for OTC use, initiating the deliberation process for potential 
switches. The administrative procedures for classifying OTC drugs as generally 
recognized as safe and effective and not misbranded, and for establishing monographs 
are described in 21 CFR 330.10. The monograph rulemaking process was essentially a 
three-step process, where: (a) FDA Commissioner appointed advisory review panels for 
each designated area of OTC drugs and all areas of OTC drugs were considered. Also, 
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requests for data and views on OTC drugs were made. (b) The review panels upon 
completion of their evaluation submitted to the FDA Commissioner their report of 
recommendations covering all areas of OTC drugs reviewed. They classified all the 
reviewed OTC drugs into the following three categories, (i) Category I, where category 
of drugs were found to be suitable for OTC use and a recommended monograph was 
established (ii) Category II, a statement of all active ingredients, labeling claims or 
other statements, or other conditions reviewed and excluded from the monograph on the 
basis of the panel's determination that they would result in the drug's not being 
generally recognized as safe and effective or would result in misbranding, and (iii) 
Category III, a statement of all active ingredients, labeling claims or other statements, or 
other conditions reviewed and excluded from the monograph on the basis of the panel's 
determination that the available data are insufficient to classify such condition and for 
which further testing is therefore required. (c) The FDA then used the panel's 
recommendations to publish initially, tentative final monographs for public evaluation 
that were later published as final monographs upon consideration of public views. 
The drugs switched to OTC status via the monograph approach, in contrast to 
the other approaches, are not considered as new drugs. A summary of the regulatory 
mechanisms that may be employed to facilitate reclassification of an approved 
prescription human drug to OTC status in the US has been presented in figure 1. In 
recent times, the NDA approach has been the most frequently used mechanism for 
obtaining approval for an Rx-to-OTC switch. MAPP 6020.5 in the Manual of Policies 
and Procedures of Center for Drug Evaluation and Research establishes the Office of 
Review Management (ORM) procedures for assessing investigational new drugs (IND) 
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and marketing applications for OTC drugs to be marketed under the authority of an 
approved NDA, either initially or as Rx-to-OTC switch (24). These procedures describe 
how the ORM interacts with the sponsors who intend to market OTC drug products 
(initially or as a switch) during the IND/NDA review, and the relevant post approval 
oversight necessary. 
The FDA has not published any formal guidance describing the data 
requirements (scientific evidence) it deems as necessary for a switch petition to receive 
approval. The FDA has, instead, taken the position that switch petitions will be 
reviewed on a case-by-case basis, based on the weight of scientific evidence presented 
to demonstrate general suitability for OTC use. Hence, there does not exist any 
universally applicable guidance useful in the preparation of a switch petition. However, 
helpful insights into the general requirements and standards for safety, effectiveness and 
labeling in the OTC context may be gained by studying the procedures for classifying 
OTC drugs as generally recognized as safe and effective and not misbranded, and for 
establishing monographs described in 21 CFR 330.10. These procedures were codified 
in 21 CFR 330.10(a)(4) as instructions to the advisory review panels as: 
"(4) Standards for safety, effectiveness, and labeling. The advisory review 
panel, in reviewing the data submitted to it and preparing its conclusions and 
recommendations, and the Commissioner, in reviewing the conclusions and 
recommendations of the panel and the published proposed, tentative, and the final 
monographs, shall apply the following standards to determine general recognition that 
a category of OTC drugs is safe and effective and not misbranded: 
(i)Safety means a low incidence of adverse reactions or significant side effects under 
adequate directions for use and warnings against unsafe use as well as low potential for 
harm which may result from abuse under conditions of widespread availability. Proof 
of safety shall consist of adequate tests by methods reasonably applicable to show the 
drug is safe under the prescribed, recommended, or suggested conditions of use. This 
proof shall include results of significant human experience during marketing. General 
recognition of safety shall ordinarily be based upon published studies which may be 
corroborated by unpublished studies and other data. 
24 
(ii)Effectiveness means a reasonable expectation that, in a significant proportion of the 
target population, the pharmacological effect of the drug, when used under adequate 
directions for use and warnings against unsafe use, will provide clinically significant 
relief of the type claimed. Proof of effectiveness shall consist of controlled clinical 
investigations as defined in Sec. 314.126(b) of this chapter, unless this requirement is 
waived on the basis of a showing that it is not reasonably applicable to the drug or 
essential to the validity of the investigation and that an alternative method of 
investigation is adequate to substantiate effectiveness. Investigations may be 
corroborated by partially controlled or uncontrolled studies, documented clinical 
studies by qualified experts, and reports of significant human experience during 
marketing. Isolated case reports, random experience, and reports lacking the details 
which permit scientific evaluation will not be considered. General recognition of 
effectiveness shall ordinarily be based upon published studies which may be 
corroborated by unpublished studies and other data. 
(iii)The benefit-to-risk ratio of a drug shall be considered in determining safety and 
effectiveness. 
(iv)An OTC drug may combine two or more safe and effective active ingredients and 
may be generally recognized as safe and effective when each active ingredient makes a 
contribution to the claimed effect(s); when combining of the active ingredients does not 
decrease the safety or effectiveness of any of the individual active ingredients; and 
when the combination, when used under adequate directions for use and warnings 
against unsafe use, provides rational concurrent therapy for a significant proportion of 
the target population. 
(v)Labeling shall be clear and truthful in all respects and may not be false or 
misleading in any particular. It shall state the intended uses and results of the product; 
adequate directions for proper use; and warnings against unsafe use, side effects, and 
adverse reactions in such terms as to render them likely to be read and understood by 
the ordinary individual, including individuals of low comprehension, under customary 
conditions of purchase and use. 
(vi)A drug shall be permitted for OTC sale and use by the laity unless, because of its 
toxicity or other potential for harmful effect or because of the method or collateral 
measures necessary to its use, it may safely be sold and used only under the supervision 
of a practitioner licensed by law to administer such drugs." 
Further, elaboration of specific criteria used by the FDA to determine the 
adequacy of scientific evidence (with regards to safety, effectiveness and labeling) 
required for reclassification may be found in the presentation of the Director of Office 
of Drug Standards at the US FDA, who elucidated the above statements as per his 
comprehension during a workshop on reclassification (25). Also, the Senior Vice 
President of Consumer Health Products Association (CHP A, the trade association 
representing the manufacturers and distributors of nonprescription medicines and dietary 
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supplements with members representing over 90 percent of retail sales in the US OTC 
marketplace) recently authored an excellent article describing, as per his view, the 
specific scientific data requirements applicable in the determination of "OTCness" of a 
drug being considered for reclassification (26). The scientific evidence deemed 
necessary for successful reclassification as per these two articles have been summarized 
in table 2. 
Contemporary topics of interest and importance 
In describing the scope of the public hearing earlier this year, FDA solicited 
comments on general issues regarding OTC drug products such as: (a) criteria used to 
decide on the availability of OTC drug products (b) classes of products that should or 
should not be available OTC ( c) consumer understanding of OTC issues ( d) selection of 
treatment (e) current US OTC marketing system, and (f) FDA's role in switching 
products from prescription to OTC status. The specific issues under each of these 
general categories upon which the FDA requested views have been listed in table 3. The 
list of issues presented by the FDA is not complete and other important topics also need 
to be addressed. 
The scope of this public hearing as published by the FDA focuses on 
regulation of OTC drug products treating pharmaceutical nonprescription medicines in 
an isolated manner. As stated, the notion of OTC drug products being construed only as 
traditional pharmaceutical medicines is changing fast. It is perhaps beneficial to review 
and examine the regulatory aspects of OTC drug products considering them as a portion 
of the present day self-medication armamentarium that includes dietary supplements 
and other traditional medicines. In this regard, initiatives to market at least some of the 
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nontraditional medicines as regular OTC drug products by subjecting them to the same 
rigorous scientific evaluation and review criteria should be promoted upon careful 
consideration. Otherwise, FDA's general product approval philosophy based only on 
sound scientific evidence will continue to be compromised. 
Another important factor, the influence of which upon availability of new 
OTC drug products and reclassification needs to be clarified, is the direct-to-consumer 
marketing of prescription drug products. Some questions that need to be addressed are: 
Are any of such drug products suitable candidates for reclassification?; If, only a 
physician may write a prescription upon diagnosis, why are such promotional activities 
aimed at consumers creating a "quasi self-medication" possibility?; In the process of a 
consumer initiated enquiry resulting in a responsible medication choice upon 
consultation with a physician, can the physician be replaced by the pharmacist, at least 
in some cases? The Jack of dedicated initiatives aiming at global harmonization of 
reclassification policy is a cause for concern as globalization is a rising trend among the 
industry. Subsequently, some key issues that need to be addressed are: Why is there 
variation in the dosage strength of certain medicines approved for OTC use between 
nations? Why are certain medicines OTC in some nations, whereas they are prescription 
only in others? Is it possible to develop and establish globally acceptable monographs 
for OTC drug products, at least within the developed world? Lastly, the application of 
information technology to promote and achieve responsible self-medication through 
enhanced and effective consumer education needs to be explored. The authors intend to 
address some of the above issues in this, and subsequent articles. 
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One noteworthy issue concerns the clarity of FD A's role in the reclassification 
process. In particular, FDA asks: Under what circumstances should FDA actively 
propose OTC marketing for a drug in the absence of support from a sponsor?, and, 
Should FDA be more active initiating switches of prescription products for OTC use? 
Before addressing these questions, FDA's legal authority to initiate a switch proposal 
under the current framework needs to be examined. Of the four regulatory mechanisms 
discussed through which reclassification may be achieved, FDA has unambiguous 
authority to initiate a switch proposal via the switch regulation as per 21 CFR 310.200 
(b) and section 503(b )(3) of FD&C Act. As for the NDA or sNDA approaches, section 
505 of FD&C Act describes the details of the new drug application and related 
processes. More specifically, subsection 505(b)(l) while explaining the details of the 
NDA filing process states: 
"(b)(l) Any person may file with the Secretary an application with respect to 
any drug subject to the provisions of subsection (a). Such person shall submit to the 
Secretary as a part of the application (A) full reports of investigations which have been 
made to show whether or not such drug is safe for use and whether such drug is 
,ffi t" . " e11ec ive m use; ... .. . 
It is important to focus on the term "person" to understand who qualifies for filing an 
NDA. Subsection 20l(b)(e) of the FD&C Act in defining this term states: 
"The term ''person" includes individual, partnership, corporation, and 
association". 
It does not appear that FDA fits into the definition of "person" as per FD&C Act, as 
FDA is not an individual, partnership, corporation or an association. Under this premise, 
it seems reasonable to conclude that the Act did not envision FDA itself filing an NDA, 
hence disallowing FDA to do so. Consequently, FDA does not qualify to file an NDA 
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or an sNDA seeking reclassification. Finally, under the OTC Drug Review procedures 
stated in 21 CFR 330.10 there do not exist any statements suggesting unambiguously 
the authority of FDA to initiate a switch process. 21 CFR 330.1 O(a)(2) states: 
"Request for data and views. The Commissioner will publish a notice in the 
Federal Register requesting interested persons to submit, for review and evaluation by 
an advisory review panel, published and unpublished data and information pertinent to 
a designated category of OTC drugs ... ... " 
Again, use of the "interested persons" terminology perhaps disqualifies FDA 
from submitting switch proposals via the monograph system and delegates to FDA the 
role of a facilitator rather than a participant. From this discussion, it may be inferred 
that FDA has legal authority to promulgate regulation for reclassification to OTC status 
of prescription medicines only via the switch regulation mechanism under the current 
legislative framework. At this juncture, it is appropriate to consider the issue of whether 
FDA should exercise its authority to switch products only in collaboration with the 
sponsor. In the interest of public health and fairness to industry, the FDA should 
undertake any initiatives to switch products only in collaboration with the sponsor based 
on their active support. This approach is most desirable and offers the benefit of FDA 
being able to utilize the sponsor's vast knowledge database related to the development 
and marketing of the product. 
The undesirable action of FDA switching a product despite the sponsor's 
objection to do so should be carried out only under very limited and unusual 
circumstances. Such a situation may be enormous and overwhelming public support for 
OTC availability of a certain product, assuming it meets all the safety, effectiveness and 
labeling standards required of OTC products. The inherent difficulty in such an 
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approach would be that the burden of proving suitability for OTC use would lie on FDA 
and such a task may be formidable in the absence of support from the sponsor. Further, 
it is very difficult to envision FDA being able to prove suitability for OTC use without 
access to data from the original NDA (which is the sponsor's intellectual property). 
Further, FDA should also present a cogent argument demonstrating the need for such 
radical regulatory action and subsequent benefit to overall public health. This should be 
done in an open and transparent process that includes all interested persons prior to such 
a decision taking effect. 
Conclusion 
The role and significance of nonprescription medicines in overall health care 
delivery worldwide is mounting rapidly due to changing social preferences and 
associated economic benefits. The US FDA has initiated the desirable program of 
announcing a public hearing to evaluate its approach to regulating OTC products. In this 
regard, the authors have undertaken a comparative evaluation of regulatory aspects of 
nonprescription medicines within major developed nations. An examination of the 
regulatory environment of nonprescription medicines in the United States shows that 
there exists a wide gap in the scientific basis supporting the regulatory principles for 
traditional pharmaceutical nonprescription medicines and alternative medicines or 
herbal remedies. There exist many challenging issues related to the reclassification of 
products to OTC status in the United States. The authors believe that FDA should 
invoke its authority to switch products to OTC status in collaboration with the sponsor 
using their support and expertise. 
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Table 1: Trends in Alternative Medicine Use in the United States, 1990-1997 (data 
summarized from reference 7) 
Measured Outcome 1990 1997 
Use of at least one form 33.8% of population 42.1 % of 
of alternative therapy in surveyed population 
the _E!evious year surv~ed 
Probability of users 36.3% 46.3% 
visiting an alternative 
medicine Factitioner 
Total visits to an 427 million 629 million--. 
alternative medicine 
practitioner (extrapolated 
to US _Qq£_ulationl 
Concurrent use of Not available 15 million adults 
prescription medications (18.4% of all 
with herbal remedies prescription 
and/or h!_g_h dose vitamins user~ 
Estimated expenditures Not available US $ 21.2 billion 
for alternative medicine 
FOfessional services 
This estimate exceeds the total visits to all the US primary care physicians 
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Table 2: Description of scientific evidence necessary for justifying reclassification of an 
approved prescription drug product to the OTC status in the United States 
Sefety EJkcliveness labeli'!G__ 
I. Toxicity and potential for hannful effect I. The proposed OTC use should I. Intended uses 
• Clinical phannacology data (LD50, subacute be substantially similar to the and results of 
and chronic toxicity) approved prescription use. the product and 
• Phannacokinetics (absorption, excretion, ability to 
accumulation, metabolism, protein binding) 2. Controlled Clinical control that 
• Potential drug interactions investigations in the target labeling . 
• Carcinogenicity/teratogenicity/mutagenicity( esp populations proving clinically 2. Adequate 
ecially in chronic use situations) significant relief of the type directions for 
• Complete analysis of adverse event data from 
claimed in labeling. proper use . 
postmarl<eting experience, controlled clinical 3. Adequate 
trials, voluntary reports during marl<eting and 3. If OTC use is at a lower dosage warning against 
experience with overdoses not only in the than approved for prescription, use in those 
United States but also from foreign sources such then efficacy needs to be pathological 
as Medicines Control Agency of U.K. demonstrated at the new dosage. conditions, or 
• Assessment of safety in special populations 
by chi ldren, or 
such as pediatrics, geriatrics and pregnant 4. How broad of a patient against unsafe 
women population was included in the dosage or 
prescription clinical trial? methods or 
2. Overall benefit/risk assessment duration of 
• Low incidence of overall adverse events or 
5. Corroboration of effectiveness administration 
substantial side effects under use with adequate under partially controlled or or application. 
directions uncontrolled studies by qualified 4. Warnings 
• Possible reduced dosage (with demonstrated experts and reports of significant against unsafe 
effectiveness) human experience during use, side 
• Low potential for hann from abuse upon 
marketing (so called "actual use effects, and 
widespread availability study" setting). adverse 
reactions 
3. Abuse/misuse potential should be stated 
• Can the conditions be self-treated without prior 
to facilitate 
diagnosis by a physician? (or) accurate 
• Can the conditions be self-treated after 
communication 
diagnosis by a physician? 
to individuals 
oflow 
4. Are routine medical examination or laboratory 
comprehension 
work needed for continued safe use of the drug? 
under 
• Do these factors alone preclude the drug from 
conditions of 
OTC availability? 
customary 
purchase and 
5. Method of use and collateral measures necessary to 
use. These 
use 
warnings must 
• Can the condition being treated be self-
be scientifically 
diagnosed? if not, 
documented, 
• Are the symptoms to be treated self-
clinically 
recognizable? 
significant and 
• Can the condition be self-treated? 
important to the 
safe and 
effective use of 
the product by 
the consumer. 
5. include general 
OTC 
pregnancy/nursi 
ng warnings 
unless drug is 
exempt and 
limitations on 
how long the 
OTC drug 
product should 
be used before 
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Figure 1: Summary of regulatory mechanisms through which an approved prescription 
drug product may be reclassified as an OTC drug product. As all prescription drugs are 
considered to be new drugs, box 2 does not contain any products 
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Table 3: Specific issues upon which FDA intends to solicit comments 
through the Over-the-counter Drug Products Public Hearing 
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MANUSCRIPT II 
EXAMINATION OF GLOBAL REGULATORY ASPECTS OF 
NONPRESCRIPTION MEDICINES 
39 
Abstract 
Globally, rising interest in self-medication and related economic benefits highlight the 
importance of and necessity for a regulatory framework developed on sound scientific 
principles for nonprescription medicines. This area is receiving attention from 
regulatory authorities, academia and industry. The US Food and Drug Administration 
(FDA) recently announced a public hearing to evaluate its approach to regulating over-
the-counter (OTC) drug products. This study aims to review and compare: (a) 
classification of medicines, and (b) regulatory policies affecting prescription to 
nonprescription reclassification (Rx-to-OTC switch) of medicines, among major 
developed nations along with the World Health Organization (WHO) perspective. This 
paper presents an analysis of the contemporary regulatory environment in Australia, 
Canada, European Union, United Kingdom and Japan with the WHO position. The 
regulatory model in the United States has been evaluated with that in comparable 
developed nations to draw pertinent inferences. 
40 
Introduction 
Growing global interest in self-medication and potential economic benefits draw 
attention to the necessity for a regulatory framework developed on the basis of sound 
scientific principles. Hence, this area is beginning to receive much attention from global 
regulatory authorities, academia, industry and other stakeholders. The US Food and 
Drug Administration (FDA) recently announced a public hearing to evaluate the 
Agency's approach to regulating over-the-counter (OTC) drug products and solicit 
information from interested persons including scientists professional groups, and 
consumers (1). Specifically, two important questions that FDA asks are: (a) Is the 
current structure for marketing OTC products in the United States adequate? (b) What 
lessons can we learn from different OTC marketing systems? 
Consequently, an examination of the current global regulatory environment of 
nonprescription medicines has been undertaken to review and compare the US OTC 
regulations with those in other comparable developed nations. The central focus of this 
exegesis is on: (a) classification of medicines (for human use) and the underlying 
scientific rationale, and (b) regulatory policies affecting prescription to nonprescription 
reclassification (Rx-to-OTC switch) of medicines. An earlier article examined the 
regulatory environment in the United States and this article presents the same in 
Australia, Canada, European Union, United Kingdom and Japan along with the World 
Health Organization (WHO) perspective (2). The overall object is to learn from various 
global regulatory models and draw inferences that may be beneficial when applied in 
the United States context. 
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Classification of medicines 
Australia 
In Australia, the Therapeutic Goods Act of 1989 (TG Act) aims at providing a 
national framework for the regulation of therapeutic goods to ensure their quality, 
safety, efficacy and timely availability. The Therapeutic Goods Administration (TGA) 
as part of the Commonwealth Department of Health and Aged Care has the 
responsibility for administering the Act and ensuring that the necessary evaluation and 
assessment procedures are conducted to enable access to the latest treatments available 
that are safe, effective and of good quality. A general introduction to the regulatory 
process for all medicines in Australia and other pertinent matters including the role of 
TGA is presented in one of TGA publications (3). 
The TGA uses a risk-management approach to regulating medicines that forms 
the basis of the Australian classification system. Accordingly, risk is determined by a 
number of factors such as: (a) the medicine containing a scheduled substance (discussed 
later) (b) medicine's use can result in significant side-effects ( c) the medicine is used to 
treat life-threatening or very serious illnesses, and (d) there may be any adverse effects 
from chronic use or inappropriate self-medication. Essentially, any product for which 
therapeutic claims may be made must be either listed or registered in the Australian 
Register of Therapeutic Goods (ARTG) before being marketed in Australia. ARTG was 
established under Part 3 of the Therapeutic Goods Act to include a computer database 
of information about therapeutic goods for human use that are approved for supply in, 
or export from Australia (4). 
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Listed medicines are considered to be of lower risk than registered medicines, so 
the regulations allow for sponsors to self-evaluate (in terms of efficacy) their products 
in some situations and majority of listed medicines are used for self-medication without 
a prescription being required. Listed medicines only contain well known established 
ingredients with long history of use, most complementary medicines (such as herbal, 
vitamin and mineral products), medicines that are intended only for export and if they 
do not contain any scheduled substances. The TGA assesses listed medicines only for 
quality, safety and not efficacy, but sponsors are legally mandated to hold information 
to substantiate their product's claims. Registered medicines are assessed as having a 
higher level of risk. The degree of assessment and regulation they undergo is rigorous 
and detailed, with sponsors being required to provide comprehensive safety, quality and 
efficacy data prior to receiving marketing approval. Registered medicines include both 
prescription and nonprescription medicines (to include both traditional pharmaceutical 
OTC products and complementary or alternative medicines). In rare instances, some 
products may qualify for exemption from being listed or registered in the ARTG. 
The registration process for entry into ARTG is determined in part by the 
poisons classification system of the National Drugs and Poisons Schedule Committee 
(NDPSC) for inclusion in the Standard for Uniform Scheduling of Drugs and Poisons 
(SUSDP) based on their toxicity, purpose of use, potential for abuse, safety in use and 
need for the substance. The National Drugs and Poisons Schedule Committee (NDPSC) 
is a standing committee of the Australian Health Minister's Advisory Council 
(AHMAC) and determines the classification and thus, the appropriate schedule, of a 
substance (NDPSC also determines classification of veterinary drugs, agricultural and 
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household chemicals in addition to human drugs). The SUSDP includes a number of 
provisions (such as labeling, packaging and advertising) that relate to the level of 
control intended to apply to the scheduled substances (3,5). NDPSC decisions have no 
effect and do not attract controls until they are included in state and territory legislation. 
While generally, NDPSC decisions are automatically adopted by reference in most 
jurisdictions (unless action is specifically taken not to accept a specific scheduling 
decision), others require publication in the Australian Gazette before scheduling 
decisions come into force. 
The NDPSC has published guidelines for classification of drugs and poisons that 
it follows in rendering decisions related to the scheduling of substances (6). As per this 
guidance, scheduling applications are reviewed by considering all relevant information 
like: (a) need for access to a substance in context of its toxicity relative to substances 
available for a similar purpose (b) purpose of use ( c) method of use ( d) dosage form or 
formulation type (e) extent, pattern of use and proposed use in the community (f) 
misuse (g) drug interactions and adverse events (h) package type and size to prevent 
childhood poisoning, and (i) bioaccumulation. Based on this scientific rationale, a total 
of nine schedules have been developed by the NDPSC. Of these nine schedules, 
schedules 2,3,4 and 8 (S2, S3, S4 and S8) describe medicines for human use, Sl is not 
presently under use and S9 covers prohibited substances (SS, S6 and S7 describe 
poisons for agricultural, veterinary and domestic use). Among human drugs, substances 
classified under S2 and S3 do not require a prescription whereas availability of S4 and 
S8 substances is through prescription only. Further, NDPSC describes for each 
schedule, the general description, purpose, assessment factors (drug's characteristics, 
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indications for use), public health consideration and marketing experience. A summary 
of the schedules relevant to substances for human use is presented in table 1 and the 
assessment factors used in the scheduling of human medicines are tabulated in table 2. 
Canada 
The Health Protection Branch (HPB) of Health Canada is responsible for drug 
quality, safety and efficacy. It regulates drugs imported into and manufactured for sale 
in Canada, and drug distribution including conditions of sale. At the federal level, drug 
products are classified into prescription and nonprescription products (7). Schedule F to 
the Food and Drug Regulations is a listing of chemical entities or classes of drugs that, 
with exceptions, are required by regulation to be sold under prescription (8). The factors 
that are used by HPB to restrict drugs to Schedule Fare presented in table 3. 
Additionally, Provincial Pharmacy Acts, enforced by provincial pharmacy 
regulatory authorities (PRAs ), regulate the profession and the practice of pharmacy and 
may further specify conditions of sale. Within these acts, drugs are classified into 
categories (called drug schedules) with conditions imposed on their sale (9). Prior to 
1995, five provinces had provisions in their Pharmacy Acts controlling the distribution 
of drugs that provided additional levels of control to those already contained in the 
federal legislation and they did not regulate additional location of sale. This situation 
led to disharmony in how drugs were scheduled and controlled across Canada. 
The necessity for drug schedule harmonization in Canada was addressed and the 
Canadian Pharmaceutical Association (CPhA) proposed a mechanism be established to 
assess the existing scheduling system and consider the benefits derived from greater 
consistency in drug scheduling. This proposal also recommended the assessment of the 
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legislation, procedures and criteria generating these schedules. Subsequently, as a result 
of the collaborative efforts between HPB, PRAs, CPhA and other interested parties the 
final report "Harmonized Drug Schedules in Canada" was released and subsequently 
endorsed by the National Association of Pharmacy Regulatory Authorities (NAPRA). 
This proposal called for a national drug-scheduling model, to align the provincial drug 
schedules so that the conditions for the sale of drugs would be consistent across Canada. 
This harmonized national model consists of three schedules or four categories of drugs, 
consistent inclusion factors for each schedule, a standard process for scheduling, and a 
national advisory committee (National Drug Scheduling Advisory Committee, NDSAC) 
to make scheduling placement recommendations to the provincial regulatory authorities 
(7,10). 
• Schedule I drugs require a prescription for sale and are provided to the public by 
the pharmacist following the diagnosis and professional intervention of a 
practitioner. The sale is controlled in a regulated environment as defined by 
provincial pharmacy legislation. 
• Schedule II drugs, while less strictly regulated, do require professional intervention 
• 
from the pharmacist at the point of sale and possibly referral to a practitioner. 
While a prescription is not required, the drugs are available only from the 
pharmacist and must be retained within an area of the pharmacy where there is no 
public access and no opportunity for patient self-selection. 
Schedule III drugs may present risks to certain populations in self-selection . 
Although available without a prescription, these drugs are to be sold from the self-
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• 
selection area of the pharmacy that is operated under the direct supervision of the 
pharmacist, subject to any local professional discretionary requirements which may 
increase the degree of control. Such an environment is accessible to the patient and 
clearly identified as the ''professional services area" of the pharmacy. The 
pharmacist is available, accessible and approachable to assist the patient in making 
an appropriate self-medication selection. 
Unscheduled drugs can be sold without professional supervision. Adequate 
information is available for the patient to make a safe and effective choice and 
labeling is deemed sufficient to ensure the appropriate use of the drug. These drugs 
are not included in Schedules L II or Ill and may be sold from any retail outlet. 
NAPRA has developed and published national standards of practice for 
pharmacists, corresponding to the level of professional intervention and advice 
necessary for the safe and effective use of drugs by the Canadian consumer. The 
National Drug Scheduling Advisory Committee (NDSAC) functions to make drug 
scheduling recommendations to NAPRA and its member provincial pharmacy 
regulatory authorities. The model for making drug scheduling recommendations 
embodies a "cascading principle" in which a drug is first assessed using the factors for 
Schedule I. Should sufficient factors pertain, the drug remains in this schedule. If not, 
the drug is compared to the factors for Schedule II and if appropriate, subsequently 
assessed against the factors for Schedule III. Should the drug not meet the factors for 
any schedule, it becomes unscheduled. The factors that serve as the foundational basis 
for scheduling decisions by the NDSAC have been summarized in table 4. 
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The European Union 
In 1995, a new European System for the authorization of medicinal products 
came into operation. After several years of cooperation between national regulatory 
authorities at European Union (EU) level, the EU Council adopted three directives and a 
regulation in June-1993 when combined form the legal basis of the system. The 
European Agency for the Evaluation of Medicinal Products (EMEA) was established by 
the Council Regulation (EEC) 2309/93 . The European system offers, a centralized 
procedure (covering all member nations) and a decentralized procedure (covering a 
specific member nation that may then be extended to other member nations via mutual 
recognition) for authorization of medicinal products. 
In the European Union, Council Directive 92/26/EEC of 31 March-1992 
describes in detail the classification system for supply of medicinal products for human 
use (11,12). Article 1(1) of this Directive classifies medicinal products into, medicinal 
products subject to medical prescription and medicinal products not subject to medical 
prescription. Further, Article 3(1) of this Directive provides the criteria under which 
medicinal products are subject to medical prescription and states: 
Medicinal products shall be subject to medical prescription where they: 
• 
• 
• 
are likely to present a danger either directly or indirectly, even when used correctly, 
if utilized without medical supervision, or 
are frequently and to a very wide extent used incorrectly, and as a result are likely 
to present a direct or indirect danger to human health, or 
contain substances or preparations thereof of the activity and/or side effects of 
which require further investigation, or 
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• 
are normally prescribed by a doctor to be administered parenterally 
Also, Article 3(2) and Article 3(3) of this Directive state the necessary criteria 
for the sub-category of medicinal products that should be subject to special medical 
prescription or restricted medical prescription as may be required in certain member 
States. Article 4 of this Directive states: 
Medicinal products not subject to prescription shall be those which do not meet the 
criteria listed in Article 3. 
Thus, the Directive implicitly states that medicinal products should be subject to 
a prescription only when they meet the specifically defined criteria. Hence, the 
European Union classifies medicinal products into two categories, prescription 
medicines and nonprescription medicines, with the prescription requirement being 
applicable only when medicines meet certain defined criteria. 
The United Kingdom 
In the United Kingdom, Medicines Control Agency (MCA) is an Executive 
Agency of the Department of Health responsible to promote and safeguard public health 
through ensuring appropriate standards of safety, quality and efficacy for all medicines 
on the UK market. Additionally, the Agency is required to advise Ministers on policy 
relating to pharmaceuticals and regulatory systems and assist Ministers in achieving 
their high level objectives on health. The EU Directive on classification of medicines 
has been implemented in the United Kingdom. Medicinal products are classified into 
three different categories (13,14): 
1. Prescription-only Medicines (POM under section 59 of the Medicines Act, 
1968): Ingredients limited to prescription supply are listed in The Prescription 
49 
Only Medicines (Human Use) Order, 1997. This order specifies three categories 
of POM: parenteral products, controlled drugs and radioactive medicinal 
products. There are two other ways in which substances or products may be 
made POM. These are either by listing the substance in Schedule 1 of the POM 
Order or temporarily through the first Marketing Authorization (MA) for a new 
product. 
2. General Sale List Medicines (GSL under section 51 of the Medicines Act, 1968): 
Medicines that contain ingredients on the General Sale List (The Medicines 
(Products other than Veterinary Drugs) General Sales List Order, 1984) are 
nonprescription medicines that may be sold from any lockable shop. GSL may 
be appropriate for medicines "which can with reasonable safety be sold or 
supplied otherwise than by or under the supervision of a pharmacist" and 
"where the hazard to health, the risk of misuse, or the need to take special 
precautions in handling is small and where wider sales would be a convenience 
for the purchaser". 
3. Pharmacy Medicines (P): Any medicine that is not a POM or a GSL medicine is 
classified as pharmacy medicine. These medicines can be sold only from 
pharmacies under the supervision of a pharmacist. There is no list of these 
medicines in UK legislation. 
Japan 
Drugs are classified into prescription drugs, non-prescription drugs (or 
proprietary drugs) and quasi-drugs (15). Nonprescription drugs are defined as those, 
which have a mild action and a high degree of safety if used correctly within a fixed 
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range of directions and dosage. They can be purchased directly from a pharmacy or a 
drugstore and used freely in self-medication by the consumers. 
The examination for approval of proprietary drugs is based on the following 
principles (16): 
• The ingredients and quantities of proprietary drugs should be within a scope that 
assures the safety and efficacy of the products. Their action should be mild, 
products having a strong action or causing habituation or dependence should not be 
included. 
• Their indications should be within the scope of preventing or treating minor 
diseases or maintenance and improvement of health. Diseases deemed to be treated 
by physicians should not be recognized as indications of proprietary drugs. Their 
indications should be mainly described by the symptoms that are easily 
understandable to the general public. 
• Directions for administration, dosage and dosage forms shall be described in such a 
manner as to be easily understood by the general public on their own judgment. 
Products that may cause misuse or abuse, and those in such dosage forms (such as 
injections) as not used safely and effectively without the direction of physicians or 
other specialists are not recommended as proprietary drugs. 
Proprietary drugs are divided into six classes according to conditions in the 
approval application (such as ingredients, quantity, indications) and have been 
summarized in table 8 (16, 17). Also, the data requirements and clinical trial data 
necessary for the registration for each class of proprietary drugs have been presented in 
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tables 9 and 10 respectively. Quasi-drugs as stipulated by the law are: (a) products 
having fixed purposes of use (b) products having a mild action on the human body, and 
(c) products other than instruments and apparatus. For a product to be designated as a 
quasi-drug all three conditions must be satisfied (18). Quasi-drugs have been specified 
for: 
• 
• 
• 
• 
Prevention of nausea and other indispositions, foul breath or body odor 
Prevention of prickly heat, sore and the like 
Prevention ofloss of hair, promotion of hair growth or removal of hair 
Eradication or repellence of rats, flies, mosquitoes, fleas etc. for the health of man or 
other animals 
• Other articles designated by the Minister of Health and Welfare (MHW) as similar 
to the items specified above 
To facilitate rapid examination of proprietary drug approval applications, the 
MHW at the national level has been transferring the authority to prefectural governors, 
provided they adhere to uniform examinations as per established standards. Only the 
MHW may approve prescription medicines and quasi-drugs whereas nonprescription 
medicines may be approved either by the MHW or by the prefectural governments (15). 
Recently, the MHW approved fifteen categories of medicines under the quasi-drug 
status. These products are for minor ailments (sore throat, stomach discomfort), 
vitamins/minerals and for external use (topical ointments) in general. The distribution 
system in Japan is rather unique as about 66% of all prescription medicines are both 
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written and dispensed by physicians or dentists and only 1 in 3 prescription medicines is 
dispensed by pharmacists. Quasi-drugs may be sold at any retail outlet. Nonprescription 
medicines are sold through a variety of outlets such as a pharmacy, drugstore with a 
pharmacist and drugstore without a pharmacist. Additionally, outlets with special 
limited license and for household distribution also exist but are relatively uncommon. 
Reclassification of medicines 
Australia 
Reclassification (or rescheduling) of medicines in Australia is also governed by 
NDPSC guidelines for classification of medicines and poisons (6). The process of 
rescheduling may be initiated by the evaluating Agency (TGA), product sponsor, state 
and territory authorities and occasionally by NDPSC itself. If an applicant believes that 
they can justify an alternative schedule entry for any medicine, an application may be 
submitted for review to the NDPSC with suitable evidence. For rescheduling of a drug 
substance from prescription only (S4) to a lower nonprescription (S2 or S3) or exempt 
from scheduling, NDPSC usually requires at least two years of local clinical use or local 
post-marketing surveillance of the drug substance before the proposal is considered. 
Suitable evidence for rescheduling could include: (a) evidence from comparable nations 
where the drug substance is available without a prescription (b) relevant public 
exposure information in other nations with a population base greater than Australia (c) 
any available information from post-marketing surveillance (local and overseas) (d) any 
relevant previous Australian consideration of scheduling of the drug substance, ( e) any 
relevant Australian experience with the drug including a different route of 
administration. If the rescheduling application is for a new indication, then applications 
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need to be submitted to obtain approvals from the TGA and NDPSC. A detailed 
tabulation of suitable evidence justifying a rescheduling application is presented in table 
5. 
Canada 
Reclassification (or de-scheduling) to nonprescription status in Canada has been 
addressed by the HPB in an information letter issued in June-1990 (19). The purpose of 
this information letter was to inform interested parties of the data requirements for 
applications to remove drugs for human use from Schedule F to the Food and Drug 
Regulations and outline the internal mechanism for handling such applications. 
Applications must demonstrate that a favorable ratio exists between the benefit to 
patients that will occur versus the risk to their health that may be inherent in permitting 
the nonprescription sale of the drug product. HPB requests the following information 
for assessment of the reclassification applications: 
• Efficacy data f or new indications and safety data 
Efficacy data will be required if the indications of use or dosage differ from those 
approved fo r prescription use. A summary of all animal and human clinical safety 
data, including data that may have been part of an original submission and the data 
accumulated after the product's introduction. 
• Drug adverse reaction data 
A summary of all known domestic and foreign adverse drug reaction reports since 
the introduction of the medicinal ingredient, adverse effects with their frequency 
and the dose at which they occurred. Any adverse effects that could require patient 
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• 
• 
• 
monitoring by a physician should be clearly described. Any potential for misuse or 
abuse and actual occurrences should also be discussed. 
Labeling 
All proposed nonprescription labeling and promotional material demonstrating that 
the safe and effective use of the product can be assured by nonprescription labeling 
rather than depending upon the professional judgment of a physician. Appropriate 
cautions and contraindications must be addressed in lay terms. 
Chemistry and manufacturing data 
Differences from the original submission and supplements must be identified. 
Chemistry and manufacturing data will be required where they differ from the 
prescription drug. 
Market data 
Date of introduction of the prescription drug in the Canadian market and a summary 
of sales data must be included. If the product in consideration was not the first 
product introduced as a prescription drug, then date of introduction of the first 
product also must be provided. A summary of international market status (countries 
where requests for prescription or nonprescription status have been made, approved, 
rejected or are pending) is required. If a request has been refused, the reason for 
refusal is required. If the request was approved, the date of introduction in that 
market and confirmation that the product is currently marketed is required. 
Additionally, the Drug Evaluation Unit of the HPB also published an 
information pamphlet on the subject of prescription to nonprescription switches in 
April-1999 (20). In this publication, HPB took the position that the switch process be 
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initiated by the manufacturer only, through the filing a supplemental new drug 
submission (SNDS) with HPB performing the assessment of the evidence provided to 
determine the suitability of the product and its indication for OTC use. The factors to be 
considered while evaluating the suitability for a switch and the data requirements for 
switch SNDS have also been briefly listed in this pamphlet. Also, HPB recently 
finalized revised guidelines for preparing submissions seeking to change the status of a 
drug from prescription to nonprescription. These guidelines for a switch divide switches 
into two types, Type I and Type II, based on the nature of the switch and complexity of 
the review. 
Type I switch is for drugs which have same strength, dose, dosage form, 
indication and route of administration as the prescription product. Type I switches 
usually do not require the submission of new clinical trials or chemistry and 
manufacturing data. The review is mainly of the safety profile and whether self-
medication is effective. Type II switch is for drugs which have a change in, the 
indication, dosage form, strength or dose, route of administration, relative to the 
prescription product. Hence, a type II switch request requires data from clinical trials to 
support the new strength or dosage formulation as a nonprescription product. 
Removal of drugs from Schedule F, or addition of a qualifier to Schedule F (for 
dual status products) requires the promulgation of a regulatory amendment which is 
subject to federal regulatory process and involves several stages and levels of approvals, 
that include the Minister and the Governor-in-Council who are advised by the Special 
Committee of c · 
ounc1l (SCC). The steps involved in the regulatory amendment process 
are outlined in table 6. A switch becomes law at the federal level once registered at the 
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SCC. After the drug is reclassified at the federal level, each province must then 
determine how the product will be sold and this determination is made by the National 
Drug Scheduling Advisory Committee (NDSAC) at the provincial level as discussed 
earlier. 
The European Union 
Reclassification within the EU has been addressed by the issuance of a guideline 
on changing the classification for the supply of a medicinal product for human use in 
September-1998 (2 1 ). This guideline is divided into two parts. Part one concerns the 
criteria for classifying a medicinal product as subject to medical prescription or not. Part 
two describes the data requirements for an application requesting reclassification of a 
prescription product to nonprescription status. As per this guideline, suitability of a 
medicinal product for nonprescription status is elaborated by examining the converse of 
each criterion (discussed earlier) that justifies the prescription requirement. A medicinal 
product not subject to a prescription should have the following characteristics under 
each specified attribute: 
Direct danger/safety profile 
• 
• 
• 
Low general toxicity and no relevant reproductive toxicity, genotoxic or 
carcinogenic properties 
Low risk of serious type A adverse reactions (those that result from exaggeration of 
a drug's expected pharmacological actions when given in the usual therapeutic dose; 
normally dose-dependent) in the general population 
Very low risk of serious type B reactions (those that represent a novel response not 
expected from known pharmacological action) 
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• 
No interactions with commonly used medicines which can produce serious adverse 
reactions 
Indirect danger/safety profile 
• 
• 
No indirect danger such as hiding/masking an underlying condition requmng 
medical attention and supervision even when the product is used as directed. 
Nonprescription medicines should be approved primarily for short-term treatment 
when the possibility of "masking" could occur. 
No increased risk of resistance to product with a wider use of a product within the 
general population to such an extent that the usefulness of any medicinal product is 
likely to be compromised. 
Self-assessment 
• Conditions or symptoms should be such that can be correctly assessed by the patient 
and the product can be used without medical supervision. Consumer communication 
may be facilitated by the use of written information, advice of pharmacist and other 
appropriate sources. 
• The natural course of the disease, the condition, the duration of symptoms and their 
reoccurrence and consequences should be correctly self-assessable. 
• Contraindications, interactions, warnings and precautions should be those that can 
be understood by the consumer. 
Risk and consequences of incorrect use 
• Absence of a high incidence of conditions listed as contraindications, precautions or 
warnings or a high rate of usage of interacting drugs in the population in case of 
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• 
patients likely to use the medicine that may increase the incidence and risk of 
misuse. 
Low danger to health if the patient uses the product where it is not indicated or uses 
it for a longer period than recommended or exceeds the recommended dose or fails 
to heed warnings or contraindications. 
Patient information 
• 
Leaflet and label must contribute effectively to safe and effective use of medicine 
and should be sufficient so that it substitutes for absence of medical supervision. All 
information should be provided in layman's terms and prominently presented in the 
leaflet. Leaflet and label should describe in equal prominence when and when not 
the product should be used. 
Known incorrect use 
• If known incorrect uses exist, then such a product may not be considered for 
nonprescription medicine status. Similarly, products with low expenence, where 
marketing authorization was only recently granted or when further investigation is 
required should also be not considered for nonprescription medicine status. Further, 
post-marketing information in an uncontrolled environment should be examined 
while reclassification. 
Recent authorization/limited experience 
• For reclassification at a new dose, m a new strength or usmg a new route of 
administration further investigation is necessary. At a lower strength, efficacy 
should be demonstrated. A re-evaluation of the risk to benefit ratio is necessary 
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under the proposed conditions of nonprescription status. The same is true when a 
combination of two or more active ingredients is considered. 
Other considerations 
• 
• 
No parenteral products or products classified as special or restricted prescription 
products under Council Directive 92/26/EEC. 
Pack size should be decided in relation to the intended length of the treatment. 
Packages should be child resistant in nature and generally in restricted sizes as a 
possible safeguard against misuse. 
Part two of the EU guideline describes the data requirements and documentation 
concerning safety and efficacy in support of an application for reclassification. This is 
usually dependent on the nature of the active substance and the extent of changes to the 
existing marketing authorization. In all cases, an expert report should be provided 
taking a clear position and defending the proposal with scientific knowledge and 
demonstrate why none of the criteria that lead to the prescription requirement should be 
applicable. In addition to scientific data addressing all points related to determining the 
suitability of the product for nonprescription status, other requirements summarized in 
table 7 should also be included in the expert report. 
The United Kingdom 
In the United Kingdom, two types of reclassification are possible. The first type 
of reclassification is from prescription only medicine to pharmacy medicine status 
(POM to P) and the second type is from pharmacy medicine to general sales list (P to 
GSL). The UK Medicines Control Agency (MCA) has specified a set of guidelines 
related to each type of reclassification. The POM to P reclassification has been 
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explained in Medicines Act Leaflet 77 (MAL 77) (13) and the P to GSL reclassification 
is discussed in Medicines Act Leaflet 82 (MAL 82) (22). 
For POM to P reclassification, MAL 77 describes the procedure for amendment 
of the POM Order applying to products that are prescription medicines because they 
contain one or more substances listed in Schedule 1 to the POM Order. Applications 
under this procedure may be submitted as a variation or a new abridged application. The 
variation route is appropriate if the marketing authorization (MA) holder has a product 
suitable for reclassification, the proposal to amend the POM Order should be 
accompanied by an application to vary the legal status of the product. Other product 
particulars may also need to be varied in order for a product to be suitable for 
reclassification. If reclassification is agreed, amendment to the POM Order will proceed 
and the MA will be appropriately varied to take effect when the POM Order comes into 
force. If an MA holder wishes to make a change, for example to introduce a new 
strength, which requires a new application, a new abridged application should be made. 
A new abridged application should also be made if the MA holder wishes to hold a 
separate MA for the P product. Also, any interested party such as a professional body 
that does not itself hold an MA may request the reclassification of a substance. The 
content of the applications should be similar to that of applications from MA holders. 
Since, Schedule 1 to the POM Order is substance based, amendment will usually affect 
the legal classification of products containing that substance. If the MA is in line with 
the amendment to the POM Order, the product becomes classified as pharmacy 
medicine. However, MA holders should apply to vary their MAs in accordance with the 
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amendment to the POM Order, and provide appropriately amended labeling and patient 
information leaflets for approval. 
Following assessment of the application, advice from the Committee on Safety 
of Medicines (CSM) will usually be sought on the proposed reclassification. If the 
reclassification proposal is supported, wider interests are then consulted. Responses to 
the consultation are examined by the MCA whose advice is passed to Ministers. It is for 
the Ministers to determine, in the light of the advice received, whether the POM Order 
should be amended. If the CSM recommends that a request for reclassification be 
refused, the originator of the proposal will be notified as to which POM criteria have 
been considered to apply and the reasons for advising against the change, and will 
receive a copy of the assessment report. 
As stated earlier, the EC Directive on the classification of medicines 
(92/26/EEC) has been implemented in the United Kingdom and incorporated into 
section 58A of the Medicines Act, 1968. Although the prescription criteria of Council 
Directive 92/26/EEC apply to all EC member states, the procedure for assigning 
prescription classification remains the responsibility of each individual member state. In 
the United Kingdom, the required documentation in support of a POM to P 
reclassification request is substantially similar to that described in the EU guidance on 
the same subject. Applications should contain the following key information that has 
been discussed in detail in the earlier section in the European Union context. The key 
elements to be addressed in the expert report must include: 
• Consideration of reclassification proposal in relation to the four criteria for 
prescription control (reference to Article 3(1) of Council Directive 92/26/EEC) 
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• 
• 
• 
Summary of data relating to safety and where appropriate efficacy 
Proposed patient information (labeling and patient information leaflet) 
Clinical expert report . 
MAL 82 provides guidance on pharmacy to general sale list (P to GSL) 
reclassification procedures and requirements. As discussed earlier, similar procedures, 
steps and possible routes as for POM to P reclassification also apply to P to GSL 
reclassification. But, substantial differences exist in the criteria applied to evaluate 
suitability for GSL and the contents of the supporting application. Criteria applied to 
evaluate suitability of human medicines for GSL has been defined earlier. The 
supporting application for a P to GSL reclassification must contain: 
• Expert report 
o Clear demonstration in light of scientific knowledge why the GSL criteria 
must apply 
o Discussion of maximum dose, maximum daily dose and the indications 
suitable for use. Explanation of contra-indications, warnings, adverse 
reactions, interactions and problems of overdose and other misuse under 
GSL conditions. 
o Justification for the need for special handling precautions as being very 
small. Discussion of difficulties in the extrapolation of P to GSL use. 
• Data requirements 
o Experience m exposure to substance should be considerable. GSL use 
suitable medicines should have been in P use for many years. 
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0 Description of safety profile, to include, post-marketing surveillance/clinical 
studies, adverse drug reports under GSL conditions in UK and foreign 
nations. Comparison of safety with other approved GSL medicines for 
similar indications. 
0 New PK/PD or efficacy data are usually not required. Animal studies are 
also not required except under special circumstances. 
o Complete analysis of any experience of therapeutic misuse or abuse that may 
be deliberate or accidental. Description of symptoms from overdose or 
misuse along with recommended treatments. 
o Proposed patient information leaflets, labeling, pack size and any other 
changes in product presentation should be provided. Safety warnings such as 
limited duration treatment or the need to consult a doctor or pharmacist 
should be listed. 
The guidance states that anthelmintics, parenteral products, drops/ointments for 
ophthalmic use, enemas, products for irrigation of wounds or of the bladder, vagina or 
rectum and products for administration to children that are preparations of aloxiprin or 
aspirin are not included in the GSL. 
Japan 
The procedures, application format and data requirements for registration and 
approval of nonprescription medicines, as discussed earlier, apply exactly and in same 
measure to reclassification application dossiers in Japan (18). The future course of 
MHw related to reclassification is presently under consideration and additional 
guidance (15) in the interim may be summarized as: 
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• 
• 
The active ingredients proposed for switching application should have undergone 
complete re-examination or re-evaluation. 
Review of switch applications should be conducted upon serious consideration of 
the opinjons of Central Pharmaceutical Affairs Council to determine whether the 
product is suitable for nonprescription medicines status. A rate of incidence of 
adverse medicine reactions, administration and dosage, actual examples of use of 
the medicine in foreign countries, results of either re-examination should be taken 
into consideration. 
• To ensure appropriate use and safety of the medicine, conditions may be imposed at 
the time of approval such as to conduct post-marketing surveillance (PMS), 
directions on information provision and sales methods and advertising standards. 
• Upon approval of the switch application, the product may be sold only in a 
pharmacy or a drugstore with a pharmacist. 
• PMS of the prescription product and actual use trials (AUT) should be conducted to 
support switch applications. PMS should include two kinds of surveillance 
emphasize actual use/administration of proposed OTC drugs by subjects and 
adverse reactions documented after the product's launch. 
• New clinical trials are required and should be carried out in at least five locations in 
Japan with not less than 150 cases even ifthe prescription product is considered for 
switching without any changes. 
World Health Organization perspective 
The WHO finalized and published guidelines on the regulatory assessment of 
medicinal products for use in self-medication in March-2000 (23). This guidance states 
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that a medicinal product for self-medication should, at least, meet the following three 
criteria: 
J. Active ingredient: The active ingredient at the intended dose should have low 
inherent toxicity (no reproductive toxicity, genotoxic or carcinogenic properties 
relevant to human use, unless such hazard can be appropriately addressed by 
labeling). 
2. Intended use: The intended use should be appropriate for self-medication. Use of 
the products should not unduly delay diagnosis and treatment of a condition 
requiring medical attention. 
3. Product properties: The product should not have properties that make it 
undesirable. For example, it should not have an unfavorable adverse event profile, 
require a physician's supervision for monitoring during drug therapy, represent a 
significant risk of dependence or abuse or display other limiting characteristics 
such as interaction with commonly used medicines or foods that may result in 
serious adverse reactions. 
If the product meets these criteria, the following additional requirements may be 
applied: 
• 
• 
• 
The use of the product has been sufficiently extensive or in high enough volume . 
The product has been marketed on prescription for at least five years . 
Its adverse events give no cause for concern and their frequency has not increased 
unduly during the marketing period. 
A basic principle for the regulatory assessment, as per WHO guidance, is that 
the pharmacokinetics, pharmacodynamics, indications, safety, efficacy, toxic or 
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allergenic potential of a medicinal product should have been reasonably well 
established and documented in humans before its eligibility for use in self-medication 
can be evaluated. The general regulatory assessment approach should, in detailed terms, 
investigate the following five complementary aspects: 
• 
• 
• 
• 
• 
Active substance and rationality of its indications 
Specific routes of administration, dosage forms and formulations 
Specific safeguards 
Suitability for self-medication status 
Labeling and package inserts and other information forming a basis for advertising 
and promotion 
The guidance also provides details on the collection and regulatory assessment 
of evidence for medicinal products intended for nonprescription status hitherto available 
only on prescription. The objective of the regulatory assessment, while considering 
reclassification should be to form an opinion on the basis of evidence that will generally 
comprise: 
• The original regulatory data (chemistry, manufacturing, pharmaceutical, 
pharmacological, toxicological, clinical pharmacological, clinical trial, therapeutic 
efficacy and safety data) 
• 
This is relevant only if the product is being considered for reclassification 
without any changes to the marketed prescription product. If the original animal 
investigations suggested severe risks (like carcinogenicity) the risks should be 
reassessed in light of subsequent experience in humans. 
Clinical data obtained after the approval of the drug 
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• 
• 
Trials performed according to current standards and relating closely to the 
proposed use in self-medication should be accorded the greatest weight. 
Drug utilization and consumption data 
This is helpful in determining the way in which the product has hitherto been 
employed by physicians (volume of use, major indications in practice, 
precautions normally taken) and particularly in interpreting alleged risks. 
Reported adverse events/reactions and interactions 
This should be examined with respect to their profile, frequency and severity. 
Sources in which the evidence is critically assessed (especially in well 
controlled clinical studies or epidemiological studies) are preferable to those in 
which unevaluated observations of possible adverse reactions are accumulated. 
Data from sources that have collected adverse reactions information from 
different countries for long periods of time may be useful, in particular, from 
WHO's International Drug Monitoring Programme. 
• Current scientific data 
The pharmaceutical form and packaging should be considered, any available 
clinical studies, field data and market-related studies on consumer use of the 
product for self-medication should be examined. 
Comparative evaluation 
An evaluation of the regulatory systems for nonprescription medicines in 
comparable developed nations demonstrates the unequivocal recognition of their vital 
role in public health care. The basic scientific rationale used to designate 
nonprescription status to medicines is very similar within the considered models. But, 
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there exists wide variation in the categories of nonprescription medicines available in 
these markets. Some classification models (Australia, Canada, United Kingdom and 
Japan) recognize an intermediate class of nonprescription medicines, controlled by the 
pharmacist, whereas other models (the US and EU) do not. The issue of an 
intermediate, pharmacist-controlled nonprescription category being included within the 
US regulatory model has been quite controversial. The major proponent of an 
intermediate class of medicines has been the American Pharmaceutical Association, 
whereas the Consumer Health Products Association (CHP A, the trade association 
representing the manufacturers and distributors of nonprescription medicines and dietary 
supplements in the US OTC marketplace) has strongly opposed such a new class of 
medicines (24,25,26). The US General Accounting Office (GAO) upon congressional 
request in 1995 issued a report titled "Nonprescription Drugs: Usefulness of a Restricted 
Sale Class has Not Been Demonstrated" (27). To date, this is the most comprehensive 
study conducted in the US on this subject and performed a detailed investigation of drug 
classification/distribution systems across ten countries. The US GAO reached the 
conclusion that "reliable and valid studies that examine the effect of drug distribution 
systems on overall health and healthcare system costs do not exist". This GAO conclusion 
clearly demonstrates the need for reliable, objective and valid studies through which useful 
information may be elicited to reach a definitive conclusion on this matter. 
Although, the appropriate scientific principles used to categorize 
nonprescription medicines are remarkably similar across various regulatory systems, the 
end results of each classification system are highly variable. There exist many examples 
of the same drug substance being subject to conflicting status across the considered 
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regulatory models. Also, there exists wide variation in classification of the same drug 
substance based on dosage level. In Canada, UK and Australia, substance based lists of 
drugs subject to prescription control are maintained whereas in the US, such is not the 
case. The US approach of classification based only on the approved submissions, 
without any substance based lists, offers greater clarity. The OTC monograph system in 
the US that resulted from the OTC Drug Review benefits the pharmaceutical industry 
by simplifying the approval process. A similar system as the OTC monographs, on a 
global basis would benefit other regulatory systems also. 
The scientific principles and the supporting data requirements based on which 
reclassification applications are reviewed are also remarkably similar in the regulatory 
systems studied here. As is the case with classification of drug substances, although the 
process and principles used for evaluation of reclassification request are quite similar, 
they have produced varying results for the same substance in different nations. 
Regulatory bodies in the US, Australia, Japan have taken the position that they can, 
themselves, initiate reclassification requests, whereas in Canada and the United 
Kingdom such requests should be initiated only by the holders of marketing approval or 
other interested bodies. All the regulatory models (Australia, Canada, UK, EU, Japan 
and WHO guidance) elaborated here have well-defined and structured data 
requirements that need to be submitted in support of reclassification requests. Such is 
not the case with the US FDA. Although, 21 CFR 330.1 O does provide general insights 
into the requirements and standards for safety, effectiveness and labeling in the OTC 
context, the US FDA has not issued any specific guidance on the details of 
structure/format of the justification and the types of data required to prove suitability for 
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nonprescription use. An important lesson that would be very useful in the US context is 
that US FDA should develop a guidance document for industry describing the nature of 
data required for justification of a reclassification petition. Another major contrast 
relates to the possibility of new chemical entities (NCE) being marketed as 
nonprescription medicines (i.e. direct-to-OTC) if they meet all the necessary 
requirements. There is no uniformity among the various regulatory models on the 
duration for which a drug substance must be marketed as a prescription medicine before 
it may be considered for reclassification to nonprescription status. That duration in, 
Australia is two years, Canada is three years Japan is six years, and WHO regulations 
require five years. The UK and EU regulations also state that any NCE must be 
marketed as a prescription medicine for a substantial duration before reclassification 
may be considered. The US position on this issue is unique as no such requirement is 
explicitly stated, leaving open the possibility of an NCE being marketed directly on 
OTC status. Reclassification requests in some markets (Australia, Canada and Japan) 
require approval from regulatory bodies at both federal and state level. In the US and 
UK such is not the case. Necessity to obtain approval from federal and state level 
agencies (especially in Canada) is burdensome for the industry. Under the US and UK 
models, approval is obtained primarily at the federal level which is efficient and 
desirable. 
Conclusion 
Nonprescription medicines in major developed nations have been recognized as 
crucial to efficient public health care. Accordingly, Australia, Canada, the United 
Kingdom, the European Union and Japan have all established regulatory frameworks 
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based on scientific principles for classifying drug substances under the nonprescription 
status and reclassifying prescription medicines as nonprescription medicines. However, 
there exists significant opportunity for improvement of current regulatory systems 
within these nations to enhance efficiency of regulatory review, convenience to drug 
manufacturers and consumer access to nonprescription medicines. In this regard, the US 
OTC regulatory system should seriously consider issuing guidance to industry on 
specific data requirements for reclassification petitions and investigating the merits of 
an intermediate pharmacy-class of nonprescription medicines. 
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Table 1: Summary of the schedules relevant to substances for human use as per the 
Australian classification system 
Schedule Description Purpose 
Schedule Two • Substantially safe but counseling To allow effective 
(S2, available if necessary drugs for which 
nonprescription • For minor ailments that can be easily pharmacist advice on 
medicine) recognized by the consumer and do not use may be required 
require medical diagnosis by the consumer to be 
available without a 
_l)fescription. 
Schedule Three • Substantially safe but require professional To allow effective 
(S3, advice by a pharmacist drugs which require 
nonprescription • Use of which requires pharmacist advice, professional advice on 
medicine) management or monitoring use by the consumer to 
• For ailments or symptoms which can be be available from the 
identified by a consumer and verified by a pharmacist without a 
pharmacist and do not require medical prescription. 
diagnosis or only require initial medical 
diagnosis without need for close medical 
management 
Schedule Four • Use of which requires professional To make available 
(S4, medical, veterinary or dental drugs the use, supply 
prescription management/monitoring and prescribing of 
medicine) • For ailments or symptoms that require which should be by 
professional medical, veterinary or dental registered medical, 
diagnosis or management veterinary or dental 
• The safety or efficacy of which may practitioners and 
require further evaluation supply of which 
• Which are new therapeutic substances should be on 
_Eescrigtion 
Schedule Eight • Which are dependence producing To allow potent drugs (S8, 
• Which are likely to be abused or misused to be available for 
prescription medicinal use with 
medicine) restrictions on 
manufacturing, trade, 
distribution, 
possession and use to 
prevent abuse, 
addiction and 
dependence 
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Table 2: Summary of the assessment factors used in scheduling nonprescription 
medicines for human use as per the Australian classification system 
Schedule Assessment_fEctors 
S2- . Suitability for self treatment of a minor ailment or symptom 
Nonprescripti capable of being monitored by the consumer 
on medicine • Extremely low abuse potential, low potential for harm from 
(regular OTC inappropriate use 
products) . Low adverse effects and contra-indications for which counseling is 
available 
• Low interactions with commonly used substances or food for which 
counseling is available 
• A wide therapeutic index and low risk of masking a serious disease 
and compromising medical management of a disease 
• Not require ongoing or close medical diagnosis or management 
• Easy recognition of ailment by consumer 
• Amenable to short term treatment and monitoring and self-
manl!&_ement b_y_ consumer with counselin_g_ 
S3- • Low abuse potential, harm from inappropriate use, incidence of 
Nonprescripti side-effects or adverse events likely to require medical intervention 
on medicine • Only common drug/food interactions that may be managed by a 
(Pharmacist pharmacist 
only • Medium to wide therapeutic index 
medicine or • Risk of masking a serious disease or compromising medical 
behind-the- management can be managed by a pharmacist 
counter . Not require close medical management or direct supervision by a 
products) doctor 
. Ailment easily recognized with assistance of a pharmacist 
• Amenable to short term treatment and monitoring and self-
manl!&_ement b_y_ consumer with assistance of a __Q_harmacist 
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Table 3: Summary of the factors used for listing drugs for human use in Schedule F 
(subject to prescription control) as per the Canadian classification system 
Drugs will be listed in Schedule F if: 
• 
• 
individualized instructions and/or direct practitioner supervision, adjunctive therapy with 
scheduled drugs or routine laboratory monitoring are required; 
there is a narrow margin of safety between the therapeutic and toxic doses, especially in 
populations such as geriatrics, children and pregnant or nursing mothers; 
there are potential or known undesirable or severe side effects at normal therapeutic dosage 
levels; 
they are known by experimental data to induce toxicity in animals but have not been in 
clinical use long enough to establish the pattern or frequency of long-term toxic effects in 
humans; 
• they are used in treatment of a serious disease easily misdiagnosed by the public; 
• their use may mask other ailments; 
• they have contributed to, or are likely to contribute to, the development of resistant strains of 
micro-organisms in humans; 
• they possess a dependence or abuse potential that is likely to lead to harmful non-medical 
use; 
• they possess a high level of risk relative to expected benefits; or 
• they have a therapeutic effect based on recently elucidated pharmacological concepts, the 
consequences of which have not been established. 
Exceptions will be considered for drugs which: 
• 
• 
• 
are required to be readily available under emergency circumstances where it is not practical 
to obtain a prescription (such as adrenalin in insect bite kits) ; 
are rarely used without a practitioner's supervision, and where the need for free availability 
outweighs the need for protection under Schedule F (such as insulin and nitroglycerin) ; or 
have potential to produce dangerous interactions with other drugs or food constituents but 
effective labeling can minimize the risk. 
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Table 4: Description of factors that serve as the foundational basis for scheduling drugs 
in Canada 
Schedule I 
• 
Indications for use of the drug are identifiable only by the practitioner . 
• 
Use of the drug requires adjunctive therapy or evaluation . 
• 
Use of the drug may produce dependency . 
• 
Serious adverse reactions to the drug are known to occur or have a recognized potential to occur at normal 
therapeutic dosage levels. 
• 
There exists a narrow margin of safety between the therapeutic and toxic dosages of the drug, either in the 
general population, or in identified subpopulations, or in patients with multiple medical problems. 
• Serious interactions of the drug are known to occur . 
• Use of the drug has contributed to, or is likely to contribute to, the development of resistant strains of 
microorganisms. 
• The mechanism of action of the drug is known but the consequences of widespread use are not adequately 
establ ished. 
• The therapeutic effects of a newly released drug are based on new or unknown mechanisms of action, but 
the cons~uences ofwide~ead use are not a~uate.!.Y. established. 
Schedule II 
• The initial need for a drug is normally identified by the practitioner, in addition chronic, recurrent, or 
subsequent therapy must be monitored by the pharmacist. 
• The drug must be readily available under exceptional circumstances when a prescription is not practical. 
• The drug is intended for administration in a health care setting or under direction of a health care 
professional, or is in an injectable dosage form and is not otherwise included in Schedule I. 
• Evidence of abuse of the drug has been reported, due to its inherent pharmacological action that has the 
potentia l for abuse. 
• The selection of the drug requires intervention by the pharmacist to confirm that an appropriate self-
asse sment has been made by the patient. 
• Use of the drug may delay recognition or mask the symptoms of serious disease . 
• The drug may cause important adverse reactions, including allergies, or interacts with other drugs, foods, 
or disease states that cannot be adequately addressed through product labeling. 
• Use of the drug requires reinforcement or an expansion of the directions for use, through pharmacist -
patient dialogue. 
• The drug is a new ingredient for self-medication and monitoring by the pharmacist is necessary to 
faci li tate observation and reporting of any unexpected event. 
• The maximum labeled dosage directions exceed the generally accepted or usual limits for Schedule Ill 
status. 
Schedule Ill 
• The initial need for a drug is normally identified by the patient, physician, or pharmacist, but chronic, 
recurrent, or subsequent therapy can be monitored by the pharmacist. 
• The maximum recommended duration of use of the drug is limited and specified on the product label. 
• The maximum recommended duration of use of the drug is not specified on the label, but continued use 
may delay recognition or mask the symptoms of serious disease. 
• The drug is used to treat a persistent, chronic or recurring condition and the availability of the pharmacist 
to provide advice can promote appropriate use. 
• The drug is used for self-treatment of self-limiting ailments; however, where product selection has been 
identified as likely to cause patient confusion and the availability of the pharmacist to provide advice can 
promote appropriate use. 
• The drug demonstrates adverse effects, including allergies, or interacts with other drugs, foods, or disease 
states that can be identified in product labeling, but appropriate product selection and explanation of risk 
• 
may require the advice of the pharmacist. 
The drug is a new ingredient for self-selected self-medication and the availability of the pharmacist to 
• 
provide advice can promote appropriate use. 
The drug has inherent pharmacologic action that has the potential for non-medical use that may result in 
adverse patient outcomes. 
• The maximum labeled dosage directions exceed the generally accepted or usual limits for unscheduled 
status. 
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Table 5: Summary of suitable evidence required for justification of a rescheduling 
application submitted to NDPSC review in Australia 
Name of chemical/active constituent Toxicological database 
• Its approved name • Toxicokinetics 
• JUPAC name • Acute studies 
• 
All proprietary, non-proprietary or other names • Lethality or lower toxic dose 
and code numbers . Skin & eye initancy 
. Skin sensitization 
• Corrosivity 
• Repeat dose studies 
. Short term 
. Sub chronic 
. Chronic 
• Reproductive studies 
. Teratogenicity 
. Fertility 
. Peri/postnatal 
• Carcinogenicity 
• Genotoxicity 
• Other 
• Mechanistic 
. Specific organ toxicity 
. Immunotoxicity 
• Neurotoxicity 
• Toxicity of metabolites and 
impurities 
. Human toxicological data 
• Toxicity of mixtures 
• In-vitro studies 
End-use product details Clinical data 
• Distinguishing trade name . Postmarketing reports 
• Formulation type • Adverse drug reaction reports 
• Active constituents and concentration • Additional clinical reports 
• Formulation composition • Epidemiology studies 
• Basic _ph_}'._sical and chemical _Q!"~erties • Poisoni'!S_ r~orts 
Physicochemical properties of the active ingredient Monitoring for public health impact of 
• Structure of the drug or chemical rescheduling decision 
• All relevant chemical and ~ical_Q_r~erties 
Pharmacology Occupational health and safety details (if 
• Structural and pharmacological relationship to applicable) 
other drugs 
• Pharmacokinetic and pharmacodynamic 
profiles 
• Interactions, incompatibilities, side-effects or 
adverse effects 
Toxicology Regulatory status in Australia and overseas 
• Summary of known toxicology of the drug • Approved indications for drugs 
• Summary of known metabolism of the drug • Detailed information relating to the 
• Summary of previous submissions, if applicable classification or regulation of the 
• Relevant details of any published and availability of drug in significant overseas 
unpublished toxicological investigations of the countries (Canada, Sweden, Netherlands, 
dl"I!&_ New Zealand, UK & USA_l 
Statistical ana!J'sis Consumer education _Q_r~ams 
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Table 6: Steps in the regulatory amendment process to de-schedule drugs to 
nonprescription status at the federal level in Canada 
Step 1: Consultation 
Draft of Regulatory Impact Assessment Statement (RIAS) 
• 
• Internal Consultation 
• 
Review and analysis of internal comments 
• 
External consultation _{stakeholders, other manufacturers etcl 
Step 2: Pre-publication in Canada Gazette Part I 
• Review and analysis of external comments 
• 
Preparation of full official Part I package for Canada Gazette. This package includes RIAS, 
approved copies of regulation, memos to the Director General (DG) and the Minister, 
Communications Plan, letter to the Assistant Clerk of the Privy Council and a prepublication 
notice 
• Approval of the proposed regulatory amendment by the DG, Assistant Deputy Minister (ADM), 
Deputy Minister (DM) and Minister 
• Approval by SCC 
• Pre-publication in Canada Gazette Part I 
• Comment Period 
Step 3: Publication in Canada Gazette Part Il 
• Review and analysis of stakeholders' comments from Part I 
• Preparation of a package for publication in Canada Gazette Part II. This package contains the 
RIAS, stamped copies of the regulation and an order, memos to DG and Minister, letter to the 
Assistant Clerk of the Privy Council, a recommendation and a communication plan. 
• Approval by the DG, ADM, DM and Minister 
• Approval by Special Committee of Council 
• Registration 
• Publication in Canada Gazette Part II 
80 
Table 7: Summary of data requirements for a reclassification application in The 
European Union 
Safety 
• 
Summary of animal or human studies showing low general toxicity and no reproductive 
toxicity, genotoxic, carcinogenic properties with the experience/exposure to the product. 
• Post-marketing experience in wide ranging patient population under prescription status for 
preferably five years, or shorter period if active substance has been in use as a foodstuff or 
as a metabolite of a known active substance. 
• Adverse reactions information, experience of use without medical supervision from foreign 
sources, including numbers of patients treated, demographic details, indications for use and 
dose. 
• Safety profile summarized as per EU guidelines, to include: 
• Post-marketing surveillance study reports . 
• Clinical trials and published literature related to safety . 
• Discussion of reactions arising from misuse and unknown reasons . 
• Data extrapolation from the prescription use population to nonprescription use 
population. 
• Potential and consequences of drug interactions with commonly prescribed drugs . 
• Consequences of misuse, abuse or overdose . 
• Consequences of consumer using upon misdiagnosis of symptoms . 
• Consc::ciuences of incorrect or del!l}'ed di~osis of ~m.£!oms related to the..E_roduct. 
Efficacy 
• When application includes changes in indications or posology, otherwise not needed . 
• Justification of a suitable time-period for treatment of the suggested indication(s) . 
• A ..E_r~osed _£._ack size . 
Product information 
• Label and leaflet examined for comprehensive information and effectiveness in protecting 
consumers from any safety hazards (very important) 
• Description of use of the product and circumstances when referral for medical advice is 
appropriate from the label. 
• Compliance of labels with requirements as per Council Directive 92/27/EEC on the 
readability of the label and package leaflet. 
• Contraindications and warnings, such as advice limiting duration of treatment or the need 
to consult a doctor in certain situations. 
Package 
• Discussion of a chang_e of container when applicable to_g_ether with neces~ documentation . 
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Table 8: Classification of proprietary drugs (nonprescription medicines) in Japan 
Cate_s!>f]I__ Descrff!!ion 
Class 1 Drugs which contain active ingredients which have been used neither in 
_E!escription nor in OTCs _(referred to as "New active ingredients'1 
Class 2 Drugs which contain active ingredients, other than "New active ingredients" , which 
have not been used as active ingredients in already approved OTCs (referred to as 
"New non- p_rescrij)_tion i~edients'1 
Class 3 Drugs which consist of active ingredients which have been used in already 
approved OTCs but which have not been used in the therapeutic category in 
question (referred to as "Newly combined ingredients"), and drugs which are 
different from already approved OTCs in the therapeutic category in question in 
terms of combinations of active ingredients, or indications and effects, or 
administration and dosage. (However, drugs in either Classification 4 or 5 and 
dru__g_s which com_£!.Y_ with Approval Standards shall be excluded.}_ 
Class 4 After completion of Post Marketing Surveillance on safety during use of drugs in 
any one of Classifications, 1, 2, and 3 (collectively hereinafter referred to as "New 
non-prescription medicines"), drugs which are applied for approval as drugs 
containing either "New active ingredients" or "New non-prescription ingredients" 
or "Newly combined ingredients" but which have differences in combination of 
active ingredients used in already approved OTCs. The differences correspond to 
the following two cases. However, these drugs shall be limited to those with the 
same administration and dose, and indications and effects as already approved 
OTCs, and with the same or slightly different dose forms from already approved 
OTCs. 
(1) When only active ingredients with pharmacological actions different from those 
of "New active ingredients" , "New non- prescription ingredients" or "Newly 
combined ingredients" are different. 
(2) Where ingredients with different pharmacological actions in the case(!) have 
mild actions with no direct relations to ther'!£_eutic effica~ 
Class 5 Drugs which belong to the therapeutic categories with the Approval Standards and 
only whose dose forms are different from those specified in the Approval 
Standards, and drugs which belong to the therapeutic categories without the 
Approval Standards and only whose dose forms are different from those of the 
already approved OTCs in the therapeutic categories in question (Limited to those 
with ~ecial dose forms}_. 
Class 6 Drugs which conform to the Approval Standards, or drugs which do not fall into 
an_x. one of the Classifications 1 throl!.&_h 5 above. 
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Table 9: Data required for approval of nonprescription drugs in Japan 
Class oj_Drip,_s 
Data required I 2 3 Jillj_s 6 
a b 
A. Data on or!g!n and use in fore!g_n countries 
I . Product ori_g_in and details of discov~ 0 0 0 0 0 0 x 
2. Use in foreig_n countries 0 0 0 0 0 0 x 
3. Product_Eofile and com_E_arison with other dru_g_s 0 0 0 0 0 0 x 
B. Data on j>_h_y_sical and chemicalj>_ro.I>_erties 
1. Determination of chemical structure 0 x x x x x x 
2. P~sical and chemical_E_r~erties 0 x x x x x x 
3. ~ecifications and testi'!& methods 0 0 0 0 0 0 0 
C. Data on stabili~ 
I . Long-term storag_e test 0 x x x x x x 
2. Severe test 0 x x x x x x 
3. Acceleration test x 0 0 0 0 0 0 
D. Data on toxici_ty 
l . Acute toxic~ 0 # # x x x x 
2. Subacute toxici!)'_ 0 # # x x x x 
3. Chronic toxicity 0 x x x x x x 
4. Effects on r~oduction 0 x x x x x x 
5. Dei>_endence # x x x x x x 
6. Antigenici!)', # # x x x x x 
7. Mutag_enici_!Y # x x x x x x 
8. CarcinQg_enici!Y_ # x x x x x x 
9. Local irritation # # # x x x x 
E. Data on j>_harmacol~ical action 
l . Test supportirig effectiveness 0 x x x x x x 
2. Generalj>_harmacol~ 0 x x x x x x 
F. Data on ADME 
I . Abs()J"Qtion 0 # # x x # x 
2. Distribution 0 x x x x x x 
3. Metabolism 0 x x x x x x 
14. Excretion 0 # # x x # x 
5. Bioequivalence x x x x x x x 
G. Data on results of clinical trials 0 0 0 # x x x 
Key to symbols: o=Required #=Depending on the case x=Not required 
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Table 1 O: Description of clinical trial requirements for nonprescription medicines in 
Japan 
Class Descri]J!ion 
Class 1 Clinical trials need to be conducted at more than five medical institutions with more than 150 _£atients 
Clinical trials need to be conducted at more than five medical 
institutions with more than 150 patients 
Note: Clinical data may be reduced to three medical institutions 
Class 2 with 60 patients for those Rx-to-OTC switch drugs whose safety 
and efficacy profile for general use has been well demonstrated by 
clinical investigations or post-market surveillance previously 
conducted. 
Class 3 Clinical trials need to be conducted at more than three medical institutions with more than 60 _J>_atients 
Class 4a Clinical trials may need to be conducted at more than two medical institutions with more than 40 _£atients 
84 
MANUSCRIPT III 
OTC SWITCH CASE HISTORY EVALUATION: NICORETTE® 
85 
Abstract 
As part of the FDA's current review of its regulatory approach to 
nonprescription medicines, it is necessary for stakeholders to contribute to the ongoing 
discourse. Reclassification of prescription medicines to over-the-counter status is an 
important topic attracting the attention of many in the United States and elsewhere. This 
article presents a detailed examination of FD A's application of switch regulatory policy, 
the use of innovative consumer communication and education tools in the OTC 
environment and overall public health impact of the switch using the Nicorette case as 
an example. Post switch evidence shows that OTC reclassification of Nicorette achieved 
the anticipated goal of balancing increased access with decreased control in the OTC 
atmosphere resulting in a positive public health outcome in the area of smoking control. 
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Introduction 
The US Food and Drug Administration (FDA) is currently conducting a 
comprehensive review of its regulation of nonprescription medicines and has asked for 
public comment (1). Hence, interested professionals are closely scrutinizing the FDA's 
application of regulatory policy for reclassification of prescription medicines to over-
the-counter (OTC) status. Accordingly, to appraise a recent and successful OTC switch 
from the perspectives of the regulatory basis and public health impact, the case of 
Nicorette® is useful. The switch of Nicorette® chewing gum, a smoking cessation aid, to 
OTC status by the FDA in 1996 is a unique and important example. This switch is very 
important as it resulted in the availability of the first smoking cessation aid available 
without a prescription for adults in battling nicotine addiction. 
Within the context of studying the application of regulatory policy by the US 
FDA in rendering switch decisions, this case is rather exclusive. The Federal Food, 
Drug & Cosmetic Act requires that prescription control be applied to habit-forming 
drugs as per Sec.503(b)(l). As the addictive properties of nicotine are widely 
documented and acknowledged, the switch of Nicorette (that contains nicotine as active 
ingredient) to OTC status is remarkable (2). Nicorette is distinctive among OTC 
medicines, as it is part of a larger behavioral program that emphasizes individual 
commitment to achieve smoking cessation. The concomitant tools used for effective 
consumer communication employed by the sponsor in this case are also matchless 
within the OTC medicines arena. For these reasons the OTC switch of Nicorette is 
worthy of detailed examination. 
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Background 
Nicotine is a ganglionic cholinergic-receptor agonist (2,3). The pharmacologic 
actions of nicotine are complex and include a variety of effects mediated by 
stereospecific binding to receptors in autonomic ganglia, the adrenal medulla, the 
neuromuscular junction, and the brain. Nicotine exhibits both stimulant and depressant 
effects in the peripheral and central nervous systems. The principal pharmacologic 
effect of small doses of nicotine is initial, transient stimulation of autonomic ganglia; 
large doses or prolonged neuronal receptor exposure to nicotine results in subsequent 
persistent depression of receptor activity. Nicotine produces marked CNS and 
respiratory stimulation. The cardiovascular effects of nicotine generally are dose 
dependent and are mediated principally via stimulation of sympathetic ganglia and the 
adrenal medulla. Chronic use of nicotine may result in psychologic and physical 
dependence, and tolerance to some of the pharmacologic effects may occur. As adjuncts 
in the cessation of cigarette smoking, nicotine polacrilex and transdermal systems of 
nicotine provide alternative sources of nicotine that help reduce the withdrawal 
symptoms associated with nicotine dependence. 
The FDA in January-1984 and June-1992 approved Nicorette 2mg and 
Nicorette 4mg respectively. In December-1994, the sponsor submitted a supplement to 
the new drug application (sNDA) to switch Nicorette from prescription to OTC status. 
A summary of the proposed Nicorette OTC product is presented in table 1. The 
proposed OTC doses and label indications were same as those for the approved 
prescription product. At the time of switch application, Nicorette was available as a 
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prescription product in over 50 countries and as a nonprescription product in over 30 
countries. 
On 28 September-1995, the Nonprescription Drug and Drug Abuse Advisory 
Committees to the US FDA met jointly to consider the OTC switch application for 
Nicorette®. Present on behalf of the Drug Abuse Advisory Committee (DAAC) were 
four members and a consumer representative. The Nonprescription Drug Advisory 
Committee (NDAC) consisted of seven members, one guest member and a 
representative each from the industry and consumers. An analysis of the deliberations 
that took place at this meeting ( 4) is presented in the subsequent sections. The 
objectives are to expound the application of the OTC switch regulatory policy, evaluate 
the regulatory options in rendering the switch decision by the Advisory Committees and 
examine the public health consequences of this switch decision. 
Open hearing 
During the public comment section, Thomas Cooper, D.D.S., C. Everett Koop, 
M.D., Alfred Munzer, M.D. and Rev. Herbert Watson Jr., stated their opinions on this 
matter. Dr. Everett Koop, former Surgeon General speaking on his own as a physician 
and private citizen supported the switch of nicotine gum from prescription to OTC use. 
He said, "! believe one important answer is to make treatments that have been proven to 
be safe and effective in the prescription setting more widely available by shifting them 
to OTC availability. I believe nicotine gum is one of those treatments and I urge to 
consider this switch application favorably. Smokers do want help. And everything that 
we can do safely and prudently to get them that help will speed the day when we will 
truly have a smoke-free society". Dr. Thomas Cooper, a dentist, retired professor, 
89 
smoking-cessation researcher and a smoker for 36 years gave personal testimony on the 
effectiveness of Nicorette in helping him quit nicotine addiction. He also endorsed the 
safety of nicotine gum based on data observed from first hand experience as a 
researcher in the area of smoking control. He urged that easily understood directions for 
proper use are essential and that the benefits of OTC availability of nicotine gum are far 
greater than the risks. Dr Munzer, Co-Director of the Department of Pulmonary 
Medicine at the Washington Adventist Hospital and a past president of the American 
Lung Association said that the reasons for making nicotine replacement therapy 
available OTC are its safety, effectiveness and lack of significant interactions with other 
medications. He added that the most important reason is, "because it answers a major 
public health need". 
Rev. Herbert Watson, Jr. , a pastor in East Baltimore and the board chairperson 
for a program called Heart, Body, and Soul, a cooperative partnership between CURE, a 
ministerial group in East Baltimore and the Johns Hopkins Center for Health 
Promotion, who was instrumental in developing a church based smoking cessation 
program stated his concern about the restrained access for nicotine gum within the 
prescription setting. He emphasized the need for free and convenient access to nicotine 
gum, not only in medically underserved communities, but also across the entire nation. 
He encouraged the panel to make nicotine gum easily available to communities and 
individuals who can use it safely and effectively . 
.S..Oonsor presentation 
The sponsor's presentation to assist the advisory committees in assessing the 
risks and benefits and demonstrate the validity of Nicorette OTC switch can be broadly 
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divided into five parts. An overview of the entire structure of the presentation was 
followed by the epidemiology and treatment of smoking, results of prescription-to-OTC 
switch development program for Nicorette and how they satisfy FDA's switch 
requirements for safety and efficacy, risk-benefit analysis of Nicorette in terms of 
dependence potential, abuse and misuse liability, and, marketing plan for Nicorette, 
accompanying behavioral materials including development of the label for Nicorette 
and how it satisfies the switch requirements for patients to self-select. The types of 
studies conducted and results presented by the sponsor to elucidate each of the 
aforementioned aspects have been tabulated in table 2. Information pertaining only to 
the unique aspects of Nicorette in the context of OTC switches will be elaborated. 
As the proposed OTC product was at the same doses and for the same 
indication as the prescription product and as enormous post-marketing safety data in 
prescription and OTC settings in a variety of regulatory environments was available, 
proving the safety and efficacy for Nicorette 2mg and 4mg in the OTC setting was 
relatively simple. The sponsor demonstrated the safety and efficacy by conducting 
multi-center, simulated OTC actual use studies to replicate the absence of physician 
intervention. The two most remarkable aspects of this OTC switch case are 
demonstration of an acceptable risk in terms of dependence potential, abuse and misuse 
liability and the development of labeling material and consumer communication tools 
that facilitate effective self-selection in the uncontrolled OTC atmosphere. 
The sponsor addressed the issue of long-term dependence by arguing that 
mere long-term use of a medication does not indicate dependence. Additionally, long-
term use must be characterized by compulsive use and impaired control, i.e. the drug 
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comes to control your behavior. So long-term use in and of itself does not necessarily 
mean dependence. Results from the meta-analysis of all the clinical trials that reported 
long-term use showed that 18% of users still used the gum at the end of six months and 
this statistic decreased to about one percent in two years. Among the special subgroup 
of people who quit smoking by using the gum, the percentage using the gum at end of 
six months was 35% and decreased to 3% in two years. Clearly, there was longer than 
directed use observed in all the clinical trials. The reasons that the sponsor listed to 
contend that these results do not represent long-term dependence were as follows: 
(1) In the clinical trials, the nicotine gum was provided free of cost. A study where 
people were randomly assigned to differently priced nicotine gum showed that 
the simple intervention of having to pay for the gum decreased long-term use by 
two thirds. 
(2) Similar users of cocaine and cigarettes upon absence of any intervention showed 
a very small decrease in the proportion of users over a two-year period, relative 
to the fall to 3% with the nicotine gum. 
(3) Further, there was no dose escalation observed among the long-term users with 
the nicotine gum. Also, simple reassurance and education of long-term users 
was adequate to wean them off the nicotine gum. 
( 4) The observed long-term use may be attributed to the fear of falling back into the 
smoking habit having once quit smoking with the nicotine gum and residual 
craving for nicotine upon smoking cessation that takes a long time to be weaned 
off completely. 
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The sponsor contended that the abuse liability associated with Nicorette was minimal 
and acceptable. They asserted that in the context of abuse liability, more important than 
the chemical effects of the drug is the drug delivery device. Upon cigarette smoking, 
nicotine enters the arterial circulation from the pulmonary circulation and goes straight 
to the brain without being diluted with the venous blood leading to high nicotine 
concentrations. With the gum, nicotine is absorbed through the buccal membrane and is 
diluted with the venous blood before entering the brain. Also, inhaling the drug is the 
fastest way to get it to the brain. Hence, the addiction to nicotine via cigarettes is due to 
the very rapid onset of the effect. The sponsor argued that the addiction to nicotine via 
cigarettes is due to the high arterial concentrations, the rapid time to reach the brain, the 
frequency of use and not due to the chemical per se. Also, when the dose of nicotine (as 
cigarettes) was increased and the users were asked to rate their liking for nicotine, the 
liking increased with the dose. With the gum, the response of the users was the opposite 
as craving for nicotine decreased with higher dose. The differences in the responses 
between cigarettes and gum were attributed to the different pharmacokinetic 
characteristics. The potential for abuse by young adults was countered based on the 
following: 
(1) Nicotine chewing gum is difficult to chew and does not taste good (but is 
palatable). 
(2) Drug use among teenagers generally is initiated due to peer-pressure, 
rebelliousness and anti-authoritarianism. Chewing gum is not considered "cool" 
and does not conform to the badge behavior of being "cool" as is the case with 
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alcohol or cigarettes. Also, increased doses with the nicotine chewing gum do 
not lead to faster onset of action, but only increased nausea. 
Based on this rationale of the benefits arising from increased access, especially for 
young adults and medically underserved, and the minimal risks of long-term 
dependence and abuse liability due to the benign pharmacokinetics of the nicotine 
chewing gum, the sponsor urged the Advisory Committees to favorably consider their 
OTC switch application. 
The labeling for OTC Nicorette was developed based on labeling 
comprehension studies and was suitable for sixth to seventh grade reading 
comprehension levels. The marketing plan and associated consumer communication 
methods proposed for OTC Nicorette were exceptional by any measure. The sponsor 
claimed that its objective is to help Americans quit smoking and become Nicotine free. 
Their two-fold strategy was to very carefully manage the expectations for the OTC 
product and develop a marketing plan to balance control with the greater access of the 
OTC product. The Nicorette target consumer was that smoker who has successfully 
crossed the stages of thinking about quitting, firming up their determination to quit and 
is ready to take action. The sponsor termed such smokers as "Committed Quitters" and 
did not wish to speak to smokers in the evolutionary stages before the committed quitter 
stage in their programs and marketing. The sponsor's advertising plan positioned OTC 
Nicorette as an aid that can help quit smoking as opposed to a magic bullet. Further, 
Nicorette OTC product was only one part of the complete package that would consist of 
a user's guide, an audiotape and a number of program elements that are motivational 
and can influence the individual's behavioral patterns and ability to successfully quit. 
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The sponsor developed a program called the Committed Quitters (CQ) 
program. The program becomes apparent immediately upon opening the package and 
contains an 800 number encouraging the individual to call and enroll in a support 
program. Upon calling the 800 number, the individual is interviewed to clarify the 
reasons for their decision to quit and informed of the barriers they need to overcome to 
successfully quit. Subsequently, a personalized user's guide calendar is put together for 
the individual with the reasons driving their decision to quit and the barriers they could 
not overcome in the past. Following initial enrollment in the CQ program, there are 
about five interventions to help keep the individual from relapsing into smoking. If the 
individual was chewing too many pieces of gum than recommended, there were also 
programs that assisted them to wean off the gum, another 800 number is provided to 
call and talk to a counselor who can assist the individual in weaning off the gum or who 
has relapsed into smoking. The CQ program of which Nicorette OTC product was only 
one part, was an active and interactive program for not only helping individuals as a 
behavioral program but also assist those who have relapsed to smoking. 
In terms of merchandising activities, the product would be priced above the 
impulse level, it would not be sold in vending machines, no free samples would be 
distributed even to physicians, it would be part of a theft deterrence program and would 
be sold only to individuals above over 18 years of age. The sponsor also declared that 
they were working with many insurance companies to urge them to cover this OTC 
product and said that most insurers agreed to do so. In terms of cultural barriers, stores 
in predominantly Spanish speaking communities would be provided with special 800 
numbers and all the educational material would be in Spanish. As the proposed OTC 
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product was relatively expensive, the sponsor had convened an independent advisory 
panel to propose strategies for developing an outreach program for the medically 
underserved areas and increasing their access to OTC Nicorette. The sponsor also 
proposed the use of an exhaustive post-marketing surveillance program for OTC 
Nicorette. As detailed here, the sponsor developed a comprehensive behavioral 
program, pioneered the use of communication tools such as toll free numbers, audio 
tapes and counselors to achieve effective consumer education, voluntarily committed to 
numerous restrictions, clearly defined their target consumer and market positioning of 
the OTC product, addressed the special needs of medically under served and ethnically 
diverse communities and proposed a comprehensive post-marketing surveillance 
program to balance control and increased access within the OTC setting. An 
examination of the OTC medicines arena will clearly distinguish these aspects of OTC 
Nicorette making it a unique and exclusive OTC switch. 
FDA presentation 
FDA focused on the methodology and results from labeling studies submitted 
by the sponsor. The main concerns expressed in this area were: 
(I) The sponsor conducted labeling studies based on the assumption that the intent 
to heed (observing the directions) the label was a direct indicator of 
comprehension (obeying the directions) when compared with the same for an 
existing OTC product (as control). This assumption was not justified based on 
results presented for self-selection of right dose (based on number of cigarettes 
smoked), the decision not to use Nicorette by patients who had cardiovascular 
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conditions or were pregnant, as subjects understood the label directions but did 
not obey them. 
(2) During the process of refining the label content, evaluative questions for the 
subjects were phrased and iterated in such a manner to inevitably lead to the 
desired response. Also, details of demographics were not presented to 
understand the nature of the subject population. Questioning was leading and 
did not delve into the attitudes and motivations that affect the actual behavior. 
(3) Study methodology and design of questionnaire make it difficult to rely on the 
results. They do not demonstrate with reasonable confidence that patients who 
are directed to see a doctor first may do so at a high rate despite the warnings. 
The following were comments on the results from two quit rate studies in the 
prescription setting. 
(1) Participants in clinical trials such as those for the NDA are different from 
consumers in the general OTC population and quit rates may not be 
representative of the actual results that may be expected in an OTC setting. 
(2) The demographic distribution of the study samples also may not be as 
representative of the smoking population who may elect to use the OTC 
smoking cessation product. 
Commenting on the issue of abuse and dependence, the FDA reviewer summarized that 
most long-term use is seen in quitters than in non-quitters, who represent the positive 
outcome. Continued use declines for Nicorette gum generally after six months to one 
year and there are very few reports at two years. 
97 
Regulatory options 
FDA informed the committees and the sponsor that to approve an OTC switch, 
it is essential that the following two conditions be met: 
(1) The product is safe and effective under conditions of self-medication when used 
as directed in the proposed label. 
(2) The availability of the product in the OTC environment is of acceptable risk. 
Additionally, the law states in this context that neither the toxicity of the drug, 
the method of use, or any other potential harmful effect of the product 
necessitate that the product remain prescription only. 
These conditions offered the committees the criterion by which they were to 
judge the suitability of Nicorette as an OTC medicine under the sponsor's plan. The 
FDA officer stated that the Agency received numerous requests to address the issue of 
pediatric access to therapeutic OTC nicotine upon publication of this meeting in the 
Federal Register. The committees were requested to phrase their recommendations 
solely in terms of what the Agency should accomplish. The committees were asked to 
describe their recommendations in terms of the objective to be reached and not in terms 
of specific means of accomplishment. Also, any recommendation to restrict the OTC 
access to Nicorette will have to be subject to careful review and potential modification 
by the Agency. The list of specific questions related to the proposed Nicorette OTC 
switch, upon which the committees had to vote was also made available for discussion. 
This list of questions is presented in table 3. 
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Committee discussion 
Over the topic of safety and efficacy, concern was expressed on adverse 
effects related to Nicorette use in conjunction with smoking. The clinical data from 
OTC use trials, original submission and post-marketing surveillance showed that 
Nicorette was frequently used in combination with smoking, but there was no evidence 
of any undue risk associated with this behavior. Also, it was suggested that the labeling 
for both proposed OTC doses be indistinguishable and must reinforce the augmented 
success with participation in a full behavioral/support program as opposed to just 
chewing the gum. The sponsor was asked if there was a recommended time at which 
users should restart the program, if they were not successful in quitting on first attempt. 
The sponsor replied that there was no such recommendation being made. The issue of 
the product being efficacious for adolescents (12 to 18 years) if purchased by a 
responsible party and used under their supervision and pregnant women was raised. The 
sponsor responded that while their clinical trials do not support any such conclusions, 
there was empirical evidence that the product was effective in adolescents and a better 
alternative than cigarettes for pregnant women. There was strong consensus that the 
efficacy in the 12 to 18 year population needed to be studied. The committees' vote on 
safety and efficacy ofNicorette in the OTC environment was unanimous in consent. 
On question two (need for learned intermediary in special populations) posed 
to the committees, it was concluded that adolescents, pregnant women and individuals 
with coronary artery disease might require special physician intervention. During 
discussion a committee member raised the consequences of making the product OTC in 
terms of reimbursement. Specifically, the committees were concerned that the access to 
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the OTC product may be diminished due to lack of reimbursement if the prescription 
product is eliminated. Under present law, it is not possible to classify the same product 
for the same indications at the same dose simultaneously as OTC and prescription 
products. Hence, the FDA was urged to retain both prescription and OTC 
classifications. Also, the sponsor reassured that they would be working with managed 
care organizations to make the coverage universal and they were in the process of 
developing a pilot program to identify strategies that would help increase affordability 
of the product especially to medically under served and poor section parts of our 
population. The committees did not express any apprehension for misuse or abuse with 
the exception of individuals chewing the gum longer than directed. However, that was 
considered a positive cost benefit ratio provided the total tobacco consumption is cut 
down. Also, the Canadian experience with the 2mg product, where it was OTC since 
1993, reinforced the consensus that there was no serious risk of abuse. 
Addressing the issue of special protection against abuse by children, the 
committee strongly recommended the need for the Agency to take active steps in 
examining the usefulness of nicotine replacement therapies in populations that are 
beginning to use tobacco. The committees did not regard children as a potential source 
of abuse for this product, but they were very concerned that the product was not 
designed to assist children in smoking cessation due to lack of studies and urged the 
FDA to devise solutions for this problem. The question related to efficacy claim based 
on numerical quit rates is specific to the Nicorette case as the medication is part of a 
larger behavioral program. Further, depending on the patients and the kind of 
concomitant behavioral therapy they received, the quit rates vary form less than one 
100 
percent to over eighty percent. In order to manage the consumer expectations within a 
clinically realistic domain and prevent a numbers war between sponsors based on 
claims of effectiveness, this question was posed to the committees. The committees 
strongly endorsed phraseology that would positively reinforce the consumer's 
determination to quit without exaggerating the level of success. They urged that that 
label refrain from any numerical characterization of quit rates and emphasize relief from 
withdrawal symptoms (to assist in quitting) and participation in a concomitant 
behavioral program. 
An additional question that was also discussed by the committees was on the 
subject of warnings related to concomitant medications. Specifically the question was, 
is there a need to have specific warnings about theophylline and antidepressants or is a 
general warning about prescriptive medications adequate? On this question the 
committees arrived at the consensus that warnings on the label be general and broad in 
nature against all prescription medicines and suggested that the label be subject for 
review and change if evidence is found that such an action is necessary. 
Post committee meeting 
Based on the recommendations of the joint advisory panel, FDA approved 
OTC status for Nicorette in both 2mg and 4mg strengths on 12 February-1996. In a 
related talk paper, FDA stated that almost half of those who use Nicorette are able to 
stop smoking for at least a few days, but many start smoking again. FDA also said that 
most smokers must try to quit several times before they completely stop. Evidence also 
suggests that the OTC availability of Nicorette led to an overall positive public health 
impact by promoting cessation. A report published by the Center for Disease Control 
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and Prevention in 1997 concluded that the OTC availability of nicotine medications 
encouraged smoking cessation activity (5). Additionally, results of a study evaluating 
the use of FDA approved pharmacologic treatments for tobacco dependence in the 
United States between 1984 and 1998 published in 2000 indicated that the availability 
of OTC products increased pharmacologically assisted quit attempts (6). The estimated 
number of quit attempts ranging from 2 to 3 million during 1993-1995 increased to 
approximately 6 million in 1996, coinciding with the availability of nicotine gum as an 
OTC product. Also, the number of average monthly estimated quit attempts was 
642,000 during May 1996-May 1997 when nicotine gum became available OTC, 
compared with 259,000 during January 1993-April 1996. 
Conclusion 
This OTC switch demonstrates that the sponsor employed innovative 
consumer education and communication tools, pioneered the development of 
concomitant behavioral support programs and emphasized the enormous public health 
benefit of OTC Nicorette in successfully obtaining OTC status for a habit forming drug 
substance. Post switch evidence shows that OTC reclassification of Nicorette achieved 
the anticipated goal of balancing increased access with decreased control in the OTC 
atmosphere. It may be concluded that sponsors of OTC switch applications must devise 
creative methods to balance the risk associated with increased access in an OTC 
environment to maximize the overall public health benefit and effectively switch 
prescription drugs to OTC status. 
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Table 1: Description of proposed OTC Nicorette® product 
Name Nicorette~chewing gum formulation 
Active Nicotine from nicotine polacrilex 
ingredient 
Dose 2mg for smokers under 25 cigarettes a day and 4mg for smokers 
over 24 cigarettes a day 
Action Stop smoking aid 
Use To reduce withdrawal symptoms, including nicotine craving, 
associated with quitting smoking 
Program Committed Quitters program: 
• Six month duration 
• Toll free numbers for behavioral support and counseling 
• User's guide, audio tape and calendars 
• Starter kit of 108 pieces for 12 weeks, followed by refill pack 
of 48 pieces 
• Emphasizes the importance of "individual commitment" in 
successful quitting 
• Manages consumer expectations in a realistic manner 
Restrictions • Not for sale to those under 18 years of age 
• Proof of age required 
• Not to be sold in vending machines 
104 
Table 2: Summary of types of studies and information presented by the sponsor 
Epidemiology, treatment and behavior associated with smoking 
• Mortality due to cigarette smoking and public health significance 
• Initiation of teenage smoking and difficulty in quitting without treatment 
• Rationale for nicotine replacement in smoking cessation 
• Effectiveness and success of nicotine replacement in conjunction with behavioral support in 
smoking cessation 
• Evidence demonstrating smoker attitudes favoring "free access" in smoking cessation 
Safety and efficacy ofNicorette in the OTC environment 
• Two 12 week long studies conducted to prove safety and efficacy in an OTC setting 
• One follow-up study to the above two studies was conducted at 6 and 12 month intervals 
upon initiation of treatment to evaluate extensive treatment 
• Two studies were conducted to evaluate effectiveness in the prescription setting 
• Post-marketing safety data collected since the initial marketing ofNicorette 
Risk-benefit assessment of making Nicorette available OTC 
• Higher cessation rates due to OTC availability ofNicorette 
• Prevention of tobacco related mortality due to OTC status 
• Dependence, abuse liability and misuse data from several sources 
Development of labeling 
• Label comprehension studies 
• Additional components of marketing plan 
• Behavioral support and program 
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Table 3: List of questions presented to the Advisory Committees for voting by the FDA 
in relation to the proposed Nicorette OTC switch 
Number Question 
1 Is there evidence to demonstrate that the product is safe and effective 
through self-medication, when used as directed? This question was 
posed for both the proposed 2mg and 4 mg OTC doses. 
2 Are there some consumers who should use this product under the 
direction of the physician or under the supervision of a physician? 
3 Is there a risk of misuse or abuse of this product in the OTC 
environment? 
4 Should the Agency take appropriate measures to protect the misuse 
or abuse of this product by children and adolescents? 
5 Should the sponsor's efficacy claim be based on numerical quit rate 
or a general statement indicating that the product is effective in 
relieving withdrawal symptoms and of benefit in smoking cessation? 
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MANUSCRIPT IV 
OTC SWITCH CASE HISTORY EVALUATION: METAPROTERENOL 
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Abstract 
Globally, due to increasing use of nonprescription medicines, the associated 
regulatory aspects are receiving close attention and scrutiny. The US Food and Drug 
Administration (FDA) is presently conducting a comprehensive review of its regulatory 
approach to nonprescription medicines. The FDA has asked if the Agency should itself 
initiate prescription to over-the-counter switches. A response is presented through the 
analysis of FDA's unsuccessful attempt, upon its own initiative, to switch 
metaproterenol sulfate and the lessons derived from this unique switch case. Also, 
certain important switch issues scheduled to be debated at an unprecedented joint 
advisory committee meeting convened to consider a citizen switch petition in May 
2001 , are addressed in this article. It is concluded that FDA is encouraged to initiate 
switch proposals, but refrain from doing so unilaterally, and properly manage the 
process of considering its switch proposals to ensure active participation of all 
stakeholders. 
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Introduction 
Growing global interest in self-medication and related economic benefits 
accentuate the importance of and necessity for a regulatory framework developed on the 
basis of sound scientific principles. The US Food and Drug Administration (FDA) 
recently announced a public hearing to evaluate the Agency's approach to regulating 
over-the-counter (OTC) drug products (1). The purpose of the hearing was to solicit 
information from, and the views of, interested persons, including scientists, professional 
groups, and consumers. One specific question that the Agency posed in this context is: 
should FDA be more active in initiating switches of prescription products to OTC use? 
In the development of an objective response to this question, it is helpful to 
review and evaluate the well-known incident of the metaproterenol switch, when FDA 
upon its own initiative allowed OTC marketing of metaproterenol and later had to 
rescind on its decision. In the historical context of examining the application of FD A's 
OTC switch policy, the metaproterenol case is unique and offers important lessons. 
Hence, a detailed examination of the metaproterenol case history is of enormous 
instructional value. 
Background 
In 1972, FDA initiated OTC drug review and rulemaking as to the classification 
of OTC products as safe, effective and not misbranded. Initially, FDA established an 
advisory panel for each of the twenty-six OTC therapeutic categories. After each 
advisory panel completed its work, FDA published its Report and Proposed 
Monograph, allowing a ninety-day comment period. After reviewing these comments 
FDA published a tentative final monograph (TFM), allowing an additional thirty-day 
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period for comments or request for oral hearing before the Commissioner, after which it 
published a Final Monograph (FM) for the particular OTC product class. 
Metaproterenol was first approved for marketing as a prescription 
bronchodilator under an NDA in 1973. As part of the OTC review, the Advisory Panel 
on OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products presented 
its report to the FDA that was published in 1976 (2). This panel's report did not contain 
any discussion pertaining to metaproterenol as no one presented any data or information 
for its OTC use. 
In October-1982 the FDA issued a notice of proposed rulemaking in the form of a TFM 
for OTC bronchodilator drug products (3). In this TFM, FDA on its own initiative 
included metaproterenol sulfate as eligible for OTC use although the advisory panel had 
not examined its suitability for OTC use. As per the prevailing enforcement policy 
mechanism, two pharmaceutical manufacturers began interim OTC marketing of 
metaproterenol upon publication of the TFM and while awaiting the final monograph. 
The controversy 
Shortly after the OTC marketing of metaproterenol began, FDA started 
receiving the first of many letters questioning the Agency's decision to allow 
metaproterenol to be marketed OTC. The letters criticized, the decision to allow OTC 
marketing, not notifying the professional community in advance and the Agency's 
failure to await comment, or seek the advice of its Pulmonary-Allergy Drugs Advisory 
Committee (P ADAC). 
Specifically, some of the critical comments received by the FDA were: 
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1. Recognized experts in the area of allergy treatment either disagreed or were 
divided in opinion over the safety of metaproterenol under OTC conditions. 
2. Pediatricians expressed concern over the potential misuse of OTC 
metaproterenol by children. Potential for misuse of OTC metaproterenol by 
asthmatics seeking more relief by exceeding the dose instructions on the OTC 
label. 
3. As metaproterenol has a longer elimination half-life than epinephrine (another 
drug used for similar conditions and was available OTC for a long time) the 
drug could mask the symptoms of a serious asthma attack deterring persons in 
need of immediate medical attention. 
4. As metaproterenol had a longer onset of action, patients may overuse than the 
recommended dosage under the mistaken belief that they are not obtaining the 
expected relief at the suggested dosage. 
5. There was unsatisfactory experience with OTC metaproterenol in other 
countries. Although the drug remained OTC in some countries, Great Britain 
had reverted the OTC status of metaproterenol sulfate inhalers and other similar 
aerosol bronchodilators containing isoproterenol to prescription status on the 
basis of misuse or improper use of such products that led to increased mortality 
among asthmatics in the mid 1960s. 
Resolution of controversy 
In response to these criticisms, FDA arranged a meeting of its P ADAC to 
discuss the OTC status for metaproterenol. After the P ADAC heard presentations from 
the proponents, principal critics, FDA staff and the manufacturers who were marketing 
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OTC metaproterenol on an interim basis, and based on its own deliberations, the 
committee recommended to FDA that it rescind its decision to permit OTC marketing 
of metaproterenol by a vote of 4 to 3. 
FDA response 
Following the recommendation of its PADAC, FDA published in the Federal 
Register on 3 June-1983 that it has concluded that it should accept the advisory 
committee's recommendation (4). FDA stated that it reached such conclusion based on: 
1. Reservations within the medical community about whether metaproterenol 
sulfate metered dose inhalers can be safely marketed without the safeguard of a 
prescription limitation and professional supervision of the drug's use in 
asthmatics. FDA intended to more fully consider such reservations before it 
could allow metaproterenol to be marketed OTC. 
2. The procedure by which metaproterenol was permitted to enter the marketplace 
as an OTC product led to unintended confusion and controversy that, if allowed 
to continue may, disrupt the relationship between physicians and their patients 
and produce unnecessary anxiety among asthma sufferers seeking relief from 
their symptoms through OTC therapy. 
In order to further clarify the Agency's positions on this matter, FDA elaborated its 
opinion on the safety of OTC metaproterenol and the regulatory mechanism by which it 
was switched. FDA stated that the decision to switch metaproterenol to OTC status was 
made in the context of an OTC bronchodilator market in which the only metered dose 
inhaler products available were epinephrine preparations that the Agency believed to be 
no safer or less effective than metaproterenol sulfate. FDA asserted that despite the 
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advisory committee's recommendation to rescind, it continued to believe that a careful 
weighing of the risks and benefits supports the proposal that metaproterenol sulfate 
should be made available without prescription. On the concern that patients may not 
follow carefully the label directions, FDA believed that asthmatic sufferers are capable 
of understanding and heeding instructions for safe use of OTC metaproterenol. In 
relation to potential for abuse by children, the Agency thought that essentially the same 
potential existed for children using the product without parental supervision whether the 
product was sold on prescription or OTC. Nevertheless, the Agency was committed to 
respect the judgment of the specialists in the field who believed OTC metaproterenol 
posed a public health risk and consequently decided to disallow the OTC marketing of 
metaproterenol sulfate metered dose inhalers until the safety issues were resolved. 
The Agency also explained its interpretation of the regulatory mechanism based on 
which OTC sale of metaproterenol was allowed. The enforcement policy to include an 
opportunity for FDA review for prescription to OTC switches before they occurred was 
issued in 1975 and codified as 21 CFR 330.13 after allowing public comment. The 
enforcement policy was later amended in 1982 (47 Federal Register, 17738, 23 April 
1982) to permit a prescription drug to be marketed OTC if the drug is classified by an 
OTC advisory panel in Category I (category of drugs that were found to be suitable for 
OTC use as per the OTC Drug Review process). Also, a prescription drug may be 
marketed OTC if FDA subsequently concludes that a drug not classified by an advisory 
panel in Category I later tentatively qualifies for classification in Category I and so 
states in a Federal Register announcement. 
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FDA stated that the enforcement policy of 21 CFR 330.13 describes both a general 
principle and a specific procedure. The specific procedure relates to drugs originally 
considered by an advisory review panel. The general principle is that a prescription 
product can be marketed OTC if it is included in the OTC Drug Review and FDA 
tentatively concludes that it qualifies for Category I. The Agency reasoned that it 
allowed interim marketing of OTC metaproterenol based on the general principle 
underlying the enforcement policy of 21 CFR 330.13, although an advisory panel did 
not consider this drug in its deliberation. In retrospect, due to the enormous public 
criticism that this switch decision generated, the Agency conceded "the use of the 
enforcement policy to allow interim marketing of metaproterenol sulfate metered dose 
inhaler was inappropriate". 
Discussion 
Based on the metaproterenol expenence, it is possible to respond to FDA's 
question stated at the outset of this article. This discussion of what FDA's regulatory 
policy should be, on switching prescription products to OTC status, unilaterally, without 
the support of sponsors is very timely, as FDA has decided to bring a citizen petition 
seeking OTC status before a joint meeting of its advisory committees. The Agency's 
P ADAC and Nonprescription Drugs Advisory Committee (NDAC) met in an open 
public hearing on 11 May, 2001 to consider a citizen petition submitted to request the 
switch of fexofenadine hydrochloride, loratadine and cetirizine hydrochloride (three low 
and non-sedating antihistamine drugs) to OTC status (5). This response also addresses 
some important questions to be debated at this "unprecedented" joint advisory 
committee meeting (6). 
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Under the current regulatory framework the FDA can initiate a prescription to 
OTC switch based on two separate mechanisms, 21 CFR 330.13 which is part of the 
OTC monograph procedures or 21 CFR 310.200 known as the switch regulation. 
Although, the metaproterenol case was not based on the switch regulation (21 CFR 
310.200) the key instructional principles from this controversy may be applicable to 
both circumstances. 
From the metaproterenol case, it is abundantly clear that the primary cause for 
controversy was the lack of adequate notice and opportunity for comment, to all 
interested parties that would be affected by the switch proposal. It is informative to note 
that although FDA published its proposal to switch metaproterenol to OTC status as a 
TFM in the Federal Register, the Agency did not receive much comment on this matter 
except for two manufacturers who stated their intention to market this OTC product. 
However, the criticism against the switch proposal mounted rapidly once the interim 
OTC marketing of the product began. This clearly demonstrates that the proposed 
rulemaking published in the Federal Register as a TFM failed to reach to all 
stakeholders interested in this switch proposal. It may be reasoned that a forum such as 
a public advisory panel review meeting would have been more successful in facilitating 
effective participation from all interested stakeholders. In fact, FDA's statements in 
explaining its actions buttress this reasoning. The Agency stated that, "Not only would 
the panel's deliberation afford notice that a "switch" of an ingredient was under 
consideration but those who might object to the switch could convey their concerns to 
the panel. Finally, any prescription drug converted to OTC status after initial 
consideration by an advisory panel was necessarily reviewed by outside experts (i.e., 
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the panel members), in addition to medical staff, before any conversion was allowed to 
take place". 
Based on, the growing societal preferences for self-medication, the experiences 
with medically safe and economically beneficial practice of responsible self-medication 
since the OTC Drug Review and the learning from the metaproterenol case, the FDA is 
encouraged to initiate switch proposals that it considers to be safe and effective in an 
OTC environment and offer overall public health benefit. But, the Agency, in the 
absence of support from the sponsor, must refrain from unilaterally switching 
prescription medicines to OTC status except under the very rare circumstances of 
overwhelmingly dire public health necessity. The Agency must switch medicines to 
OTC status by ensuring active participation from all interested parties such as the 
scientific, medical, pharmacist, industry, public and consumer interest communities in 
the evaluation of its switch proposals and before reaching a decision to allow OTC 
marketing. The metaproterenol case proves that the FDA could have enormously 
benefited in its decision making, if it was aware of the rationale on which opposing 
groups thought that metaproterenol was not suitable for OTC marketing and objected to 
its switch. Regardless of the enforcement mechanism (OTC monograph or switch 
regulation) the Agency must achieve effective participation of all stakeholders in an 
open and transparent manner before reaching a final decision to allow OTC marketing. 
Conclusion 
The case of metaproterenol OTC switch by the FDA upon its own initiative 
offers valuable information in the comprehension of FD A's application of OTC switch 
regulatory policy. The FDA is encouraged to initiate switch proposals that it considers 
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to be safe and effective in an OTC environment and offer overall public health benefit. 
The learning from the failed metaproterenol switch demonstrates that a collaborative 
effort with the sponsor and all interested parties is more likely to result in a 
scientifically robust switch decision. Hence, the Agency must properly manage the 
consideration of switch proposals that it has initiated by ensuring active participation of 
all possible stakeholders that may be impacted by its rulemaking. 
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MANUSCRIPT V 
EV ALU A TI ON OF PROPOSED OTC SWITCH FOR LOV AST A TIN 
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Abstract 
Heart disease is a major cause of mortality among Americans, and the risk factor 
of cholesterol elevation is well recognized. Making effective drug therapy more readily 
available to consumers could facilitate improvements in managing this very costly 
problem. Thus, it has been suggested that making antihyperlipidemic products available 
over-the-counter (OTC) may contribute a solution. The goal of this article is to describe 
and evaluate clinical data presented as evidence in determining the benefit to risk ratio 
of lovastatin in the OTC setting and draw pertinent inferences from this switch case. 
Based on the lovastatin switch experience, it may be reasoned that for drugs used for 
chronic illnesses, that require the involvement of a learned intermediary, it may be 
feasible to favorably balance the benefit to risk by classifying them under an 
intermediate, pharmacist controlled class of drugs, where a physician's prescription is 
not required. 
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Introduction 
Heart disease is a major cause of mortality among Americans, and the risk factor 
of cholesterol elevation is well recognized. Hyperlipidemia affects 50 million 
Americans and the first approach to lowering cholesterol levels is through lifestyle 
changes. However, most patients are unable to sustain such lifestyle changes over the 
long term. Making effective drug therapy more readily available to consumers could 
facilitate improvements in managing this very costly problem. Thus, it has been 
suggested that making antihyperlipidemic products available over-the-counter (OTC) 
may contribute a solution. 
Attempts to switch two antihyperlipidemic products from the "statins class" of 
drugs to OTC status in the United States were made in 2000. One such product was 
lovastatin (Mevacor®). The goal of this article is to describe and evaluate clinical data 
presented as evidence in determining the benefit to risk ratio of lovastatin in the OTC 
setting and draw pertinent inferences from this switch case. The Mevacor® switch case 
is exceptional and offers key lessons related to application of US Food and Drug 
Administration's (FDA) OTC switch policy. A detailed review of the Mevacor case 
history is central to comprehending the current positions of interested parties and FDA's 
opinion, on switching products to OTC status for chronic illnesses such as 
hypercholesterolemia. 
Background 
Lovastatin (Mevacor®) has been marketed in the United States since 1987 as a 
prescription drug, at doses of 1 O mg a day to 80 mg a day. It is indicated for use as an 
adjunct to diet for the reduction of elevated total and LDL cholesterol (TC and LDL-C) 
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in patients with primary hypercholesterolemia, when the response to diet restricted in 
saturated fats and cholesterol and, to other nonpharmacological measures alone has 
been inadequate. It is also indicated to slow the progression of coronary atherosclerosis 
in patients with coronary heart disease (CHD), as part of a treatment strategy to lower 
TC and LDL-C to target levels. 
The manufacturer of Mevacor presented to the FDA, a switch application 
describing their rationale for OTC access to lovastatin at 10 mg a day (1 ) . The sponsor's 
target population consisted of individuals (men over the age of 40 and postmenopausal 
women) without CHD. The issue of OTCness of cholesterol-lowering drugs was 
addressed previously at two meetings of joint advisory committees to the FDA in 1995 
and 1997, when an application for the OTC switch of Questran® (a prescription product 
that contains cbolestyramine resin, which is a bile acid sequestrant antilipemic agent) 
was discussed and refused. Following the 1997 meeting, FDA published a guidance 
document indicating that hypercholesterolemia was not an OTC indication (2). The 
guidance concluded that irrespective of the intrinsic safety and efficacy of the drugs 
targeting this disease, hypercholesterolemia per se, was not an OTC disease. It also 
stated that healthcare practitioner supervision was necessary in diagnosis, 
individualization of treatment, and in follow-up, and that safe and effective use of drugs 
in this area and the overall treatment of the disease could be assured only within the 
context of prescription access. 
Against this background, the Agency convened a joint meeting of its 
Nonprescription Drug Advisory Committee (NDAC) and Endocrine and Metabolic 
Advisory Committee (EMAC) on 13 July 2000 to consider this switch application and 
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address the ''precedent-setting issues" raised by the OTC Mevacor petition (3). 
Open hearing 
Several interested parties strongly endorsed the proposed OTC status for 
lovastatin during the open hearing (4). Dr. Ernest Madu, Cardiologist and Assistant 
Professor at Vanderbilt University speaking on behalf of the Association of Black 
Cardiologists, Dr. Rene Rodriguez, an orthopedic surgeon and President of an 
organization of Hispanic physicians, Dr. Debra Judelson, an internist, cardiologist and a 
past president of the American Medical Women's Association, Suzie Hughes, a nurse 
clinician in the Department of Preventive Cardiology at the Cleveland Clinic 
Foundation, representing the Board of Directors of the Preventive Cardiovascular 
Nurses Association, Dr. John A. Gans, Vice President of the American Pharmaceutical 
Association, Dr. Penny Kris Etherton, a distinguished professor of Nutrition at Penn 
State University and a member of the second Adult Treatment Panel of the National 
Cholesterol Education Program (NCEP-ATP 11), Brett Kay of the National Consumers 
League, Dr. Bernie Kasten, Vice President and Chief Medical Officer of Quest 
Diagnostics Ventures and a pathologist, Mr. Warren Pinckert of Cholestech 
Corporation, a company that manufactures a point-of-care clinical instrument and has a 
national testing service, Dr. Tom Pearson, Chair of the Department of Community and 
Preventative Medicine at the University of Rochester, made statements supporting the 
proposed OTC switch. In summary, these groups based their endorsement on, the 
serious need to increase access to medicines to eliminate risk factors for cardiac 
diseases, the established safety and efficacy profile of lovastatin, surging interest for 
patient involvement in pharmacotherapy, the availability of technology to rapidly and 
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easily obtain cholesterol levels by the public, to offer new pharmacological 
interventions for minorities and medically underserved communities who are at greater 
risk for cardiac diseases and to make available proven medicines beneficial to the 
general public who are increasingly using unproven and untested products in the form 
of dietary supplements and other traditional medicines for cholesterol lowering. 
Dr. Sidney Wolfe of Public Citizen's Health Research Group strongly opposed the 
proposed switch. The basis for this conflicting view was, serious questions about the 
accuracy of several home diagnostic kits for cholesterol testing because of the 
inexperience of the user; serious problems in self-selection which would not likely be 
detected in the real world relative to experimental world where people screen 
themselves, often without a cholesterol test and decide to use the drug; lack of evidence 
of cholesterol reduction in any group with a 10-milligram dose and with a 20 to 40-
milligram dose the lack of clinical benefit for cases with HDL cholesterol (HDL-C) 
over 40; diet and exercise may be thought to be less important if the primary strategy is 
an OTC statin drug; excessive drug interactions associated with lovastatin and an 
unacceptable benefit-to-risk ratio. 
Sponsor presentation 
The sponsor stated that OTC lovastatin targets use for primary prevention in a 
population that was generally not recommended for treatment under NCEP-ATP II 
guidelines. Specifically, the nonprescription lovastatin treatment population was defined 
as being men aged 40 and older, and postrnenopausal women (at least 1 year past last 
menses), without CHD and with TC of 200 to 240 mg/dL and LDL-C ~130 mg/dL (5) . 
On this basis, the sponsor estimated that there are approximately 15.5 million men and 
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women potentially eligible to choose self-treatment with nonprescription lovastatin in 
the United States. 
The sponsor justified its request for OTC Mevacor based on: (1) existing 
guidelines for cholesterol-lowering treatment conserved pharmacological treatment only 
for those at highest risk for CHD (2) a substantial proportion of CHD events occur in 
men and women with average TC who were generally not recommended by existing 
guidelines for prescription cholesterol-lowering treatment, and (3) for motivated men 
and women in the OTC-eligible population, access to the nonprescription lovastatin 
treatment program of drug therapy and extensive education and support would provide 
an effective new option for lowering cholesterol and maintaining cardiovascular health 
(6). 
Efficacy 
The benefit of treatment with lovastatin 10 mg daily m the defined OTC 
population was demonstrated using these approaches (7): 
• Observing the effect on lipid parameters associated with CHD risk (i.e., TC, LDL-
C, HDL-C and ratio of TC/HDL-C). 
• Observing the percentage of OTC eligible men and women who attain desirable 
levels of TC and LDL-C as defined in NCEP ATP-II guidelines. 
• Estimating the effect on reduction of first acute CHD events (defined as fatal or 
nonfatal myocardial infarction (Ml), unstable angina or sudden cardiac death) in the 
OTC-eligible population. 
Results were based on four studies that specifically measured the lipid-modifying 
efficacy of the lovastatin 10-mg regimen; 2 double-blind, placebo-controlled trials and 2 
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open-labeled trials. For reference, the efficacy of the 20-mg daily regimen oflovastatin, 
the usual prescription starting dose, was used. The effects of the 20-mg regimen are 
based upon data from 2 large, double-blind, placebo-controlled clinical trials: Air 
Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) and 
Expanded Clinical Evaluation of Lovastatin (EXCEL). 
The sponsor stated that majority of individuals treated with 10-mg daily 
regimens attained desirable levels of TC ( <200 mg/dL). The vast majority treated with 
10 mg achieved the NCEP-ATP II goal for primary prevention (68.8% to 75% had 
LDL-C<130 mg/dL). Notably, 17.4 to 25.7% of individuals treated with 10 mg also 
attained the goal targeted for secondary prevention (LDL-C<l 00 mg/dL), and this 
percentage was similar to the 21.5% observed with lovastatin 20 mg in 
AFCAPS/TexCAPS. Based on these results, the sponsor asserted that permitting the use 
of lovastatin 10 mg daily in an OTC population would allow the majority of users to 
achieve desirable levels of these atherogenic lipids, even without dose titration. 
Lovastatin 10 mg/day was the lowest approved prescription dose. Studies in 
OTC populations revealed that lovastatin favorably modifies lipids by reducing TC-
11 %, LDL-C-18% and TC/HDL-C-15% and increasing HDL-C-7%. As the OTC-
eligible population was defined as having TC<240 mg/dL, LDL-C is expected to be less 
than 160 mg/dL for a majority of those who are OTC-eligible. With lovastatin 10 mg 
daily, approximately 70% of OTC eligible men and women could attain levels of LDL-
C considered by NCEP-A TP II to be desirable for high risk primary prevention patients 
(LDL-C <130 mg/dL). The risk of first CHD event was estimated to be reduced by 35% 
based upon reductions observed in the TC/HDL-C ratio with lovastatin 10 mg daily. 
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Given these data, the sponsor suggested that lovastatin 10 mg/day represents a 
conservative but effective and appropriate dose for OTC therapy. 
Pharmacology and pharmacokinetics 
The sponsor reviewed the human pharmacology and pharmacokinetics of 
lovastatin to show that, lovastatin is an inactive lactone that, upon hydrolysis, is 
converted to the P-hydroxyacid (coded L-154819) that is an inhibitor of HMG-CoA 
reductase (8). Lovastatin and its active metabolite P-hydroxyacid are highly (>95%) 
bound to human plasma proteins. Lovastatin is extensively metabolized to active and 
inactive metabolites including, L-154819 and four other lactone: P-hydroxyacid pairs, 
all of which account for about 80% of the total HMG-CoA reductase inhibitory activity 
observed in plasma. Lovastatin at the 10-mg dose was not an inhibitor of CYP3A4 (Ki 
= 7. 7 µM) in humans. Biliary excretion is an important route of elimination. L-154819 
is rapidly cleared from the body (total body clearance and half-life averaged 639 
mL/min and 1.5 hours, respectively). The systemic availability of L-154819 following 
an oral dose of lovastatin is less than 9% of the dose because of first-pass hepatic 
extraction. The plasma area under the curve (AUC) of active and total HMG-CoA 
reductase activity increased 2-fold in patients with severe renal impairment (GFR=l 0 to 
30 mL/min). Nonprescription lovastatin was not to be used in patients with renal 
insufficiency without consultation with a physician. When lovastatin was administered 
with food, as in clinical studies, the AUCs of active and total inhibitors are about 50% 
higher compared to administration in the fasting state. For maximum benefit, lovastatin 
should be given with meals. With lovastatin dosages of 10-, 40-, 60-, 90-, and 120-mg, 
peak concentrations are achieved in 3 to 5 hours and the AUC and Cmax of both active 
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and total HMG-CoA reductase inhibitory activity in plasma increase nearly 
proportionally with dose. With once-a-day dosage regimens of lovastatin (10,40 or 
80mg) there is modest steady-state accumulation of active and total inhibitors in plasma 
(<10 to 50%). These data indicated that the pharmacokinetics of lovastatin are linear 
throughout the therapeutic dosage range. Upon co-administration with a potent inhibitor 
of CYP3A4 (such as itraconazole), the plasma exposure to active or total HMG-CoA 
reductase inhibitory activity on the 10-mg dose of lovastatin was below the plasma 
exposure observed following 80-mg of lovastatin, the maximum approved prescription 
dose. No dose adjustment was required during co-administration of nonprescription 
lovastatin with less potent inhibitors of CYP3A4, including calcium channel blockers 
and moderate daily consumption of regular-strength grapefruit juice. Appropriate 
labeling was proposed to reduce the likelihood that potent CYP3A4 inhibitors will be 
used concomitantly with nonprescription lovastatin. 
Safety 
The proposed nonprescription dose of 10 mg has been available by prescription 
and was estimated to account for approximately 720,000 patient-years of treatment (3% 
of total use). Long-term, chronic use of lovastatin was generally well tolerated in both 
EXCEL and AFCAPS/TexCAPS participants (9). The safety profile of lovastatin 20 to 
40 mg/day was comparable to that of placebo. A review of the worldwide adverse event 
data did not reveal a new association between lovastatin and any adverse experience not 
currently included in the package circular. The spontaneous reports generally reflected 
the known side effects of the drug (myopathy and aminotransferase elevations), 
previous warnings within the product circular (lenticular disorders), or concomitant 
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disease in the patient population (congestive heart failure, myocardial infarction). Dose-
proportional increases in hepatic transaminases (>3 x Upper limit of normal (ULN)) 
were observed with lovastatin; however, in studies of lovastatin 20 to 80 mg/day, the 
incidence with 20 mg was no different than that observed with placebo. The 
spontaneous reporting rate for serious hepatic adverse experiences of heterogeneous 
pathology was extremely rare, on the order of 10 per million patient-treatment years of 
lovastatin, did not appear to be dose related, and the relationship to lovastatin is unclear 
in many of the reports. Routine monitoring of liver function tests (LFT) in users of 
nonprescription lovastatin was expected to produce a high proportion of abnormal tests 
which were not indicative of any hepatotoxicity associated with lovastatin. Routine 
monitoring of LFT did not reduce the extremely low risk of serious liver disease in 
people taking lovastatin 10 or 20 mg daily. The risk of myopathy or rhabdomyolysis 
was low and dose related. In clinical trials, the incidence of myopathy in those receiving 
lovastatin 20 mg daily was similar to that reported for those taking placebo. There were 
no reported cases of rhabdomyolysis during marketed prescription use of lovastatin 10 
mg daily. Myopathy is a rare symptomatic condition that can be recognized by patients 
with warnings provided in the nonprescription lovastatin label. The condition usually 
resolved after discontinuation of the drug. There was no apparent association between 
exposure to lovastatin during pregnancy and the occurrence of any adverse pregnancy 
outcomes. However, the number of reported cases with a known outcome was small. In 
view of the limited benefit of this drug in premenopausal women, nonprescription 
lovastatin was to be indicated only for postmenopausal women and would be 
contraindicated m pregnancy. The lack of evidence for risk may provide some 
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reassurance to women who are inadvertently exposed to lovastatin during pregnancy, 
and to the health care professionals responsible for their care. Other lipid-lowering 
agents (gemfibrozil and niacin) may increase the risk of myopathy through an unknown 
mechanism in patients taking any of the HMG-CoA reductase inhibitors. Concomitant 
treatment with potent CYP3A4 inhibitors may increase plasma HMG-CoA reductase 
inhibitory activity levels, and therefore may increase an individual's risk of myopathy. 
The risk of myopathy was very low with lovastatin 10 mg and 20 mg daily regimens, 
and would be expected to remain low even with concomitant use of a potent CYP3A4 
inhibitor. Use of these drugs concomitantly with lovastatin was contraindicated on the 
nonprescription label. 
Long term, chronic use of lovastatin at prescription doses of 10 to 80 mg daily 
has been well tolerated. In controlled clinical trials, the safety profile of lovastatin 20 
mg daily was comparable to that of placebo. Asymptomatic serum transaminase 
elevations were dose-dependent, and were not proved to progress to clinical liver 
disease even when drug therapy is continued; the incidence of confirmed ALT 
elevations (>3 x ULN) was similar with lovastatin 20 mg daily and placebo. Clinically 
apparent liver disease (hepatitis, hepatic failure) associated with lovastatin use at any 
dose was very rare. Therefore, the sponsor argued that routine monitoring of LFT was 
not of value in users of lovastatin 10 mg once daily. Although myopathy, and 
rhabdomyolysis are considered the adverse experience of primary concern for the 
HMG-CoA reductase inhibitors, both clinical study expenence and market-use 
experience indicated that their occurrence is rare. The risk of lovastatin-associated 
myopathy increased with increasing dose of lovastatin. In postmarketing experience 
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collaboration with healthcare professionals. The ESP focused before purchase, on the 
infonnation necessary for consumers to make an appropriate purchase decision and, 
after purchase on the information needed to refine and extend the understanding of the 
product and its use. The importance of cholesterol testing and monitoring was 
emphasized both before and after purchase. Before the purchase decision is made, 
eligibility criteria for the initial selection of the product was introduced through 
informative advertising which provides the basic information about who should and 
should not use the product. The carton label then summarized all information necessary 
for an appropriate purchase decision. After purchase, the consumer has access to several 
label reinforcement tools contained within the package that refines the product selection 
decision. More comprehensive information was available after purchase and educates 
consumers on the importance of a healthy lifestyle and encourages long-term use in 
order to maintain the benefit. The core elements of the labels specified the age and stage 
of life when men and women are at increasing risk of CHD and therefore most likely to 
obtain the benefit. Also listed were specific values for TC and LDL-C and those who 
should not use the product reflect the warnings from the prescription labeling. 
Additional materials called label reinforcement tools were also provided. These 
included the package insert, a video-tape which introduces and reinforces the label 
messages, an information booklet on cholesterol and the importance of maintaining a 
healthy lifestyle and further communication links beyond the package for the purpose of 
promoting appropriate use. A key feature of the ESP was the toll-free service which was 
developed and tested in the sponsor's studies. Use of the toll-free service was 
encouraged, not only for questions, but for reinforcement of key label messages after 
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purchase. By talking with the product specialists at the toll-free service, consumers 
could learn more about their eligibility and appropriate use of the product. This service 
recommends that consumers with higher risk of heart disease see their doctors and 
provided an information card to enroll them in the compliance program. The 
compliance promoting features were a key element of the product which requires long-
term use to achieve the benefit. Once enrolled the consumer received a series of regular 
newsletters with information, aids and the use of Mevacor OTC over the long term in 
increasing and maintaining a healthy lifestyle. Further, it emphasized the importance of 
reassessing ones risk profile over the long term. Also provided was a wallet-sized 
reminder card for tracking lipid changes and avoiding potentially interacting drugs. The 
product was contained in compliance-promoting calendar packaging. Cholesterol 
testing and monitoring was encouraged throughout the process and a healthcare 
professional could help guide the consumer at any time in the process. The first thing 
consumers recognized upon opening the pack was the need to know their cholesterol 
numbers. The ESP encouraged consumers to obtain a complete lipid profile and 
provided guidance on where in the community to have a test conducted. Four 
increasingly improved versions of the labeling materials were tested in a series of label 
comprehension tests and in-home use studies. The final label was the one submitted in 
the NDA. The first three labels were tested sequentially in three in-home use studies 
conducted in community settings where consumers used the product under simulated 
real-world conditions. One study was conducted from actual retail pharmacies and 
allowed long-term use of Mevacor for up to 18 months. Two studies were conducted in 
rented store space in local shopping centers and tested the toll-free service. Follow-up 
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surveys were conducted in subsets of study participants in order to supplement the 
information collected from the clinical studies A fourth study, was ended early due to 
poor enrollment. The sponsor also conducted three label comprehension tests finishing 
with one round of improvements to create the NDA label. These studies showed that 
effective labeling guided most consumers to make an appropriate selection decision and 
that the ESP further improves the correctness of that decision to use the product. 
The sponsor asserted that consumer behavior testing showed that, (a) most 
consumers made an appropriate product selection decision (b) accuracy of the product 
selection decision was further improved when consumers reviewed the label 
reinforcement tools contained in the package (c) toll-free telephone label reinforcement 
service was highly effective as a label reinforcement tool (d) results support the 
conclusion that the nonprescription lovastatin 10 mg labeling system of communication, 
education and support effectively guides consumer product selection (e) comprehension 
testing showed that strong scores were achieved on key messages in the general 
population and the safety subgroup, and that low literacy subgroup scores were also 
acceptable. 
The sponsor stated that even though excellent label comprehension was 
achieved, additional minor refinements were made to further enhance the final label 
submitted in the NDA. These minor refinements included: reformatted liver disease and 
pregnancy warnings for increased prominence; strengthened drug interaction warning 
text; doctors and pharmacists added as individuals the consumer can contact to 
detennine if they are taking a "Do Not Use" medication; and a caution to consumers 
with continuing medical conditions that they may need further medical care. 
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The sponsor concluded that, (a) consumers maintain or improve eating and 
exercise habits while taking nonprescription lovastatin 10 mg in a nonprescription 
setting (b) a substantial segment of interested consumers comply well with long-term 
daily dosing with nonprescription lovastatin 10 mg to achieve clinically meaningful 
lipid changes, and ( c) nonprescription lovastatin labeling system encourages 
collaboration with health care professionals. 
FDA PRESENTATION 
OTC population and efficacy 
AFCAPS/TexCAPS was a randomized, double-blind, placebo-controlled clinical 
trial designed to demonstrate that treatment with lovastatin 20 to 40 mg every day in 
6,605 patients without clinical evidence of CHD and moderately elevated TC and LDL-
C and low HDL-C levels would reduce the incidence of a first acute coronary event 
(composite endpoint consisting of: fatal CHD; nonfatal MI; and unstable angina). After 
a mean follow-up duration of 5 years, treatment with lovastatin 20 to 40 mg daily in 
conjunction with a low saturated fat diet resulted in a 3 7% risk reduction in 
experiencing an acute coronary event compared to placebo. 
The selection of study subjects in the OTC Mevacor development program was 
based on the sponsor's definition of the target OTC population. A review of the OTC 
efficacy data by the FDA found that HDL-C level was never specified as a criterion for 
selecting these individuals from the primary prevention population who would be 
eligible for treatment with lovastatin (11). AFCAPS specifically enrolled individuals 
with below average HDL-C levels based on an exclusion criterion specifying that HDL-
C levels be <45 mg/dL in males and <47 mg/dL in females. When the estimates of CHD 
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risk and treatment benefit were summarized in the OTC-eligible subgroup of AFCAPS 
based on baseline HDL-C levels; of <35, 35 to < 40, and 2':40 mg/dL, the risk reductions 
were greatest in those with HDL-C levels <40 mg/dL. There was no treatment 
difference seen in those individuals with HDL-C levels 2':40 mg/dL who otherwise met 
the sponsor's definition of being eligible for nonprescription lovastatin treatment. 
A subgroup (n=4,092) of the AFCAPS/TexCAPS cohort was selected for 
baseline lipid levels which matched those of the OTC-eligible population. After 
excluding for the presence of diabetes and/or use of multiple antihypertensive 
medications, there were 3,805 patients (57.6%) remaining in the AFCAPS/TexCAPS 
cohort meeting the eligibility criteria for treatment with nonprescription lovastatin. Of 
these, 1,884 (49.5%) were treated with lovastatin 20-40 mg daily and 1,921 (50.5%) 
were treated with placebo. Based on analyses of the AFCAPS OTC-eligible subgroup, 
treatment with lovastatin 20-40 mg per day for an average of 5 years resulted in a 44% 
reduction in risk of experiencing an MI, unstable angina, or sudden cardiac death 
compared to placebo. From these results, the sponsor concluded that treatment with 
nonprescription lovastatin in the targeted OTC-population could reduce the risk of 
CHD. FDA asserted that this conclusion may not be valid based on the following: 
• The lovastatin dose for which a clinical benefit was demonstrated is 2 to 4 times 
higher than the proposed nonprescription dose. The LDL-C lowering results 
associated with the 20 to 40 mg per day dose are not comparable to the 
nonprescription dose. 
• The average duration of treatment in AFCAPS/TexCAPS exceeds the treatment 
duration observed in any trial conducted in the OTC clinical development program 
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• 
The benefit of lovastatin treatment in the AFCAPS/TexCAPS OTC-eligible 
subgroup was greatest in those with HDL-C levels ~40 mg/dL. In the targeted OTC 
population, the majority of individuals had HDL-C levels exceeding this value, 
suggesting that any potential benefit will apply to a much smaller proportion of the 
target OTC population than estimated by the sponsor. 
Based on the data reviewed from studies in the OTC development program and 
the OTC-eligible AFCAPS cohort, the FDA medical review concluded that the 
sponsor's proposal cannot be justified for the following reasons (12): 
• The clinical benefit of lovastatin treatment observed in AFCAPS was associated 
with the 20 to 40 mg dose whereas the proposed nonprescription dose is 10 mg. The 
LDL-C lowering effect of 20 mg in AFCAPS exceeds that of the 10 mg dose 
observed in the efficacy study. 
• The risk reductions associated with lovastatin therapy in AFCAPS was over an 
average 5-year treatment duration with approximately 70% of those randomized to 
lovastatin treatment remaining on therapy for this duration. In contrast, the actual-
use studies suggest that any potential benefit associated with nonprescription 
lovastatin use will be limited by the high number of individuals discontinuing 
treatment after a few months of treatment. 
• The potential clinical benefit of nonprescription lovastatin relies on the ability of the 
consumer to appropriately initiate treatment based on his/her CHD risk profile. The 
individuals in the primary prevention population most likely to benefit from drug 
treatment are those with low HDL-C levels. The sponsor did not evaluate whether a 
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consumer could appropriately initiate drug treatment based on his/her HDL-C level 
since this criterion was not on the proposed package label. 
Hence, the FDA medical review concluded that, "the aforementioned reasons add 
significant uncertainty to any estimates of benefit associated with lovastatin 10 mg use 
in the nonprescription setting. Given the unknown clinical cardiovascular benefits of 
treating the primary prevention population with the unrestricted availability of 
lovastatin 10 mg, the benefit-to-risk relationship of this drug in this population cannot 
be adequately assessed. " 
Safety 
FDA argued that safety evaluation of OTC lovastatin should not be limited to 
the I 0 mg dose because in the OTC setting due to unrestricted access some individuals 
will self-titrate. At the I 0-milligram dose FDA found that the safety and tolerability of 
the I 0 mg dose of lovastatin to be comparable to that of placebo. And the incidence of 
myalgias was low and similar across the studies. There were no cases of 
rhabdomyolysis, myoglobinuria, or liver toxicity reported. At the higher dose of 
lovastatin, FDA found that consecutive elevations in liver enzymes to more than 
3xULN was dose related and at the highest approved dose, the instance was about 1.5 
percent, but there were no cases of liver toxicity associated with this enzyme elevation. 
FDA contended that the sponsor acknowledged this safety concern, and 
proposed that this concern can be adequately conveyed to consumers through proper 
labeling. The sponsors proposal was to warn/advise consumers not to take 
nonprescription lovastatin if they were on any medications such as erythromycin, 
clarithromycin, ketoconazole itraconazole, nefazodone, cyclosporin, protease inhibitor, 
137 
niacin, gemfibrozil, or any other prescription statin drugs. FDA asserted that this was an 
extensive list and likely to increase as more drugs are approved. So FDA felt that this 
method of risk communication was challenging to the consumer. This method of risk 
communication in the prescription setting was apparently not effective enough to avoid 
some of the drug-related toxicities. So it raised concern that the proposed method of risk 
communication for OTC lovastatin may also be ineffective. 
A comprehensive review of post marketing safety surveillance of all currently 
available statins in the United States by the FDA led to the conclusion that a significant 
concern exists over liver failure associated with HMG-CoA reductase inhibitors given 
that liver transplants, irreversible and fatal hepatic damage, have occurred. Of the liver 
failure cases, more than 50% of the patients expired while on lipid-lowering therapy 
consisting of an HMG-CoA reductase inhibitor. Despite this fatal consequence, the 
labeling in OTC package inserts did not mention liver failure as an adverse reaction to 
HMG-CoA reductase inhibitor administration. Additionally epidemiological analysis 
indicated that the reporting rate of liver failure for the HMG-CoA reductase inhibitors 
exceeds the background rate for liver failure. Based on the severity of liver failure they 
recommended that liver failure be included as an adverse event in the labeling of 
package inserts for OTC lovastatin. 
FDA's safety review concluded that, "Given the fact that there is very little 
compliance with liver function test monitoring and this class of drugs have been 
associated with other potentially serious adverse events (including rhabdomyolysis), 
and have the potential to cause dangerous drug and drug-food (grapefruit) interactions, 
it is prudent to defer any decision on the OTC switch of these drugs (13)." FDA opined 
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that for safety, there are rare, but serious adverse events associated with lovastatin use, 
particularly that of muscle toxicity which can be potentiated by certain drugs or 
substances which impair lovastatin's metabolism through the 3A4 isoenzyme. This 
safety concern was further amplified by the use of lovastatin as a nonprescription drug. 
As an OTC drug it would be in an unsupervised setting such that the safety of OTC 
lovastatin is dependent upon the consumer's comprehension of the label, its use 
according to label instructions, such that there would be no self-titration to higher doses, 
and no use by individuals at risk for drug-related toxicities. 
In evaluating the prescription to OTC switch of lovastatin 10 milligrams, FDA 
asked the question: What is the balance of benefit versus risk of nonprescription 
lovastatin? On the benefit side they found LDL-C reduction and agreed that lovastatin 
does reduce LDL-C. But stated that the effectiveness of this treatment approach in the 
OTC population will likely be diminished by poor adherence to drug therapy. Another 
part of the benefit side was that of clinical cardiovascular benefit. FDA asked if drug 
treatment, in the OTC target population resulted in reductions in cardiovascular 
mortality and morbidity? And asserted that there is no evidence from controlled clinical 
trials to demonstrate that. On the risk side, FDA found the safety concerns to be rare, 
but believed the seriousness of muscle toxicity potentiated by certain drugs and 
compounded by the unrestricted, unsupervised use of this product in the OTC 
environment to be excessive and unacceptable. 
Consumer behavior and labeling 
An FDA review of the actual use studies conducted by the sponsor led to these 
observations (14). The sponsor proposed drug treatment for cholesterol in an OTC 
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population without CHD. The target population is designed to include healthy subjects 
who have fewer than 2 risk factors for CHD in addition to subjects who have ~2 risk 
factors and the protocols use the cholesterol level as a surrogate marker for clinical 
benefit. The FDA reviewer argued that this population did not meet the NCEP-ATP II 
guidelines for drug therapy. The AFCAPS/TexCAPS trial, did not demonstrate 
significant clinical benefit for the < 2 CHD risk factor population who took Jovastatin 
20 mg or 40 mg. There was no proof that lowering cholesterol with Jovastatin 10 mg in 
the proposed population would decrease the incidence of myocardial infarctions or 
strokes. In the OTC marketplace, subjects with minimal risk of developing CHD, could 
choose to take lovastatin 10 mg and thereby place themselves at risk of side effects. The 
mean HDL in one study was higher than for AFCAPS/TexCAPS. An HDL-C level 
below 35 mg/dl justifies more intense efforts to lower the LDL-C level. It has been 
recommended that tailoring therapy to the individual patient be accomplished. 
In AFCAPS/TexCAPS, the compliance at approximately 6 months was close to 
90%, but there was a steady decline to approximately 71 % at the end of the study. It has 
been demonstrated that a 15% 1-year probability of lovastatin discontinuation was 
observed for patients in a health maintenance organization setting. In the OTC 
lovastatin actual use trials, compliance was, 27.6% of subjects discontinued during the 
first 24 weeks, 31.3% of subjects discontinued the 8 week study and 25.6% of subjects 
discontinued the 4 week study for three study protocols. This Jed to the conclusion that 
subjects who self-prescribe lovastatin 1 O mg are not as compliant as subjects who 
receive their medication from and are followed by a physician. 
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FDA found that many subjects did not self-select properly with regard to 
whether they could take lovastatin. This was attributed to not having an accurate 
knowledge of their cholesterol values or of their concomitant medications. None of the 
labels were in the FDA required "Drug Facts" format for OTC labeling. The laboratory 
measurements in the actual use trials were performed on a desktop analyzer, and 
presumably, this is the way consumers would check their lipid values in a pharmacy 
when deciding whether to purchase lovastatin. FDA opined that desktop analyzers are 
fairly accurate on average, but measurements tend to be more variable than those 
obtained with laboratory methods. 
The NCEP-A TP II guidelines recommended a 9-12 hour fast as opposed to a 2-hour 
fast. Because of variability in measurements, as per NCEP-A TP II guidelines, and as 
was done in AFCAPS/TexCAPS, subjects should have had at least, two blood samples 
analyzed for lipids to determine drug eligibility. As OTC consumers would not comply 
with enough, properly fasted, cholesterol measurements to provide an accurate 
determination of their baseline cholesterol profiles, this would argue against the 
appropriateness of OTC self-diagnosis and treatment. 
The FDA review found the design and results of the actual use trials to be 
inadequate in the following ways: 
1. Since the HDL value is an important determinant of risk for CHD, it should be 
included as a factor to determine who can take lovastatin 10 mg. Consumers should 
be tested to determine if they understand the meaning of their HDL level and can 
appropriately use this information as a factor in self-selection. 
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2. A single cholesterol test performed without a proper fast is a poor way to decide 
whether someone should take lovastatin 10 mg. The sponsor should demonstrate 
that proper screening methods and compliance can be achieved in the OTC setting. 
3. The labels did not provide sufficient information to use the product effectively. Self-
selection errors were too frequent. The safety information was incomplete because 
laboratory data (especially LFT and creatinine phosphokinase (CPK)) was not 
provided. 
4. The compliance rate in the OTC setting was poor. This would probably impact on 
any long-term benefit to be derived from taking lovastatin 10 mg in this population. 
5. A long-term clinical benefit of taking lovastatin 10 mg in the population at low risk 
for CHD (especially those with< 2 risk factors) has not been demonstrated. 
FDA review of the label comprehension studies observed that the studies 
covered the communication objectives with questions that, in most cases, do not require 
participants to do more than repeat or identify the presence of information on the label. 
Hence, FDA opined that it is not possible to determine how well consumers can use the 
information and interpret it correctly. In particular, there were no questions to determine 
if participants understood that they must meet all three criteria to use the product: TC of 
200-240, LDL-C ~130, males > 40 years and females at least 1 year past menopause. 
The reviewer stated that it was likely that questions requiring participants to apply the 
information on the label to hypothetical situations would have produced lower scores, 
but would have given a better assessment of how well the label is understood. The 
results indicate that there may not be good understanding of who cannot take the 
product, including men under 40 and pre-menopausal women. 
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As the phrasing of the question on this issue permitted responses that the 
information was not on the label it was difficult to know if participants understood well 
who could not use the product if the information was not on the label. Results about 
who should not use the product, coupled with the incomplete information on 
participants' understanding about who can take the product, raised concerns about 
appropriate self-selection. FDA found although a few scores improved substantially 
after participants read the materials inside the package, correct responses remained in 
the 74-77% range for questions about pre-menopausal women and men under 40, and 
improved scores after reading all the materials may have been due to the study 
methodology rather than the effect of the additional materials. 
Further, the questionnaire collected information about the personal health status 
of participants, participants were never asked if they could use the product themselves. 
This information would have been useful in determining how well consumers could 
self-select and might have overcome some of the shortcomings of the other questions 
about who could and could not use the product. The low literate participants had 
problems understanding some of the important messages. They had particular problems 
understanding if Mevacor OTC can be used by persons with various total TC and LDL-
C levels and by women before menopause. The reviewer concluded that this study does 
not provide sufficient information to state confidently that consumers can self-select to 
use the product appropriately; or, whether they understand key information such as they 
must check cholesterol after beginning use. 
COMMITTEE DISCUSSION 
Based on the presentations made by the sponsor and the Agency, FDA posed a 
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list of questions to the committees that have been presented in table 1 (15). The 
committees deliberated each question and voted a yes or no response to each question. 
The first question related to the "clinical benefit" of lovastatin 10 mg was split by the 
committee into two parts for clarity. When clinical benefit was defined, merely, as the 
lowering of LDL-C, the committee unanimously voted in agreement (13-yes; 0-no; 0-
abstained). But, when clinical benefit was defined as reducing cardiovascular events, 
the committee voted strongly in dissent (1-yes; 12-no; 0-abstained). This split vote 
showed that the committee did not endorse the sponsor's rationale of using lowering of 
LDL-C as a surrogate marker for reduction in cardiac events to demonstrate the clinical 
benefit of OTC lovastatin. Further, the committee stated that a placebo-controlled 
clinical trial in the target population with cardiovascular endpoints should be conducted 
to demonstrate clinical benefit. 
The second question was on the global safety, not merely the OTC population, 
of I 0 mg dose of lovastatin. On this question, the committee was unanimous in 
endorsing the safety of 10 mg lovastatin (13-yes; 0-no; 0-abstained). Question three was 
on the balance of benefit and risk of OTC lovastatin, and due its close similarity to the 
earlier two questions, the committee decided not to vote on this question. On question 
four the committee unanimously voted (0-yes; 13-no; 0-abstained) that the sponsor 
failed to demonstrate that consumers could achieve a clinical benefit in an OTC setting. 
The major reasons for this dissent were inability to self-select and understand the need 
for lifelong therapy by the consumers. Question five was on the demonstration of safety 
of lovastatin in the OTC setting and seven members thought it was safe, whereas six 
others thought it was not safe (7-yes; 6-no; 0-abstained). Some reasons for the 
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dissenting vote were possible self-titration leading to overdose, lack of evidence 
showing effective communication to ineligible population, potentially numerous 
interacting drugs and the inability of consumers to see a physician when required. 
The committee modified question 6 to, has the sponsor provided sufficient 
evidence that lovastatin 10 milligrams can be used safely and effectively in an OTC 
setting? This question was answered in strong dissent by the committee (1-yes; 11-no; 
I-abstained). In terms of additional studies to demonstrate approvability of OTC 
lovastatin, the committee made these suggestions: 
• Demonstrate efficacy using better defined eligibility criterion and using LDL-C as 
a surrogate marker relative to prescription lovastatin use. 
• Study actual use in a wholly unrestricted manner to demonstrate ability of 
consumers (to cover minorities, ethnic and low literacy populations) to self-select, 
self-deselect safely and effectively the proposed OTC medicine. 
• Survey large groups to determine their interest in lipid-lowering agents, the 
obstacles involved with using such drugs and if inadequate medical care is 
considered an obstacle. 
• Study the ability of consumers to self-titrate to larger doses in a safe and effective 
manner. 
Conclusion 
Elevated cholesterol is an important risk factor for cardiac disease in the United 
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States. The public health significance of cholesterol-lowering drugs is intensifying and 
NCEP recently issued major new clinical practice guidelines on the prevention and 
management of high cholesterol in adults (16). One of the key changes in the new 
guidelines is the emphasis on aggressive cholesterol-lowering treatment. Despite the 
renewed accent on pharmacological intervention in cholesterol management, growing 
public support for OTC antihyperlipidemics, and, free and widespread availability of 
some cholesterol lowering agents in the form of virtually unregulated dietary 
supplement products, the Agency's current position is that hypercholesterolemia is 
intrinsically a non-OTC indication. Along with the lovastatin switch petition, FDA 
advisory committees also refused to approve a similar OTC switch petition for 
pravastatin (another prescription cholesterol lowering drug from the statins class). FDA 
maintains that safe and effective use of drugs in this area and the overall treatment of 
the disease could be assured only within the prescription setting where access to a 
learned intermediary is readily available. 
It is possible to reason that for drugs such as these, used for chronic illnesses, 
where FDA maintains that the involvement of a learned intermediary is necessary, it 
may be feasible to favorably balance the benefit to risk by classifying them under an 
intermediate, pharmacist controlled class of drugs, where a physician's prescription is 
not required, but pharmacists may dispense medication based upon patient consultation 
and their professional judgment. Such an intermediate class of drugs presently does not 
exist as per the current United States classification system, but other developed nations 
such as Canada, United Kingdom and Australia allow for this class of nonprescription 
medicines. However, the creation of such a pharmacist class of nonprescription 
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medicines in the United States would require legislative action to amend the Food, Drug 
& Cosmetic Act. Also, as more potent molecules become candidates for reclassification 
to OTC status, the intermediate class of drugs may facilitate the achievement of an 
acceptable benefit to risk ratio in the nonprescription setting. 
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Table 1: List of questions posed by FDA to its advisory committees on the proposed 
OTC status for lovastatin 10 mg 
Ejjjfa<]'_ and Scif!!!2'__in the PrqJ!_osed Tal]S!!t P<!E}Jlation 
I. The sponsor proposes an indication, based upon an expectation of cardiovascular benefit, for the use of 
lovastatin IO mg in individuals with TC 200-240 mg/dL and LOL-C > 130 mg/dL, regardless of HOL-C level, 
and without CHO or diabetes, Current guidelines for the treatment of hypercholesterolemia do not target such 
indi viduals for drug treatment. Based on the data submitted in the NOA, has the sponsor adequately 
demonstrated a clinical benefit of lovastatin I 0 mg in the target population? 
a. lfyes, what is the nature and magnitude of the benefit? 
b. lfno, what additional data are needed to demonstrate a clinical benefit in the target population? 
2. Statins have been associated with myopathy, including rare cases of rhabdomyolysis, as well as with 
elevations in hepatic transaminases (although the association between use of these drugs and serious hepatic 
disease is less clear). lntercurrent illness, undefined individual susceptibility factors, and interactions with other 
drugs and/or foods may increase the risk for rhabdomyolysis with statins. 
Taking into account these and other safety issues, has the sponsor presented adequate data to support the safety 
of lovastatin 10 mg in the target population? 
a. lfno, what additional data are needed to demonstrate safety? 
3. Taking into consideration the balance of risk and benefit, has the sponsor presented data that are adequate to 
support the use of lovastatin 10 mg in the low-risk population with TC 200-240 mg/dL, LOL-C > 130 mg/dL, 
regardless of HOL-C level, without CHO or diabetes? 
a. If no, what additional data are needed to su_0)_ort such an indication? 
OTC Considerations 
4. Assuming an indication for the use of lovastatin I 0 mg in the proposed target population can be justified 
based upon an expectation of clinical benefit, has the sponsor adequately demonstrated that consumers can 
achieve such a clinical benefit in an OTC setting? In responding to this question, please consider the following: 
a. The abi li ty of consumers to appropriately self-select (and de-select) based upon cholesterol levels and other 
risk factors. 
b. The ability of consumers to evaluate response to treatment and to monitor cholesterol levels (including 
understanding of how to undertake a fast and the frequency of re-testing). 
c. The abili ty of consumers to adhere to chronic therapy with lovastatin I 0 mg. 
d. The need for the physician or other healthcare professional in the effective treatment and follow up of 
dyslipidemia. 
e. The capacity of the proposed label to direct consumers in the effective use of lovastatin I 0 mg OTC. 
5. Assuming that lovastatin 10 mg is deemed adequately safe when used for the proposed indication in the 
target population, has the sponsor presented adequate evidence that consumers will be able to use lovastatin I 0 
mg safely in an OTC setting? In responding to this question, please consider the following: 
a. The ability of the consumer to identify adverse reactions to lovastatin and to act appropriately. 
b. The ability of the consumer to monitor hepatic safety including the need for monitoring of hepatic 
transami nases and the abi lity of the consumer to perform such monitoring if needed. 
c. The need for and ability of the consumer to identify and avoid interacting drugs and other substances. 
d. The likelihood of use of lovastatin 1 O mg at higher than recommended doses (I tablet per day). 
e. The ability of women who are pregnant or likely to become so to appropriately avoid use of lovastatin I 0 
mg. 
f. The need for the physician or other healthcare professional in the safe treatment and follow up of 
dyslipidemia . 
...&.: The Cl!I>_ac~ of the...e.r~osed label to direct consumers in the safe use of lovastatin 10 mg_ OTC. 
Approvabi/i!X._ 
6. Assuming that the answer to Question 3 is yes (i.e., the sponsor has provided sufficient information to 
support the safety and effectiveness of lovastatin IO mg for the proposed indication in the target population), 
has _the sponsor provided sufficient evidence that lovastatin 10 mg can be used safely and effectively in an OTC 
setting? 
a. If yes, are any additional studies needed post-approval? What are the key messages that need to be conveyed 
tlo the c~nsumer in the product label (carton and package insert) to provide for the safe and effective use of 
ovastatm 1 O mg 
OTC? 
b. If no, what additional studies are necessl!!}'._ to s~ort ~oval for OTC marketil_!g_? 
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MANUSCRIPT VI 
EXAMINATION OF PROPOSED OTC STATUS FOR NONSEDATING 
ANTIHISTAMINES 
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Abstract 
Loratadine, fexofenadine and cetirizine are orally active H1-receptor antagonists 
that do not have the sedating side effects of earlier antihistamines like 
chlorpheniramine. In 1998, Wellpoint Health Networks filed a citizen petition with the 
FDA to request the reclassification of certain marketed products containing these 
second generation antihistamines to over-the-counter status in the United States. 
Contrary to common practice, this switch request did not originate from the 
manufacturers of these drugs. This remarkable departure from conventional practice 
related to the switch process makes this citizen switch petition unprecedented in nature. 
The unparalleled nature of this case raises many significant regulatory, safety and legal 
issues related to OTC switch process in the United States. This article aims to present an 
objective and detailed examination of the regulatory and safety issues related to this 
OTC switch petition. 
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Introduction 
Loratadine (LR), fexofenadine (FX) and cetirizine (CZ) are orally active H1-
receptor antagonists that do not have the sedating side effects of earlier antihistamines 
like chlorpheniramine (1 ). They are commonly referred to as "second generation 
antihistamines" and are currently available, only by prescription, in the United States. 
LR is indicated for the relief of nasal and non-nasal symptoms of seasonal allergic 
rhinitis (SAR) and treatment of chronic idiopathic urticaria (CIU). FX is indicated for 
the relief of symptoms associated with SAR and treatment of CIU. CZ is indicated for 
symptomatic relief from seasonal and perennial allergic rhinitis (SAR and PAR), m 
addition to CIU treatment. 
In 1998, Wellpoint Health Networks filed a citizen petition with the FDA to 
request the reclassification of certain marketed products containing LR, FX and CZ to 
over-the-counter (OTC) status in the United States (2). This article aims to present an 
objective and detailed examination of the regulatory and safety issues related to this 
OTC switch petition. 
Background 
To elucidate the unprecedented nature of this OTC switch petition, it is 
beneficial to describe the underlying rationale for the prescription requirement and the 
general OTC switch process in the United States. The principles based on which 
medicines are classified into, OTC or prescription status, in the United States originate 
from the Durham-Humphrey amendment to the Food, Drug and Cosmetic Act (FDCA) 
in 1951 . This amendment clarified the dispensing obligations of the pharmacist by 
defining the kinds of drugs that cannot be safely used without medical supervision and 
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restricting their sale to prescription by a licensed practitioner (3). An implication of 
section 503(b )(1) of FDCA, which needs emphasis, is that drug products are inherently 
presumed to be nonprescription unless otherwise required. This assertion is generally 
stated as, "if it can be OTC, it must be OTC" to illustrate the inherent bias for 
"nonprescriptionness" arising from the law and is critical in the context of the current 
discussion ( 4). 
Traditionally, prescription drugs have been reclassified to OTC status via, either 
the OTC monograph process or an OTC switch petition in the form of an NDA. When 
FDA initiated the OTC Drug Review in 1972, the monograph process resulted in many 
drugs being reclassified to OTC status. More recently, drugs have been switched to 
OTC status upon approval of manufacturer initiated switch petitions (NDA). However, 
the current request to reclassify certain products of LR, FX and CZ to OTC status did 
not originate from the manufacturers of these drugs. An independent party, other than 
the drug manufacturers, requested the FDA to approve the proposed OTC status for 
these nonsedating antihistamines. This remarkable deviation from conventional practice 
related to the switch process makes this citizen petition for OTC status of LR, FX and 
CZ unprecedented in nature. The unparalleled nature of this case raises many significant 
regulatory, safety and legal issues related to OTC switch process in the United States. 
Rationale and basis of citizen petition 
The regulatory basis for this citizen petition to request OTC status was 
21CFR§l0.30 and 21CFR§310.200, wherein, any interested person may petition the 
FDA for regulatory action, and, drugs limited to prescription use under an NDA can be 
exempted from that limitation if the FDA-Commissioner determines the prescription 
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requirements to be unnecessary for the protection of public health. Additionally, the 
petitioner provided the following medical and pharmacoeconomic rationale to justify 
the request (2): 
• 
Of the 3.5 billion health problems treated annually, almost 2 billion (or 57%) are 
treated with OTC drugs as primary or major adjunctive therapy. The current 
restrictions limiting OTC access to antihistamine and antihistamine/decongestant 
medications with a higher incidence of sedation and anticholinergic side effects is 
dangerous and costly. 
• Americans are 4 times as likely to purchase an OTC medication as they are to 
consulting a physician. Many patients cannot afford the office visit associated with a 
physician. The current restrictions precluding OTC access to antihistamine and 
antihistamine/decongestant medications with a lower incidence of side effects 
predisposes many patients to dangerous antihistamine and 
antihistamine/decongestant treatment options. 
Almost 60% of all dosage units consumed by patients are for OTC medications. 
Over 500 medical conditions are treatable with one or more OTC medications as the 
primary therapy or major adjunctive therapy. These conditions occur millions of 
times each year (e.g. cold, allergy, and nasal congestion). The current restrictions 
precluding OTC access limits many patients to dangerous antihistamine and 
antihistamine/decongestant treatment options. 
• Requiring that a patient schedule an office visit to obtain safe medications is an 
undue time and financial burden to the patient. Additionally, requiring a prescription 
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• 
for these safe antihistamine and antihistamine/decongestant combinations trivializes 
the patient-physician relationship. 
Based on recent historical precedent, the cost of the OTC versions of the drugs 
listed above will be 50% of the prescription drug cost. 
Advisory committee meeting 
To decide upon this citizen petition and seek advice on the suitability of LR, FX 
and CZ for OTC status, the FDA convened an open meeting of its Nonprescription and 
Pulmonary-Allergy Drugs Advisory Committees on 11 May, 2001 (5). FDA informed 
the advisory committees that the intent of this meeting was to seek advice on whether 
LR, FX and CZ, given their marketing history, safety profiles, and that they are in a 
class of drugs already accepted for OTC availability, could be used appropriately and 
safely by consumers without the intervention of a learned intermediary. FDA clarified 
that it is not, seeking advice on the economic considerations of this switch (as this is not 
within the purview of the FDA), or, seeking debate on the regulatory and statutory basis 
for a FDA-initiated switch to OTC status, from its advisory committees. Hence, the 
FDA presented questions only on the safety of LR, FX and CZ in the OTC setting to its 
advisory committees for voting. These questions are tabulated in table 1. 
Sponsor's position 
The manufacturers of LR and FX participated in the public hearing, whereas the 
manufacture of CZ declined the invitation to join the meeting. The manufacturer of LR 
asserted that OTC status is inappropriate for these drugs and submitted the following as 
major reasons to justify their position (6): 
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• 
The citizen petition did not provide data of the type or rigor that is required to 
support an OTC switch. The petition relied solely on anecdotal safety evidence from 
a Canadian adverse drug reaction database and a meta-analysis that inappropriately 
combined data from clinical trials with differing methodologies. Further, data 
pertinent to actual OTC use would have to be generated and additional analyses 
conducted for proper assessment of safe and effective use without a physician's 
supervision. This would include prospective studies to investigate the expected 
therapeutic index for drug use in an OTC setting, as well as estimates and evaluation 
of the probability of various adverse outcomes. 
• The complexity of proper diagnosis and treatment of allergic diseases, as well as 
• 
associated comorbid conditions, suggests that self-care may often be inappropriate 
and that labeling to ensure safe and effective OTC use cannot be developed without 
further study. Prescription status may well be necessary to protect and optimize 
public health. As compared to when earlier antihistamines were made available 
OTC, there is a dramatically different understanding today of the seriousness of 
allergies, their pervasive effects on health and quality of life, and most notably, their 
very high association with other serious comorbidities. In particular, a strong 
relationship with asthma has now been documented, as well as an association with 
sinusitis and otitis. A thorough medical evaluation with identification of 
environmental allergens and clinical or subclinical comorbid conditions is essential 
for optimal treatment outcomes. 
The safety profile of second-generation antihistamines in an OTC setting is not fully 
known. Although safety is well established for prescription use, significant issues 
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require further study to ensure that equivalent safety would exist without a 
physician's care. The absence of a physician or pharmacist as an intermediary who 
would be aware of a patient's concomitant medications is a concern. The 
pharmacokinetic interaction and safety profile for each of the second-generation 
antihistamines is different and each of the antihistamines must be considered and 
evaluated independently. Other aspects of the pharmacologic profile of these drugs 
also warrant more specific evaluation, particularly were the drugs to be used without 
physician oversight. The history of this class of drugs is one in which unexpected 
interactions have been discovered many years after use by millions of patients. 
The manufacturer of FX, in contrast to LR's sponsor, did not argue that OTC 
status was completely inappropriate for FX. Instead, they took the position that it was 
premature to make an objective assessment of its OTC suitability, as FX was approved 
only in July-1996 for U.S. marketing. To justify their cautious approach, they cited the 
example of an earlier non-sedating antihistamine terfenadine (TF is the parent drug that 
is metabolized to FX). TF was initially approved in the U.S. as a prescription drug and 
was later considered for OTC status. However, within the first several years of 
marketing, a serious safety concern related to cardiac arrhythmias eventually resulted in 
TF being withdrawn from the U.S. market. 
Medical community's position 
The American Academy of Allergy, Asthma and Immunology and the American 
College of Allergy, Asthma and Immunology were strongly opposed to the non-
sedating antihistamines being moved to OTC status. The rationale for their position was 
as follows (7): 
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• 
• 
Contrary to the purpose of this switch petition, if approved, the placement of these 
compounds on the OTC market will result in a reduced availability of these valuable 
medications to patients. The cost of these drugs will likely make them unavailable to 
those patients who received them through insurance covered formularies. 
OTC availability will eliminate the physician from the care process of patients 
taking antihistamines. The appropriate use of these medications needs the 
reinforcement of health care providers with expertise about allergic disorders. 
Overuse or misuse of this class of drugs for disorders in which they have no proven 
efficacy will increase health care costs. Conversely, underuse in appropriate allergic 
disorders will negatively impact their effectiveness and result in poorer outcomes. 
Furthermore, the drugs being considered are not necessarily equivalent in their 
efficacy or their capacity to induce sedation, or cognitive and performance 
impairments depending on the dose. 
• Allergies are not necessarily a self-diagnosable condition. Although 20-30% of the 
U.S. population suffers from allergic disorders, public surveys indicate that up to 
75% of people feel they have allergies. This leads to the overuse of antihistamines 
for disorders where they have no proven efficacy. By placing these agents in an 
OTC status this problem will be compounded. 
• Subjects with allergic diseases often fail to adequately appreciate the degree of 
impairment they have from their disease as well as whether treatment impacts upon 
this impairment. By placing these agents in an OTC status, physicians will not play 
as active a role as they should in assessing disease status and response to therapy. 
By placing these agents in an OTC status, in some cases there may be a resultant 
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trivialization of the disorders for which they should be utilized. Reduced availability 
or utilization of these drugs without physician evaluation may mask or delay 
appropriate diagnosis of underlying disorders such as sinusitis, otitis, or asthma. As 
well, urticaria can be a manifestation of a serious underlying condition, which if left 
undiagnosed, could lead to substantial morbidity and mortality. 
The American Academy of Otolaryngology-Head and Neck Surgery (AAO-
HNS) stated that a physician and pharmacist is necessary in the responsible use of non-
sedating antihistamines and did not support the proposed OTC status (8). Further, they 
opined that allergic rhinitis (AR) may not be self-diagnosed as nasal polyps or tumors 
could be the problem. 
FDA's position 
The Agency asserted that AR and related conditions are generally considered 
amenable to self-diagnosis and self-treatment (9). Antihistamines as a class have a long 
history of OTC availability and are used in these indications, with correct usage guided 
by OTC monograph labeling. Hence, FDA reasoned that neither an actual use study nor 
a label comprehension study was required to support the proposed OTC switch petition 
for LR, FX and CZ. Further, FDA opined that it is not appropriate that these drugs be 
switched to OTC status for all age ranges, formulations and/or indications for which 
they are approved for prescription use. For instance, CIU, an approved prescription 
indication for all three drugs was not considered to be an appropriate OTC indication. 
Also, FDA stated that the efficacy of this class of drug products and the appropriateness 
of antihistamines in general for OTC marketing is not in question. The Agency took the 
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position that efficacy of these drugs is not in question as there is a long history of OTC 
marketing of antihistamines. 
Hence, FDA's OTC switch review team conducted an extensive review of 
worldwide safety information related to LR, FX and CZ to determine whether there are 
safety concerns that might preclude their appropriate use in the OTC marketplace. The 
safety data for all three drugs were derived from the NDA safety databases, the 
spontaneous reporting system (AERS) database, and the published literature (10). FDA 
concluded that a thorough review of all available data, from its own safety information 
and from countries where LR was available without a prescription, failed to identify 
conclusive evidence of a causal relationship between use of LR and serious adverse 
events. It must be clarified that countries where LR is available without a prescription 
allow for a third class of drugs, which require dispensing, only in a pharmacy under the 
supervision of a registered pharmacist. Under the current US classification system, there 
does not exist a comparable class of medicines. Hence, it must be emphasized that even 
in countries where LR is available without a prescription, the involvement of a learned 
intermediary is not completely eliminated. Potential safety signals were noted for 
ventricular arrhythmias and liver failure; however, the data were deemed as 
inconclusive and suggested that if such events were causally related to LR, they are 
extremely unusual. A potential association between LR use and seizures was observed, 
consistent with information contained in the current package insert, and likely 
consistent with a class effect. 
FX is the active metabolite of TF, but lacks the pro-drug's ability to inhibit the 
main subunit of the potassium channel in vitro, which is felt to be the primary 
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mechanism responsible for cardiac arrhythmias associated with TF use. As the sole 
active metabolite, FX is predicted to have a non-cardiac adverse events profile 
reflective of TF, and to be safe from a cardiac perspective. A full safety review of TF, 
excluding cardiac events, was also conducted by the Agency to supplement the 
available post-marketing data available for FX. For FX, the Agency concluded that a 
detailed review of all available safety data did not reveal evidence of a causal 
association between FX use and serious and/or life threatening adverse events. A 
possible association between FX use and seizures was noted that is not currently 
reflected in the package insert. A potential signal of ventricular arrhythmias in 
association with FX use was detected, however, the data was thought to be inconclusive 
and the known pharmacologic properties of FX argue against a causal link. 
CZ is an active metabolite of hydroxyzine, a currently marketed prescription 
antihistamine. Upon an extensive review of adverse event reports associated with use of 
CZ, FDA found possible associations between CZ and sedation, neuropsychiactric 
events, including seizures, cardiac arrhythmias, and thrombocytopenia. The Agency 
thought that there is a preponderance of neuropsychiatric adverse events, particularly 
sedation, which may exceed the rate of reporting of similar events for LR and FX. The 
Agency reviewers felt that the data were inconclusive with regard to a causal 
relationship between CZ and arrhythmias and thromobcytopenia. 
FDA also reviewed the post-marketing surveillance data related to first 
generation antihistamines and compared the observations with those of the drugs in 
question. Overall, the Agency made the inference that although generally accepted as 
appropriate OTC drugs, the first generation antihistamines agents possess a number of 
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safety concerns, some of which are serious, m addition to their widely recognized 
sedative and cognition-impairing properties. Although the occurrence rates of adverse 
events attributable to the OTC antihistamines cannot be directly compared to those of 
LR, FX or CZ due to many potential confounders, the Agency suggested that these three 
products might offer certain safety advantages over the currently available first 
generation antihistamines, primarily with regard to sedation and cognition. 
Advisory committees' recommendation 
Based on the above-described positions, testimony from other interested parties 
and their own deliberation; the advisory committees voted 19-4 endorsing acceptable 
safety profile in an OTC setting for LR and CZ. For FX, the panel voted 18-5 in favor 
of an acceptable OTC safety profile. Members of the advisory panel that voted in 
dissent reasoned that the lack of data from actual-use studies does not allow an accurate 
assessment of the benefit-to-risk ratio for these drugs in an OTC setting. The 
committees deliberated upon the nature of labeling that may be required to facilitate 
effective consumer communication. The consensus agreement was to use the existing 
labeling from the final antihistamine monograph, with some modifications. The 
committees suggested that a warning statement on sedation be included for CZ. 
Additionally, several committee members also recommended contraindications for 
consumers with renal and hepatic disorders; in particular, elder patients were suggested 
to see the physician before use. 
Discussion 
As stated earlier in the article, this unprecedented switch petition and FDA's 
consequent action lead to significant questions pertaining to the OTC switch process in 
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the United States. Two such questions relevant in the present context are, (a) Under 
what circumstances should FDA actively propose OTC marketing for a drug in the 
absence of support from a sponsor? and (b) Should FDA be more active in initiating 
switches of prescription products to OTC use? In fact, as part of an ongoing review of 
the Agency's approach to regulating OTC drug products that began in June 2000, FDA 
has solicited public comment on these two questions (11). In responding to these 
questions, it is necessary to ascertain if FDA has the statutory right to propose OTC 
marketing of a drug product. This author opines that FDA has the statutory authority to 
propose OTC marketing of a drug product. The basis for this opinion is 
21CFR§310.200(b) also known as the "switch regulation" and section 503(b)(3) of 
FDCA. As per 21CFR§310.200(b ), 
"Any drug limited to prescription use under section 503(b)(J)(c) of the act shall 
be exempted from prescription-dispensing requirements when the Commissioner finds 
such requirements are not necessary for the protection of the public health by reason of 
the drug 's toxicity or other potentiality for harmful effect, or method of its use, or the 
collateral measures necessary to its use, and he finds that the drug is safe and effective 
for use in self-medication as directed in proposed labeling. " 
Section 503(b)(3) ofFDCA states, 
"The Secretary may by regulation remove drugs subject to sections 502(d) and 
505 from the requirements of paragraph (I) of this subsection when such requirements 
are not necessary for the protection of the public health. " 
As stated earlier, Section 503(b)(l) of FDCA states the prescription-dispensing 
requirements and Section 505 of FDCA describes the pre-marketing approval 
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requirements and process for drugs. Additional evidence in favor of this opinion is 
found in the Agency's response to metaproterenol controversy (12). In 1983, as part of 
the OTC Drug Review the Agency allowed OTC marketing of metaproterenol sulfate, 
but later, due to the advisory panel's recommendation against the OTC status for 
metaproterenol, rescinded upon its earlier decision to allow OTC status for 
metaproterenol. In explaining that action, FDA wrote that although it agreed with the 
advisory committee's recommendation on that occasion, it did not believe that all drug 
decisions require the prior involvement of an advisory panel or notice-and-comment 
procedures. The Agency asserted that Congress has given the duty of approving drugs 
to FDA and argued that it has the statutory responsibility to make a broad range of 
decisions (related to safety, efficacy, prescription or OTC status, indications for use and 
labeling of drugs) involving the suitability of drugs for use by the American public. 
Also, according to FDCA all medicines are inherently assumed to be 
nonprescription in nature and the prescription restriction is applied only when necessary 
to safeguard public health. Extending this rationale to the current situation, wherein 
both the Agency and its advisory committees have endorsed the safety of these drugs in 
an OTC setting, it is possible to reason that FDA may remove the prescription 
requirement for LR, FX and CZ. One implication of applying the "if it can be OTC, it 
must be OTC" rationale to this situation is as follows and deserves explanation. It is 
well known that descarboethoxyloratidine (DCLR) is a major active metabolite of LR. 
If an interested party requests marketing approval for DCLR in a separate NDA to the 
Agency under prescription category, FDA will then be compelled to grant OTC status 
for DCLR also. As DCLR and LR have the same pharmacological safety and toxicity 
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profi les, it would be inconsistent if FDA granted OTC status for LR and approved a 
prescription NDA for marketing DCLR, LR's active metabolite. Based on this 
reasoning, it may be inferred that FDA has the authority to reclassify drugs to OTC 
status. But, it remains unclear as to what regulatory mechanism the Agency may 
employ, should it decide to allow OTC status for these drugs. 
In relation to nonsedating antihistamines FDA has taken the position that neither 
an actual-use study nor a label comprehension study is required as AR is a known self-
diagnosable condition and an OTC antihistamine monograph exists. In the absence of 
data from an actual-use trial it remains unclear how the target OTC population for these 
medicines can be determined. Also, the duration of use after which consultation with a 
physician is required is unknown for these drugs. The use of second-generation 
antihistamines tends to be chronic in nature and a warning of short duration of use may 
be inappropriate (9). In this regard, FDA's position presents a dramatic departure from 
its rigorous data and evidence based decision-making approach that was employed in 
evaluating recent switch petitions. 
The position of this author is that FDA should initiate switch proposals that it 
considers to be safe and effective in an OTC environment and offer overall public 
health benefit. Also, the Agency must switch medicines to OTC status by ensuring 
active participation of all interested parties such as scientific, medical, pharmacist, 
industry, public and consumer communities in the evaluation of its switch proposals and 
before reaching a decision to allow OTC marketing. The author believes that the drastic 
regulatory action of FDA switching a product to OTC status despite the sponsor's 
objection should be carried out only under very limited and highly unusual 
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circumstances. Such a situation may be an enormous and overwhelming support among 
the general public and other stakeholders for OTC availability of a certain product, 
assuming it meets all the safety, effectiveness and labeling standards required of any 
OTC products. 
Conclusion 
The citizen petition for OTC status of these nonsedating antihistamines 
demonstrates a remarkable deviation from common practice related to the switch 
process in the United States and makes this citizen petition unprecedented in nature. 
The unparalleled nature of this case raises many significant regulatory, safety and legal 
issues related to OTC switch process in the United States. 
Based on overall review of the safety profile of LR, FX and CZ, the Agency 
concluded that these drug products, in the OTC setting, might offer certain safety 
advantages over the currently available first generation antihistamines, primarily with 
regard to sedation and cognition. FDA also took the position that no actual use trials or 
label comprehension trials are needed to support this switch request as they fall under 
an existing OTC monograph for antihistamine products. The Nonprescription and 
Pulmonary-Allergy Drugs Advisory Committees to the FDA voted strongly in favor of 
these drugs meeting the safety profiles required for unsupervised use in an OTC 
environment. 
It may be inferred that FDA has the authority to reclassify drugs to OTC status. 
However, it remains unclear as to what regulatory mechanism the Agency may employ, 
should it decide to allow OTC status for these drugs. This author believes that the 
drastic regulatory action of FDA switching a product to OTC status despite the 
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sponsor's objection should be carried out only under very limited and highly unusual 
circumstances. 
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Abstract 
The objective of this study was to examine the attitudes of stakeholders on 
issues related to regulation of nonprescription medicines. The study was designed as an 
internet based electronic survey questionnaire. The attitudes of 473 participants in the 
United States, Australia, the United Kingdom and Canada were measured using their 
stated responses on issues related to regulatory aspects of nonprescription medicines 
using a five-point Likert scale. A majority (65%) of responses came from the United 
States whereas other responses were roughly equally distributed between Australia 
(10%), United Kingdom (12%) and Canada (13%). Response rates of 17% and 7% were 
observed for the two respondent cohorts from the United States and outside United 
States respectively. Responses from all four countries show ambivalence towards the 
role of regulatory agencies in initiating switches or unilaterally switching medicines to 
nonprescription status without the sponsor's support. Respondents unanimously stated 
that risks and benefits to individuals and public health must be the paramount criterion 
in rendering decisions on availability of new OTC medicines. A substantial majority of 
all respondents believed that chronic illnesses (such as asthma), diseases that require 
initial diagnosis by a physician (such as hypercholesterolemia) and diseases such as 
hypertension are unsuitable for self-treatment. Respondents also firmly believed that 
diuretics, antihypertensive drugs, oral antidiabetic drugs, antimicrobials, cholesterol-
lowering drugs, osteoporosis medications and oral contraceptives are not appropriate for 
self-medication. Respondents believed that the consumers do not possess the knowledge 
or ability to ensure responsible use of potent nonprescription medicines without the help 
of a learned intermediary. 
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Introduction 
The growing global interest in self-medication and the potential economic 
benefits accentuate the necessity for a regulatory framework developed on the basis of 
sound scientific principles. Hence, this area is beginning to receive much attention from 
global regulatory authorities. The US Food and Drug Administration (FDA) is currently 
examining its overall approach to regulating over-the-counter (OTC) drug products and 
has conducted a public hearing to solicit information from interested persons including 
scientists, professional groups, and consumers (1). The FDA listed specific questions 
related to regulatory aspects of OTC drug products upon which it requested comments 
of all interested groups (such as pharmacists, academicians, physicians, consumers and 
pharmaceutical industry). 
The primary objective of this investigation is to develop answers to questions 
that FDA has posed (on issues such as the OTC regulatory environment, role of 
regulatory agency in Rx-to-OTC switches, criteria for OTC classification, suitability of 
drugs for OTC status and disease conditions for self-medication, consumer behavior and 
understanding of OTC medicines and the approval of new OTC medicines) using the 
responses of some stakeholders in the United States, Canada, the United Kingdom and 
Australia. A second aim was to use the data collected to gain insight into the opinions of 
a subsection of stakeholders interested in the regulation of OTC drug products. 
Methodology 
Study participants: Requests for participation in the study and the web address of the 
questionnaire were forwarded by email to all listed faculty members in pharmacy 
practice and pharmacy administration departments in the United States, United 
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Kingdom, Canada and Australia. Upon accessing the web page the respondents were 
provided an introduction to the study and were asked to review the informed consent 
document. The University of Rhode Island Institutional Review Board (URI-IRB) 
reviewed and approved the two questionnaires and the informed consent document 
before start of the study. The questionnaires were also pre-tested in a small group of 
individuals and appropriate modifications were made before start of the study. Upon 
giving their consent, the respondents completed the electronic survey questionnaire and 
their responses were stored in a Microsoft Access database. To preserve the anonymity 
of the respondents, no information related to the respondent except the date of 
completion of the questionnaire was captured in the database. 
Measures: An internet based electronic survey questionnaire instrument was the 
primary data collection method used in this study. The statements for the questionnaire 
were adapted from the public hearing notice published by the FDA with a few 
modifications made to the phraseology as presented by the FDA. Selected questions 
posed by the FDA were presented as statements and respondents were asked to state 
their attitude using a five-point Likert scale, ranging from strongly disagree (SDA 
coded as 1), disagree (DA coded as 2), undecided (UD coded as 3), agree (AG coded as 
4) to strongly agree (SAG coded as 5). Respondents were also asked to state their 
knowledge (poor, moderate, good and very good) of nonprescription regulations, 
location (Japan, Australia, United Kingdom, United States, Canada and Other) and 
profession (registered pharmacist, pharmaceutical industry professional, government 
regulatory agency professional, academic professional and other). Respondents were 
offered the opportunity to make any additional comments. The respondents were 
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allowed to choose only one response for each statement. Two questionnaires were 
developed: one for the United States and a second for all other countries. These 
questionnaires differed minimally and the great majority of the questions were identical. 
The sets of statements used in the two questionnaires are presented as an appendix to 
this article. 
The questionnaires were developed as an electronic form for completion by the 
respondents and were made available over the internet at a website 
(www.npmsurvey.org) from March to October, 2001 to facilitate unrestricted and 
convenient global access. 
Statistical analyses: Descriptive statistics such as the mean response, the standard error 
of the mean, the mode response, standard deviation, the sample size and the 95% 
confidence level of the mean were computed. In addition to descriptive statistics, Chi-
square test of independence was performed to understand the relationship between the 
country of the respondent and variability in their responses. For statistical testing, the 
five point Likert scale was abridged to a three-point scale resulting in agree, undecided 
and disagree categories on the response scale. 
Using the contingency table constructed for each statement, the value of the Chi-
square test statistic was computed. The rejection rule was to reject the null hypothesis 
(the responses are independent of the respondent's country) if the computed test statistic 
was greater than 12.59 (standard chi-square value for 5% level of significance and six 
degrees of freedom). 
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Results 
A total of 473 responses were received from United States, Australia, United 
Kingdom and Canada. Table 1 provides a detailed summary of the composition and 
distribution of the responses received based on the profession, country and knowledge 
of nonprescription regulations of the survey respondents. A substantial majority of all 
responses (65%) were received from United States whereas the reminder of responses 
was approximately equally distributed between Australia (10%), UK (12%) and Canada 
(13%). Response rates of about 17% and 7% were observed for the two cohorts of 
respondents in the United States and outside United States respectively. Tables 2A to 
2C present an overall summary of the responses on each statement and associated 
descriptive statistics. Results are summarized below according to question content: 
Regulatory environment 
49% of Americans thought that the current regulatory environment for 
marketing OTC medicines in the US was inadequate and 41 % took the contrary view. 
Unlike American respondents, a majority of Australians (86%), Britains (59%) and 
Canadians (70%) stated that the current regulatory environment for marketing OTC 
medicines in their respective countries was adequate. When asked if the US FDA can 
learn from different OTC regulatory environments and marketing systems within 
developed nations, 64% respondents answered in the affirmative. On the same issue, 
60% of Australians, 79% of Britains and 89% of Canadians believed their respective 
regulatory authority could learn from other countries. 
An overwhelming majority (80%) of American respondents believed that the US 
should adopt a regulatory framework that includes an intermediate, pharmacist-
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controlled class of nonprescription medicines. Similarly, 85% of Americans opined that 
us FDA should issue a "guidance for industry" document on the reclassification of 
prescription products to OTC status describing the nature of the evidence required to 
substantiate such applications. An implication of this result is that although the OTC 
standards for safety, effectiveness and labeling are described in 21CFR §330.10(a)(4), it 
may be useful to delineate such data requirements in a guidance document especially to 
support an Rx-to-OTC switch petition. 
A substantial majority of all respondents (75% of Americans, 78% of 
Australians, 82% of Britains and 85% of Canadians) endorsed the development of 
globally acceptable monographs for OTC drug products within the developed world. 
Contrarily, there was no clearly inferable opinion from the American respondents on the 
issue of direct-to-consumer marketing of prescription drug products adversely 
influencing reclassification to OTC status and availability of new OTC drug products as 
approximately, 31 % disagreed, 34% were undecided and 35% agreed. 
Role of regulatory agency 
When asked if their regulatory agency should actively propose OTC marketing 
of a drug in the absence of support from the sponsor, the response was varied. American 
opinion was evenly split with 40% disagreeing, 39% agreeing and 21 % being 
undecided. Roughly two-thirds of the Australian respondents disagreed with this 
statement, whereas 42% of British respondents agreed and half the Canadians disagreed 
with this proposal. About 19% Canadians, 21 % Americans and 22% Britains remained 
undecided. Responses were found to be statistically independent of the participant's 
location in this case. On the related question of their regulatory agency unilaterally 
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initiating switches of prescription medicines to OTC use, American opinion was unclear 
with 43% agreeing, 42% disagreeing and 15% being undecided. Roughly 70% of 
Australians disagreed and 52% of Britains agreed with this idea. A majority of 
Canadians (45%) rejected this notion. 
Criteria for OTC classification 
In the US, 33% of respondents thought that the current criteria used by the US 
FDA in rendering decisions on OTC availability of OTC drug products was adequate, 
whereas 35% disagreed with this view and 32% remained undecided. This ambivalence 
reinforces the dissatisfaction of Americans observed earlier with their OTC regulatory 
framework. On the same issue, 58% of Australians, 46% of Britains and 60% of 
Canadians believed their respective criterion for decisions on OTC availability to be 
adequate, but, 13% of Australians, 28% of Britains and 25% of Canadians said they 
were undecided. These responses were found not to be statistically independent of the 
participant's location. 
The respondents almost unanimously (95% of Americans, 93% of Australians, 
98% of Britains and 95% of Canadians) stated that the risks and benefits to individuals 
and public health should be assessed and weighed in any decision on OTC marketing of 
drug products. 90% of Americans stated that initiatives to market at least some 
nontraditional medicines (dietary supplements and nutraceuticals) as regular OTC 
products by subjecting them to the same rigorous premarketing scientific evaluation and 
clinical review criteria should be promoted. Also, most respondents added that this is 
perhaps the most important public health issue in the area of OTC medicines regulation 
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Suitability of drugs for OTC status and disease conditions for self-medication 
The majority of Americans (65%), Britains (70%) and Canadians (68%) stated 
that chronic illnesses (such as asthma) are not suitable for treatment with OTC products. 
But, 56% of Australian respondents agreed to the contrary. In Australia, P-agonist 
inhalation products for asthma are available without a prescription under the pharmacist 
class of medicines due to which a majority of Australians believed that asthma is 
suitable for self-medication. A consistent majority across all countries, 59% Americans, 
71 % Australians, 70% of Britains and 73% of Canadians stated that diseases that 
require initial diagnosis by a physician (such as hypercholesterolernia) are unsuitable 
for self-medication. This attitude is in unison with FDA's position that irrespective of 
the safety profile of the drug molecule, OTC indications for cholesterol-lowering drugs 
are not appropriate as high cholesterol is a condition that is inherently unsuitable for 
self-diagnosis and self-medication. Based on this rationale, FDA recently refused to 
approve OTC status for lovastatin and pravastatin, two cholesterol-lowering 
medications (2,3). Similarly, a substantial majority of about 75% of respondents from 
all four countries believed that diseases (such as hypertension) that, if left untreated or 
are inadequately treated can lead to serious morbidity or mortality are also unsuitable 
for self-medication. 
More than three-quarters of all respondents from each country believed that 
diuretics should not be made available without a prescription. At least 83% of all 
respondents from each country disagreed that antihypertensive drugs should be 
available OTC. Similarly, more than three-quarters (78%) of all respondents from each 
country believed that oral antidiabetic drugs, and, at least 85% of all respondents from 
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each country stated that antimicrobials, should not be granted OTC status. The majority 
of all respondents, 59% Americans, 78% Australians, 61 % Britains and 68% of 
Canadians, did not believe that cholesterol lowering drugs should become 
nonprescription medicines. 69% of Australians, 46% of Britains and 54% of Canadians 
disagreed with granting OTC status for treatments for osteoporosis (including its 
prevention), whereas, a majority of Americans (48%) agreed with this proposal. 
Opinion was diverse on the idea of removing the prescription requirement for oral 
contraceptives. More Americans disagreed (45%) than that agreed (42%) with this 
proposal. 46% Australians disagreed versus 40% Australians that agreed with OTC 
status for oral contraceptives. 57% of British respondents agreed, whereas, 49% of 
Canadians disagreed with oral contraceptives being given OTC status. 
Consumer understanding and behavior 
A majority of respondents from all countries, 55% Americans, 55% Australians, 
63% Britains and 54% Canadians, rejected the idea that rational selection of treatment 
regimens by consumers may be ensured when prescription and OTC therapies coexist 
for a certain disease. Similarly, more than 80% of respondents from all countries 
thought that patients do not know the best ways to treat their illnesses in an environment 
with coexisting prescription and OTC therapies for a certain disease. At least 63% of 
respondents from all countries thought that prevention claims for OTC medicines would 
encourage ill-advised behavior (such as ignoring smoking cessation and dietary 
discretion while using an OTC cholesterol-lowering drug, if it were available) among 
consumers. 
178 
Approval of new OTC medicines 
When asked if the first drug to enter the OTC market should be the "best" drug 
in terms of benefit-to-risk ratio within a therapeutic class, a majority of respondents 
concurred. Almost half (49%) of Americans, about 56% Australians, about two-thirds 
(67%) of Britains and 58% of Canadians were in agreement with the above statement. 
In United States, this is not true as the order of availability of new OTC medicines to 
the general public is decided by the sponsor's willingness to switch and the FDA has no 
role in this decision. As discussed earlier, the issue of regulatory agencies initiating and 
pursuing switch proposals in the absence of support from the sponsor is critical in this 
context. A majority of the respondents from all countries ( 46% Americans, 60% 
Australians, 63% Britains and 50% Canadians) agreed that the availability of a ''better" 
OTC product in terms of efficacy or safety should affect the status of products already 
in the OTC market for treatment of the same condition within a therapeutic class. 
Additionally, about two-thirds of the respondents (66% Americans, 67% Australians, 
69% Britains and 65% Canadians) believed that when newer nonprescription products 
become available within a therapeutic class, older therapies that may provide less 
benefit or more risk should be either removed from the market or their labeling should 
be revised. These observations must be interpreted cautiously as the decision to remove 
older OTC medicines upon availability of newer OTC medicines must be considered on 
a case specific basis. In some cases removal of an OTC medicine (as in the case of 
phenylpropanolamine in the United States) may be the right course due to public health 
reasons. However, attempts to extend such a policy universally may be imprudent as 
individuals do not show a uniform pharmacological response to any medicine and it is 
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necessary to allow for a choice of pharmacological therapies being available to 
individuals. 
There was variability among responses on the issue of direct-to-OTC marketing 
(a new chemical entity (NCE) is directly granted OTC status without being first 
marketed as a prescription product for some duration of time). 46% of Americans, 51 % 
of Australians, 78% of Britains and 36% of Canadians agreed with the principle of 
direct-to-OTC marketing, whereas, 37% of Americans, 33% of Australians, 20% of 
Britains and 49% of Canadians disagreed. The responses on this statement were found 
not to be statistically independent of the country as each regulatory agency has taken a 
different position on this matter. Also, an opinion held by most health professionals is 
that a drug's safety profile cannot be understood based solely on controlled clinical 
trails during development and surveillance during real-world clinical practice is 
necessary. 
Discussion 
Literature m this scientific discipline does not widely document the use of 
internet, despite its obvious and well-known advantages, for administering a survey. 
This study demonstrates the utility of electronic communication in the rapid and 
effective completion of a global survey. Also, the electronic survey instrument is 
presented as an efficient alternative to traditional questionnaire-by-mail survey 
technique. 
As with any study, this study is also subject to limitations and the results must 
only be interpreted within the context of any such limitations. Some noteworthy 
limitations are: (a) the phraseology of the questionnaire may not ensure consistent 
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comprehension by all respondents, (b) responses are influenced by the inherent biases 
of the respondents (c) respondents were forced to choose only one response on the five-
point Likert scale that is closest to, but not necessarily, their true opinion (d) the 
participants did not have the opportunity to qualify their responses (e) the study sample 
population may not accurately represent the overall population (f) normal distribution of 
responses that is not fully accurate was assumed in the estimation of descriptive 
statistics. Additionally some respondents commented that their opinion could not be 
completely captured using only a five-point scale. Despite the limitations, these results 
are useful to discern the attitudes of certain stakeholders on regulation of 
nonprescription medicines. This assertion is reinforced, as the study is exploratory in 
nature and was not designed to test any specific hypotheses. Moreover, the absence of 
any information in the global context related to these important issues accentuates the 
significance of these results. 
Foreign respondents out numbered American participants in stating that their 
regulatory agency can learn from other nations, despite the observation that their level 
of satisfaction with their regulatory systems was greater than that for Americans. On 
statement 1 (current regulatory environment for marketing nonprescription medicines 
(NPM) in the US is adequate) and statement 2 (the US FDA can learn from different 
nonprescription medicine regulatory environments and marketing systems within other 
developed nations), statistical analysis showed that nature of the responses was not 
independent of the country of the participant. This dependence of responses on the 
country may be attributed to the differences in regulatory frameworks within the four 
countries. The endorsement of an intermediate, pharmacist-controlled class of 
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nonprescription medicines by the American respondents is very significant and this 
contentious matter has been debated for a long time (4,5,6). Although the respondent 
population does not include all stakeholders, it can be inferred that there is strong 
support for such a proposal amongst an important subsection of stakeholders. However, 
it is necessary to evaluate the support for an intermediate-class of OTC drugs amongst a 
broader population of stakeholders as this study focussed only on pharmacists and 
academicians. Also, it may be reasoned that this is a potential improvement to the US 
regulatory system on which American respondents may have based their earlier 
response. 
Presently, the US OTC monograph system is unique among the four countries 
wherein an OTC product may be marketed without pre-market approval if compliance 
with an approved OTC monograph is ensured. Such an initiative when expanded to 
other countries would benefit the general public and the pharmaceutical industry as best 
practices related to OTC regulation from across the developed world can be integrated 
resulting in an efficient OTC product development and approval system. Statistical 
analysis showed that the responses on statement 5 (on the US questionnaire, ''the US 
FDA should be more active in unilaterally initiating switches of prescription medicines 
to nonprescription use") were found not to be independent of the participant's location. 
Although, the inferential The Chi-square test statistics for statements 4 and 5 in the US 
questionnaire (11.39 and 14.81 respectively) although minimally different from the 
critical value for rejection (12.59) led to differing statistical inferences. Overall, there is 
ambivalence on the issue of regulatory agencies initiating and pursuing switch 
proposals in the absence of support from the sponsor. This observation is timely and 
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important in the context of proposed OTC status for second-generation, non-sedating 
antihistamines in the United States (7 ,8). Although, this topic has substantial legal 
complexity and experts in drug law did not participate in this study, it is important for 
the FDA to consider the opinion of pharmacists and academicians in formulating its 
regulatory policy on OTC status for non-sedating antihistamines. 
It is important to note that responses on statements related to suitability of 
disease conditions and drugs for self-medication were found to be statistically 
independent of the country in all but, two cases. The United States has only one class of 
nonprescription medicines whereas Australia, United Kingdom and Canada have two 
classes of nonprescription medicines (one that requires consultation with a pharmacist 
in a pharmacy before purchase and the other that may be purchased anywhere). It has 
been argued that the existence of the pharmacist-controlled class of nonprescription 
medicines offers a more efficient approach to manage the risk/benefit ratio associated 
with potent nonprescription medicines and ensures their safe use. If this hypothesis 
were true, it is reasonable to expect that the responses of participants from countries 
with a pharmacist-controlled class of nonprescription medicines might possibly be 
different from those in United States. However, the results show this trend only in two 
of the ten statements. Also, a proportion of all respondents stated that their responses on 
above statements might have been different if a pharmacist-class of nonprescription 
medicines was available and pharmacist intervention can be frequently exercised. 
Hence, it is unclear if a majority of all respondents believe that most of the diseases or 
drug classes discussed above are unsuitable for self-medication even if a pharmacist-
controlled class of nonprescription medicines were available. Two limitations of this 
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study, the phraseology of the questionnaire not possibly ensunng consistent 
comprehension by all respondents and the participants not having the opportunity to 
qualify their responses, are particularly important in this context. It is necessary that 
subsequent studies designed to specifically test hypotheses such as these must be 
conducted for an accurate assessment. 
Recently, dietary supplements have witnessed a rapid growth in usage 
(9,10,11,12) and there has been a vocal expression of concern among the professional 
community over the safety and efficacy of these products and this overall opinion is 
aligned with the views of the majority of the scientific and medical community 
(13, 14, 15, 16, 17). The responses observed on regulation of dietary supplements imply 
that such products presently regulated as per the Dietary Supplement Health and 
Education Act (DSHEA) of 1994 need to be comprehensively reviewed and 
fundamental changes must be made to the regulatory framework. Observations on the 
subject of consumer understanding and behavior related to nonprescription medicines 
indicate that the respondents believe that consumers posses neither the knowledge nor 
the commitment to correctly select and safely use OTC medicines without being 
assisted by a learned intermediary. It is vitally important for consumers to responsibly 
use OTC medicines and effective education of the general public must be accomplished. 
The significance of these observations is augmented as it is expected that attempts to 
make potent prescription medicines available without a prescription will increase in the 
future. 
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Conclusion 
This study demonstrates the rapid and effective administration of an electronic 
survey questionnaire to a global audience with the objective of developing answers to 
questions that the US FDA posed on the subject of nonprescription medicine 
regulations. It can be inferred that relative to Australian, British and Canadian 
participants more American respondents regard their regulatory framework for OTC 
medicines as inadequate. Results suggest that potential improvements to the US 
regulatory framework can include creation of an intermediate, pharmacist-controlled 
class of OTC medicines, delineation of data requirements in a guidance document to 
support a switch petition, regulation of nontraditional medicines (dietary supplements 
and nutraceuticals) based also on current OTC standards of pre-market demonstration of 
safety and efficacy, and, the development of global OTC monographs. 
Responses from all four countries show ambivalence towards the role of 
regulatory agencies in initiating switches or unilaterally switching medicines to 
nonprescription status without the sponsor' s support. Respondents unanimously stated 
that risks and benefits to individuals and public health must be the paramount criterion 
in rendering decisions on availability of new OTC medicines. A substantial majority of 
all respondents believed that chronic illnesses (such as asthma), diseases that require 
initial diagnosis by a physician (such as hypercholesterolemia) and diseases such as 
hypertension are unsuitable for self-diagnosis and self-medication. Respondents also 
firmly believed that diuretics, antihypertensive drugs, oral antidiabetic drugs, 
antimicrobials, cholesterol-lowering drugs, osteoporosis medications and oral 
contraceptives are not appropriate for self-medication. However, the study results do 
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not help in understanding if these attitudes might change if a pharmacist-class of 
nonprescription medicines were available. Respondents also thought that the consumers 
do not possess the knowledge or ability to ensure responsible use of potent 
nonprescription medicines without the help of a learned intermediary. 
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Appendix 
List of statements in the questionnaire for US respondents 
1. Current regulatory environment for marketing nonprescription medicines (NPM) 
in the US is adequate. 
2. The US FDA can learn from different nonprescription medicine regulatory 
environments and marketing systems within other developed nations. 
3. US should adopt a regulatory framework that includes an intermediate, 
pharmacist-controlled class of nonprescription medicines (i.e. behind-the-
counter medicines). 
4. The US FDA should actively propose nonprescription marketing of a 
prescription drug in the absence of support from the drug manufacturer 
(sponsor). 
5. The US FDA should be more active in unilaterally initiating switches of 
prescription medicines to nonprescription use. 
6. Current criteria used by the US FDA in rendering decisions on availability of 
nonprescription drug products is adequate. 
7. The following types of diseases/illnesses are suitable for treatment with 
nonprescription drug products: 
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a. Chronic illnesses (such as asthma) 
b. Diseases that require initial diagnosis by a physician (such as 
hypercholesterolemia, i.e. high cholesterol) 
c. Diseases (such as hypertension) that, if left untreated or are inadequately 
treated can lead to serious morbidity or mortality 
8. The following are specific classes of medicines that are not currently marketed 
as nonprescription medicines that should be available without a prescription: 
a. Diuretics 
b. Antihypertensive drugs 
c. Cholesterol lowering drugs 
d. Oral antidiabetic drugs 
e. Treatments for osteoporosis (including its prevention) 
f. Antimicrobials 
g. Oral contraceptives 
9. Rational selection of treatment regimens by consumers may be ensured when 
there are coexisting prescription and nonprescription therapies for a certain 
disease. 
10. Patients know the best ways to treat their illnesses in an environment with 
coexisting prescription and nonprescription therapies for a certain disease. 
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11. The risks and benefits to individuals and public health should be assessed and 
weighed in any decision on nonprescription marketing of drug products (for 
example, the potential benefits of nonprescription antimicrobial agents with the 
potential risks to society at large of the development of resistant organisms). 
12. Prevention claims for nonprescription medicines encourage ill-advised behavior 
(for example, use of an nonprescription cholesterol lowering drug would allow 
patients to ignore other needed interventions such as smoking cessation, dietary 
discretion and management of other risk factors). 
13. Within a therapeutic class, the first drug to enter the nonprescription market 
should be the "best" drug in terms of the benefit-to-risk ratio. 
14. Within a therapeutic class, the availability of a "better'' nonprescription product 
in terms of efficacy or safety should affect the status of products already on the 
nonprescription market for treatment of the same condition. 
15. When newer nonprescription products become available within a therapeutic 
class, older therapies that may provide less benefit or more risk should be either 
removed from the market or their labeling should be revised. 
16. Initiatives to market at least some nontraditional medicines (dietary 
supplements, vitamins, nutraceuticals and other traditional medicines) as regular 
OTC drug products by subjecting them to the same rigorous premarketing 
scientific evaluation and clinical review criteria should be promoted. 
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17. Direct-to-consumer marketing of prescription drug products adversely 
influences reclassification to OTC status and availability of new OTC drug 
products. 
18. Initiatives to develop and establish globally acceptable monographs for 
nonprescription drug products, at least, within the developed world should be 
promoted. 
19. The US FDA should issue a "Guidance for Industry" document on the 
reclassification of prescription products to OTC status describing the nature of 
evidence required to substantiate such applications. 
20. Assuming a new chemical entity meets all regulatory requirements necessary for 
nonprescription classification, it should still be marketed as prescription 
medicine for a specified duration before reclassification to nonprescription 
status may be considered. 
List of statements in the questionnaire for outside US respondents 
1. Current regulatory environment for marketing nonprescription medicines (NPM) 
in your country is adequate. 
2. Your country can learn from different nonprescription medicine regulatory 
environments and marketing systems within other developed nations. 
3. The relevant regulatory Agency in your country should actively propose 
nonprescription marketing of a prescription drug in the absence of support from 
the drug manufacturer (sponsor). 
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4. The relevant regulatory Agency in your country should be more active in 
unilaterally initiating switches of prescription medicines to nonprescription use. 
5. Current criteria used by the relevant regulatory Agency in your country in 
rendering decisions on availability of nonprescription drug products is adequate. 
6. The following types of diseases/illnesses are suitable for treatment with 
nonprescription drug products: 
a. Chronic illnesses (such as asthma) 
b. Diseases that require initial diagnosis by a physician (such as 
hypercholesterolemia, i.e. high cholesterol) 
c. Diseases (such as hypertension) that, ifleft untreated or are inadequately 
treated can lead to serious morbidity or mortality 
7. The following are specific classes of medicines that are not currently marketed 
as nonprescription medicines that should be available without a prescription: 
a. Diuretics 
b. Antihypertensive drugs 
c. Cholesterol lowering drugs 
d. Oral antidiabetic drugs 
e. Treatments for osteoporosis (including its prevention) 
f. Antimicrobials 
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g. Oral contraceptives 
8. Rational selection of treatment regimens by consumers may be ensured when 
there are coexisting prescription and nonprescription therapies for a certain 
disease. 
9. Patients know the best ways to treat their illnesses in an environment with 
coexisting prescription and nonprescription therapies for a certain disease. 
10. The risks and benefits to individuals and public health should be assessed and 
weighed in any decision on nonprescription marketing of drug products (for 
example, the potential benefits of nonprescription antimicrobial agents with the 
potential risks to society at large of the development ofresistant organisms). 
11. Prevention claims for nonprescription medicines encourage ill-advised behavior 
(for example, use of an nonprescription cholesterol lowering drug would allow 
patients to ignore other needed interventions such as smoking cessation, dietary 
discretion and management of other risk factors). 
12. Within a therapeutic class, the first drug to enter the nonprescription market 
should be the ''best" drug in terms of the benefit-to-risk ratio. 
13. Within a therapeutic class, the availability of a "better" nonprescription product 
in terms of efficacy or safety should affect the status of products already on the 
nonprescription market for treatment of the same condition. 
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14. When newer nonprescription products become available within a therapeutic 
class, older therapies that may provide less benefit or more risk should be either 
removed from the market or their labeling should be revised. 
15. Initiatives to develop and establish globally acceptable monographs for 
nonprescription drug products, at least, within the developed world should be 
promoted. 
16. Assuming a new chemical entity meets all regulatory requirements necessary for 
nonprescription classification, it should still be marketed as prescription 
medicine for a specified duration before reclassification to nonprescription 
status may be considered. 
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Table 1: Distribution of survey respondents classified by profession, country and knowledge of nonprescription regulations 
~ofession 
us Australia UK Canada All countries 
N ffo) N i_o/<tl_ N i_o/tl_ N __{_%) N i_o/<tl_ 
~eg_Phann 140 45.16 32 71.11 30 54 .55 22 34.92 224 47 .36 
j!>harm Ind Prof 4 1.29 4 8.89 1 1.82 5 7.94 14 2.96 
Q_ovt RA Prof 0 0.00 1 2.22 0 0.00 3 4.76 4 0.85 
!.icad Prof 155 50.00 7 15.56 23 41.82 30 47.62 215 45.45 
IQ_ th er 11 3.55 1 2.22 1 1.82 3 4.76 16 3.38 
[otal 310 100.00 45 100.00 55 100.00 63 100.00 473 100.00 
% of Respondents per 
~ount12 65.54 9.51 11.63 13.32 100.00 
!Knowled_g_e of non_.e.rescri~tion r~lations 
us Australia UK Canada All countries 
N i_o/<tl_ N i_o/<tl_ N i_o/<tl_ N i_o/tl_ N (o/<tl_ 
!Poor 45 14.52 2 4.44 10 18.18 4 6.35 61 12.90 
!Moderate 133 42.90 4 8.89 19 34.55 13 20.63 169 35.73 
IQ_ood 106 34.19 14 31.11 14 25.45 22 34.92 156 32.98 
IY_ e!}'__g_OOd 26 8.39 25 55.56 12 21.82 24 38.10 87 18.39 
\rota! 310 100.00 45 100.00 55 100.00 63 100.00 473 100.00 
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Table 2A: Summary of responses to survey statements and descriptive statistics 
Res_l)_onse _{_o/tl_ Descri_£!ive statistics 
~tatem ¥'.:1(95.0 
ent Countiy SDA DA UD AG SAG Mean SE Mode SD N o/tl_ ~hi-~ Sign. 
I us 6.82 42.21 9.42 40.26 1.30 2.87 0.06 2 1.07 308 0.12 45.90 .:t._es 
Aus. 0.00 8.89 4.44 71.11 15.56 3.93 0. 11 4 0.75 45 0.23 
UK 9.26 22.22 9.26 53 .70 5.56 3. 18 0.16 4 1.22 55 0.33 
Can. 3.17 19.05 7.94 65 .08 4.76 3.49 0.12 4 0.97 63 0.24 
2 us 1.30 10.06 24.03 53.57 10.71 3.63 0.05 4 0.86 307 0.10 40.01 .:t._es 
Aus. 8.89 24.44 6.67 51.11 8.89 3.27 0.18 4 1.19 45 0.36 
UK 0.00 9.26 12.96 62.96 16.67 3.85 0.10 4 0.80 55 0.22 
Can. 1.59 4.76 4.76 73 .02 15 .87 3.97 0.09 4 0.74 63 0.19 
3 us 3.57 6.17 10.06 38.96 41.23 4.08 0.06 5 1.04 308 0.12 none none 
'!Ql us 10.71 29.22 21.10 30.84 7.79 2.96 0.07 4 1.16 307 0.13 11 .39 no 
Aus. 24.44 40.00 11.11 20.00 4.44 2.40 0.18 2 1.19 45 0.36 
UK 7.41 29.63 22.22 37.04 5.56 3.04 0.14 4 1.09 55 0.29 
Can. 15 .87 31.75 19.05 23 .81 7.94 2.71 0.15 2 1.26 63 0.32 
llil us 8.44 33.44 14.94 36.69 6.49 2.99 0.07 4 1.14 308 0.13 14.81 .:t._es 
Aus. 15.56 S3 .33 4.44 22.22 4.44 2.47 0.17 2 1.14 4S 0.34 
UK S.S6 29.63 14.81 48 . IS 3.70 3.14 0.14 4 1.06 SS 0.29 
Can. 7.94 36.SI IS.87 28.S7 11.11 2.98 0.15 2 1.20 63 0.30 
fill us 3.2S 32.14 30.84 31 .82 1.62 2.96 O.OS 2 0.92 307 0.10 2S.83 .:t._es 
Aus. 4.44 24.44 13 .33 S7.78 0.00 3.24 0.14 4 0.98 4S 0.29 
UK 3.70 24.07 27.78 44.44 l.8S 3.16 0.12 4 0.94 SS 0.2S 
Can. 3. 17 11.11 2S.40 SS .56 4.76 3.48 0.11 4 0.88 63 0.22 
f7A(6A 
J_ us 2S.6S 39.29 S.84 26.30 l.9S 2.39 0.07 2 1.19 30S 0.13 17 .32 .:t._es 
Aus. 8.89 31.11 4.44 48 .89 6.67 3.13 0.17 4 1.20 4S 0.36 
UK 24.07 46.30 3.70 20.37 S.S6 2.33 0.16 2 l.2S SS 0.34 
Can. 20.63 47.62 7.94 17.46 4.76 2.33 0.14 2 1.18 63 0.30 
[~68 us 20.13 38.96 8.77 27.92 2.92 2.S4 0.07 2 1.19 304 0.13 9.20 no 
Aus. 20.00 SI.I I 8.89 20.00 0.00 2.29 O. IS 2 1.01 4S 0.30 
UK 14.81 S l.8S l.8S 20.37 9.26 2.47 0.17 2 1.32 SS 0.36 
Can. 20.63 S2.38 4.76 20.63 0.00 2.22 0.13 2 I.OS 63 0.27 
[Gi_6C us 30.52 44.16 6.49 13 .31 3.90 2.15 0.06 2 1.12 303 0.13 4.60 no 
Aus. 24.44 57.78 8.89 4.44 4.44 2.07 0.14 2 0.96 45 0.29 
UK 20.37 57.41 1.85 16.67 1.85 2.13 0.14 2 1.09 55 0.29 
Can. 26.98 46.03 7.94 12.70 4.76 2.18 0.14 2 1.16 63 0.29 
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Table 2B: Summary ofresponses to survey statements and descriptive statistics 
Res...£_onse_{_o/tl_ Descri_Eti ve statistics 
~tatem jCl(95.0 
ent Coun!!Y_ SDA DA UD AG SAG Mean SE Mode SD N o/tl_ ~hi-~ S!g_n. 
i8A(7A 
i us 26.30 49.03 5.84 15 .9 1 1.62 2.16 0.06 2 1.05 304 0.12 7.70 no 
Aus. 35.56 51.11 8.89 2.22 2.22 1.84 0.12 2 0.85 45 0.26 
UK 35 .1 9 48.15 7.41 11.11 0.00 1.94 0.12 2 0.93 55 0.25 
Can. 28.57 49.2 1 9.52 12.70 0.00 2.06 0.11 2 0.95 63 0.24 
~8(78~ us 35.39 48 .05 4.55 9.74 0.97 1.91 0.05 2 0.94 304 0.11 3.14 no 
Aus. 37.78 51.11 4.44 6.67 0.00 1.8 0.12 2 0.81 45 0.24 
UK 33.33 50.00 9.26 9.26 0.00 1.95 0.12 2 0.89 55 0.24 
Can. 33.33 52.38 6.35 7.94 0.00 1.89 0.10 2 0.84 63 0.21 
~g_1c~ us 20.78 38 .64 8.44 27.60 3.57 2.54 O.Q7 2 1.20 305 0.14 7.01 no 
Aus. 20.00 57.78 4.44 15 .56 2.22 2.22 0.15 2 1.02 45 0.31 
UK 24.07 37.04 9.26 25.93 5.56 2.52 0.17 2 1.26 55 0.34 
Can. 19.05 49.2 1 9.52 17.46 4.76 2.39 0.14 2 1.13 63 0.28 
~0(70 
J_ us 38.96 44.8 1 6.49 7.47 0.97 1.85 0.05 2 0.91 304 0.10 6.43 no 
Aus. 31.11 55.56 2.22 8.89 2.22 1.96 0.14 2 0.95 45 0.29 
UK 35.19 55.56 1.85 9.26 0.00 1.85 0.11 2 0.85 55 0.23 
Can. 33.33 44.44 11.11 11.11 0.00 2.00 0.12 2 0.95 63 0.24 
8E(7E us 7.14 30.19 13 .31 44.48 3.90 3.08 0.06 4 1.09 305 0.12 20.63 ies 
Aus. 15.56 53 .33 11.11 17.78 2.22 2.38 0.15 2 1.03 45 0.31 
UK 9.26 37.04 12.96 38.89 3.70 2.90 0.15 4 1.13 55 0.30 
Can. 19.05 34.92 6.35 36.51 3.17 2.69 0.15 4 1.24 63 0.31 
8F(71J us 58.44 28.25 7.14 3.57 1.30 1.59 0.05 I 0.87 304 0.10 7.37 no 
Aus. 46.67 37.78 4.44 8.89 0.00 1.75 0.13 I 0.92 44 0.28 
UK 40.74 44.44 3.70 12.96 0.00 1.89 0.13 2 0.98 55 0.26 
Can. 57.14 33.33 3.17 6.35 0.00 1.58 0.10 I 0.84 63 0.2 1 
i8G(7G 
) us 14.61 30.52 12.01 33.44 8.44 2.90 O.Q7 4 1.25 305 0.14 5.49 no 
Aus. 8.89 37.78 13 .33 33.33 6.67 2.91 0.17 2 1.16 45 0.35 
UK 5.56 25.93 11.11 44.44 12.96 3.27 0.16 4 1.24 55 0.33 
Can. 19.05 30.16 11.11 33.33 6.35 2.78 0.16 4 1.28 63 0.32 
9(~ us 12.34 42.53 19.81 20.13 2.60 2.57 0.06 2 1.04 300 0.12 5.91 no 
Aus. 15.56 40.00 15.56 26.67 2.22 2.6 0.16 2 1.12 45 0.34 
UK 16.67 46.30 24.07 11.11 0.00 2.21 0.13 2 0 .98 55 0.26 
Can. 14.29 39.68 19.05 23.81 3. 17 2.6 1 0.13 2 I. IO 63 0.28 
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Table 2C: Summary of responses to survey statements and descriptive statistics 
Res__£9nse (%2_ Descrijltive statistics 
jStatem )cl(95.0 
Qi-~ ent Coun!!Y_ SDA DA UD AG SAG Mean SE Mode SD N o/~ Sj_g_n. 
10(21_ us 31 .49 48.70 10.71 4.87 0.65 1.91 0.05 2 0.83 297 0.10 1.31 no 
Aus. 33 .33 48.89 11.11 4.44 0.00 1.86 0.12 2 0.80 44 0.24 
UK 18.52 66.67 9.26 3.70 0.00 1.90 0.10 2 0.75 55 0.20 
Can. 28.57 53.97 9.52 7.94 0.00 1.96 0.10 2 0.84 63 0.21 
1wQ2J us 0.65 0.32 2.27 36.04 59.09 4.55 0.04 5 0.63 303 O.Q7 4.62 no 
Aus. 4.44 0.00 2.22 44.44 48.89 4.33 0.13 5 0.90 45 0.27 
UK 0.00 0.00 1.85 51 .85 46.30 4.36 0.10 4 0.80 55 0.22 
Can. 1.59 0.00 1.59 30.16 65.08 4.52 0.11 5 0.90 63 0.23 
12(1 uJ us 2.60 21.10 10.06 50.97 13 .96 3.53 0.06 4 1.06 304 0.12 2.66 no 
Aus. 4.44 17.78 8.89 40.00 28.89 3.71 0.17 4 1.20 45 0.36 
UK 1.85 18.52 16.67 44.44 18 .52 3.52 0.15 4 1.15 55 0.31 
Can. 3.17 17.46 12 .70 47.62 19.05 3.61 0. 13 4 1.08 63 0.27 
1 3(1~ us 6.82 27.27 15.26 40.58 8.77 3.17 0.07 4 1.14 304 0.13 11.94 no 
Aus. 6.67 22.22 15.56 42.22 13.33 3.33 0.17 4 1.17 45 0.35 
UK 5.56 9.26 18.52 48 .15 18.52 3.58 0.15 4 1.17 55 0.32 
Can. 3.17 17.46 20.63 46.03 12.70 3.47 0.13 4 1.03 63 0.26 
1 4( 1 ~ us 3.57 31.17 17.21 39.94 6.49 3.15 0.06 4 1.06 303 0.12 11 .62 no 
Aus. 2.22 31.11 6.67 53 .33 6.67 3.31 0.15 4 1.06 45 0.32 
UK 0.00 18.52 18.52 57.41 5.56 3.43 0.13 4 0.98 55 0.26 
Can. 4.76 22.22 22.22 44.44 6.35 3.25 0.13 4 1.03 63 0.26 
15{1 '!)j us 4.22 19.16 9.42 53 .90 12.01 3.51 0.06 4 1.07 304 0.12 11 .25 no 
Aus. 6.67 22.22 4.44 55.56 11.11 3.42 0.17 4 1.16 45 0.35 
UK 0.00 14.8 1 16.67 61.11 7.41 3.55 0.12 4 0.96 55 0.26 
Can. 3.17 12.70 19.05 55.56 9.52 3.56 0. 11 4 0.95 63 0.24 
16 us 1.30 3.25 4 .22 38 .64 51 .30 4.37 0.05 5 0.82 304 0.09 none none 
17 us 3.25 27.92 32.79 27.60 7.47 3.08 0.06 3 0.99 305 0.11 none none 
l l!.(I ~ us 1.62 8.44 12.99 61 .36 14.29 3.79 0.05 4 0.85 304 0.10 4.53 no 
Aus. 2.22 4.44 15 .56 42 .22 35.56 4.04 0.14 4 0.95 45 0.29 
UK 0.00 5.56 12.96 53.70 27.78 3.96 0.13 4 0.96 55 0.26 
Can. 6.35 1.59 6.35 53.97 31.75 4.03 0.12 4 1.02 63 0.26 
19 us 0.65 0.32 12 .34 62.66 22.08 4.07 0.04 4 0.65 302 O.Q7 none none 
2Q{_l6) us 3.25 33.77 14.94 34.42 12.01 3.18 O.Q7 4 1.13 303 0.13 24.19 _y_es 
Aus. 11.11 22.22 15 .56 31.11 20.00 3.27 0.19 4 1.32 45 0.40 
UK 3.70 16.67 1.85 53 .70 24.07 3.70 0.16 4 1.21 55 0.33 
Can. 12.70 36.51 14.29 30.16 6.35 2.81 0.15 2 1.19 63 0.30 
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Table 2D: Description of legends for Tables 2A through 2C 
Response(%) Indicates the % of all study respondents with that view 
SDA Strongly disagree 
DA Disagree 
UD Undecided 
AG Agree 
SAG Strongly agree 
Descriptive statistics 
Mean The mean response 
SE Standard error associated with the mean reponse 
Mode The response with the highest frequency 
SD Standard deviation associated with the responses 
N Sample size or total number of respondents 
CI(95.0%) 95% confidence interval around the mean response 
Chi-sq. Value of the chi-square test statistic computed as 
described in the text of the article 
Sign. Results of the chi-square test describing the statistical 
significance or lack thereof 
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MANUSCRIPT VIII 
ATTITUDES AND OPINIONS TOWARDS REGULATORY ASPECTS OF 
NONPRESCRIPTION MEDICINES: PART 2 
200 
Abstract 
The first part of this investigation developed and described quantitative answers 
to questions that FDA has posed through the administration of an electronic survey 
questionnaire. The goal of this part was to qualitatively probe these issues further by 
conducting telephone interviews with key opinion leaders in the United States, Canada, 
the United Kingdom and Australia. This study aimed to extend the earlier effort and 
gain additional insight into issues described above and explored the opinions of thirty 
six key opinion leaders and stakeholders in the area of OTC medicines regulation from 
the United States, United Kingdom, Australia and Canada. Results suggest that potential 
improvements to the US regulatory framework can include creation of an intermediate, 
pharmacist-controlled class of OTC medicines, delineation of data requirements in a 
guidance document to support a switch petition, regulation of nontraditional medicines 
(dietary supplements and nutraceuticals) also as per current OTC standards of pre-
market demonstration of safety and efficacy, and, the development of global OTC 
monographs. Responses showed support for regulatory agencies to unilaterally switch 
drug products and such decisions to be based only on the overall public health benefit 
considerations. 
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Introduction 
As part of examining its overall approach to regulating over-the-counter (OTC) 
drug products the US Food and Drug Administration (FDA) has conducted a public 
hearing to solicit information from interested persons such as scientists, professional 
groups and consumers (1). The FDA listed specific questions related to regulatory 
aspects of OTC drug products upon which it requested comments of all interested 
groups (such as pharmacists, academicians, physicians, consumers and the 
pharmaceutical industry). 
Part one of this investigation developed and described quantitative answers to 
questions that FDA has posed (on issues such as the OTC regulatory environment, role 
of regulatory agency in Rx-to-OTC switches, criteria for OTC classification, suitability 
of drugs for OTC status and disease conditions for self-medication, consumer behavior 
and understanding of OTC medicines and the approval of new OTC medicines) 
developed through the administration of an electronic survey questionnaire. The goal of 
this part was to qualitatively probe these issues further by conducting telephone 
interviews with key opinion leaders in the United States, Canada, the United Kingdom 
and Australia. This study aimed to extend the earlier effort and gain additional insight 
into issues described above. 
Methodology 
Measures: A telephone interview survey questionnaire instrument was the primary data 
collection method used in this study. Also, to obtain a broad spectrum of views, data 
collected from the public statements of some key opinion leaders in the area of OTC 
regulation have been used. 
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Study participants: Requests for participation in the study were forwarded by email or 
telephone to individuals or organizations with established expertise or interest in the 
area of nonprescription medicines in the United States, United Kingdom, Canada and 
Australia. The group of individuals or organizations requested to participate was 
carefully selected to obtain a broad spectrum of views on OTC medicines and their 
regulation. 
Survey interview: Participants who agreed for the telephone interviews were provided 
an introduction to the study and explained the informed consent document. The 
University of Rhode Island Institutional Review Board (URI-IRB) reviewed and 
approved the questions and the informed consent document before start of the study. 
Upon giving their consent, all the participants were interviewed by the author. 
Participants were also requested to grant permission for recording the interview for 
review and transcription purposes by the author only. Participants were assured that 
their identity and individual responses will be kept anonymous and that only collective 
data from the interviews will be publicly discussed. Hence, table 1 describes the nature 
of the participants only in general terms without specific information. The statements 
for the interview survey questionnaire were adapted from the public hearing notice 
published by the FDA with a few modifications made to the phraseology as presented 
by the FDA. Selected questions posed by the FDA were presented as statements during 
the interview and respondents were asked to state their opinion. The format of the 
interview was free flowing and the participants were allowed to respond without any 
restrictions. The set of statements used in the interviews is appended to this article. 
203 
Data analysis: Data collected through the interviews and the public statements was 
pooled and qualitatively examined to discern prominent observations and trends. An 
attempt to make inferences helpful towards formulation of rational regulatory policy 
was also made. 
Results 
The opinions of thirty-six stakeholders from United States, Australia, United 
Kingdom and Canada have been collected. The nature and composition of the 
participants interviewed for this study is presented in table 1. Additionally, table 2 
presents a description of the participants whose publicly stated positions on OTC 
medicines have been used in this study. Some important stakeholders like American 
Association of Health Plans, National Association of Chain Drug Stores in the US, 
National Organization for Women and American Association of Retired Persons 
(AARP) did not respond to the authors interview requests. The Canadian Association of 
Chain Drug Stores (CACDS) stated that they do not have an official position on this 
matter. Also, attempts to interview key members of the US House of Representatives 
and US Senate in the area of healthcare delivery were not fruitful. A majority of the 
participants (72%) were from United States, representation from UK (11 %) and Canada 
(11 %) was equal and the reminder of participants was from Australia (6%). Results 
have been summarized below according to the nature of the question content. 
Regulatory environment 
When asked if the regulatory environment for nonprescription medicines was 
adequate and if learning from other regulatory models can be gained, responses of the 
participants varied widely. Respondents who thought the regulatory systems were 
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adequate cited public health and safety as being the underlying criterion for OTC status, 
the multi-tier scheduling system in Australia allowed better balance between access and 
safety and the OTC monograph model of product approval in the US was built on 
strong scientific foundation as reasons. Others disagreed saying that, there was an 
aggressive thrust towards deregulation by the industry at the risk of public health, the 
growing demand for counseling and education for nonprescription medicines was 
unmet, over-regulation was observed where self-regulation could have been adequate, 
the US Food, Drug & Cosmetic Act does not clearly define an OTC product and FDA 
does not have adequate resources to regulate OTC medicines. 
The American Medical Association (AMA represents physicians), Consumer 
Health Products Association (CHPA represents manufacturers of nonprescription 
medicines in the USA) and the Pharmaceutical Research and Manufacturers of America 
(PhRMA represents research-based pharmaceutical and biotechnology companies in the 
USA) stated that the existing regulatory model for nonprescription medicines in the 
United States was adequate and satisfactory due to the success observed since the 
implementation of OTC Drug Review in the early seventies. Mr. Peter Hutt, a food and 
drug lawyer who led the FDA's OTC review in the seventies opined that the current 
priority attached to regulating OTC medicines within the Agency is inadequate and 
greater importance needs to be placed on this matter. He stated that the present OTC 
division must be elevated to an office within FDA's organizational hierarchy. He also 
stated that the unfinished monographs in certain therapeutic areas must be finalized. Mr. 
Pineo and Mr. Steinberg, two food and drug lawyers also agreed with this view of 
bringing incomplete monographs to final status. 
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The views of the participants on the utility of a pharmacist-controlled class of 
nonprescription medicines were wide-ranging. Almost all respondents interviewed said 
that the US would benefit from an intermediate class of OTC medicines, but, there were 
differences in how such an intermediate class was envisioned. However, most 
respondents said that the creation of such a class of drugs in the US is unlikely due to 
political reasons. Respondents from Australia, Canada and United Kingdom where such 
a class of OTC medicines already exists stated that this class facilitates better 
management of risk and benefit in case of nonprescription medicines. National 
Community Pharmacist's Association (NCP A) and American Pharmacist's Association 
(APhA) strongly supported an intermediate class of medicines. Specifically, the NCPA 
supported a transitional class of medicines that can serve as a bridge between 
prescription and OTC medicines. The NCP A also stated that the Controlled Substances 
Act allows for a C-5 category that is sold only under a pharmacist's supervision or by 
prescription. The APhA also suggested that in some states there are collaborative 
practice agreements between states and manufacturers allowing limited prescriptive 
authority for pharmacists. Dr. Wolfe, a physician and consumer advocate and the 
Women's Health Network also supported the utility of a third class of pharmacist 
dispensed OTC medicines. 
The CHP A and AMA opposed the establishment of a behind-the-counter class 
of medicines. They cited the study "Nonprescription Drugs: Value of a pharmacist 
controlled class has yet to be demonstrated" conducted by the US Congress' General 
Accounting Office as evidence for their position. They asserted that this concept 
restricts access and has been rejected by the FDA. 
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A substantial majority of the respondents interviewed stated that direct-to-
consumer advertising of prescription pharmaceuticals does not affect the reclassification 
of those products to OTC status. Also, they strongly endorsed a proposal to create 
global OTC monographs so that the scientific basis and knowledge used in approval of 
OTC products may be efficiently shared across nations. Respondents also supported the 
issuance of a guidance document prepared by the FDA for sponsors describing the 
nature and kind of evidence required in switch petitions. 
Role of regulatory agency 
When asked if their regulatory agency should actively and unilaterally propose 
OTC marketing of a drug in the absence of support from the sponsor, the responses 
were assorted. Most of the respondents said that it would be appropriate for a regulatory 
authority to force a switch against the willingness of a manufacturer if such a move 
meets public health needs. However, respondents also stated that the most productive 
and efficient approach to switches would be a collaborative one between the 
manufacturer and the regulatory authority. The reasons provided to justify a unilateral 
switch by the regulatory authority were; (a) public health benefit must be the paramount 
criterion for driving such actions (b) in some therapeutic areas the safest treatment 
options are available by prescription only and not OTC, and (c) sponsors should not be 
allowed to wait until the economically opportune time for them to initiate switch 
proposals. 
Some participants said that while they agree with unilateral switching by the 
regulatory authority in principle, they envisioned legal and intellectual property 
problems, if the US FDA takes such an action. The legal and intellectual property 
207 
difficulties were also the rationale on which the CHP A and PhRMA vigorously opposed 
the authority of FDA to unilaterally switch drugs to OTC status. Dr. Woodcock, 
Director, Center for Drug Evaluation & Research (CDER), FDA stated that FDA has 
the legal authority to unilaterally switch drugs to OTC status during a recent 
Congressional hearing on this subject. Kaiser Permanante, the largest nonprofit health 
maintenance organization in America took the position that OTC status must be 
determined only on the basis of the pharmacological profile of the drug and safe use by 
consumers irrespective of manufacturers willingness to switch. Well Point Health 
Networks, a managed care company also agreed with the Kaiser's position and 
suggested that FDA must take an activist role to reclassify prescription drugs deemed 
safe for OTC use regardless of sponsor's willingness. 
Criteria for OTC classification 
A substantial majority of the participants opined that the current OTCness 
criterion of safety/efficacy of drug, self-treatment of condition and overall public health 
benefit of a medicinal product in the absence of a learned intermediary as adequate for 
making decisions on OTC suitability. However, a reasonable portion of the respondents 
also stated there were inconsistencies in the implementation of these criterion in the 
decision making process and evaluating OTC suitability. One participant stated that 
there should not be any limitations on who can petition for reclassification to OTC 
status in the US. Also, some respondents requested clarifications in the regulatory 
process for OTC evaluation of prescription medicines. 
CHPA, PhRMA, Kaiser Permanante and Well Point Health Networks agreed 
that the existing regulatory criteria applicable in the estimation of risk-to-benefit ratio 
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for OTC availability were adequate. The APhA recommended that the FDA must 
additionally consider the environments surrounding the use of the drug and the disease 
or symptom for which it is used. Dr. Wolfe suggested that ease of self-diagnosis, self-
limited or chronic condition, benefit-to-risk ratio and its evaluation, low potential for 
abuse, adverse reactions and drug interactions, and long-term prescription use data as 
six principles that must be used to evaluate potential Rx-to-OTC switch candidates. 
A significant theme that was repeatedly observed among the participants was 
serious concern over the unscientific approval process for non-traditional OTC 
medicines under the Dietary Supplement Health and Enhancement Act (DSHEA). 
Almost all respondents felt that the robust scientific and data-driven decision making 
process followed for most pharmaceutical OTC products as per the OTC Drug Review 
was completely eliminated for DSHEA products and such was medically unjustifiable. 
Suitability of disease conditions for self-medication and drugs for OTC status 
The opinion of participants interviewed on the suitability of disease conditions 
and drug classes for OTC use was diverse. Almost all the participants strongly opposed 
the OTC use of medicines such as diuretics, antihypertensives, cholesterol-lowering 
drugs, oral antidiabetic drugs, osteoporosis treatments, antimicrobials and oral 
contraceptives. But, a reasonable subsection of the participants said that they would be 
more amenable to OTC status for some of these drug classes (such as cholesterol-
lowering drugs, some types of osteoporosis treatments, diuretics and antihypertensives) 
if pharmacist intervention and prescription are made mandatory in the purchasing 
process. The Preventive Cardiovascular Nurses Association strongly recommended that 
FDA consider OTC status for some cholesterol lowering statin medications. Dr. Wolfe 
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strongly opposed consideration of OTC status for statins. None of the participants 
thought that antimicrobials should be made OTC and very few groups supported OTC 
status for oral contraceptives. The National Women's Health Network and the American 
Life League opposed OTC status for oral contraceptives. But, the National Women's 
Health Network joined the American Society for Emergency Contraception in strongly 
supporting OTC status for emergency contraceptives. 
The views of respondents were similar on the suitability of conditions such as 
chronic illnesses (such as asthma), diseases that require an initial diagnosis by a 
physician (such as a hypercholesterolemia) and hypertension for self-treatment. 
Respondents were more favorable to certain classes of asthma medications being OTC, 
if pharmacist involvement were mandatory. Mr. Hutt stated that at the time of the OTC 
Drug Review, the committees were asked to approach the evaluation of OTC suitability 
with a very open mind, with no conditions or classes presumed to be unsuitable as the 
philosophy was to have all drugs available for consideration and deliberation before the 
committees. The CHP A also advocated a similar approach of open-mindedness without 
presuming unsuitability and arriving at decisions based on a data-driven and case-
specific basis. 
The AMA was concerned at a number of prescription drugs used to treat various 
chronic diseases being considered for switch to OTC status. The AMA recommended 
that the FDA move with extreme caution in this area. AMA argued that the benefits of 
physician diagnosis (including other pre-exisiting conditions), prescription of the right 
drug at the right dosage, counseling, and monitoring for compliance, therapeutic 
response and adverse effects for these chronic diseases are very important. In the 
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AMA's view, to potentially lose the benefit of physician supervision by switching drug 
products to OTC status would be detrimental to the public health. 
Overall , the participants felt that complete elimination of a learned intermediary 
(physician or pharmacist) would be imprudent and supported a collaborative system 
where a close relationship between the physician and the pharmacist is preserved with 
the responsibility for maintenance and monitoring of the treatment placed largely on the 
pharmacist. 
Consumer understanding and behavior 
A reasonable proportion of the study participants believed that consumers could 
neither make a rational selection of treatment regimens nor choose the best way to cure 
their illness, when there are coexisting prescription and OTC therapies for a certain 
disease. Further, they also thought that prevention claims for OTC medicines might 
encourage ill-advised behavior among consumers. Respondents reasoned that 
consumers are neither trained nor qualified to make such decisions and most often do 
not have the appropriate information to use medicines properly in an OTC environment. 
CHP A asserted that its research showed that 95% of consumers read the labels 
before using OTC medicines and that there is a very high level of label comprehension. 
Also, they stated that OTC does not necessarily eliminate the physician from the self-
treatment process. National Consumer's League's behavioral research data showed that 
consumers were willing to learn and had good understanding in some areas of OTC use, 
but in other aspects they needed professional counseling. APhA and NCPA stated 
support for methods that assess consumer understanding of proposed labeling that 
involves the pharmacy and the pharmacist. Dr. Bradford, a researcher in the area of 
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OTC clinical trials, suggested active surveillance as a tool to estimate how consumers 
interface with the labeling and use the OTC medicine. One respondent representing a 
women's health group stated that FDA must ensure that consumers receive unbiased 
information and not rely solely on manufacturer's advertisements. Mr. Hutt who 
oversaw the OTC Drug review commented that the review was conducted on the 
premise that consumers are intelligent, can be educated, interested in their own health 
and want a share of their healthcare decisions. 
Approval of new OTC medicines 
When asked if the first drug to enter the OTC market should be the "best" drug 
in terms of benefit-to-risk ratio within a therapeutic class, a majority of respondents 
concurred. A majority of the respondents agreed that the availability of a "better" OTC 
product in terms of efficacy or safety should not affect the status of products already in 
the OTC market for treatment of the same condition within a therapeutic class. 
Additionally, participants stated that when newer nonprescription products become 
available within a therapeutic class, older therapies that may provide less benefit or 
more risk should not be removed from the market or their labeling should not be 
revised. On the issue of direct-to-OTC marketing (a new chemical entity directly 
marketed as an OTC product without being a prescription medicine for some duration), 
there was universal agreement that products must be marketed as a prescription 
medicine under the supervision of a learned intermediary for some duration before 
reclassification to OTC status may be considered. Respondents stated that a drug's 
safety profile cannot be understood based solely on controlled clinical trials during 
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development and surveillance during real-world clinical practice is necessary before 
OTC status may be considered. 
Discussion 
As with any study, this study is subject to limitations and the results must only 
be interpreted within the context of any such limitations. An important limitation of this 
study is that the study sample population may not accurately represent the overall 
population of stakeholders. Although attempts were made to interview all stakeholders, 
it is rarely feasible to fully realize this objective. Also, responses are influenced by the 
inherent biases of the respondents and must be accounted in analyzing the data. Despite 
the limitations, these results are useful to discern the attitudes of important stakeholders 
on regulation of nonprescription medicines. This assertion is reinforced, as the study is 
exploratory in nature and was not designed to test any specific hypotheses. Moreover, 
the absence of any information in the global context related to these important issues 
accentuates the significance of these results. 
Study results demonstrate that opinions of respondents over most issues were 
wide-ranging in nature. This observation is reasonable as all stakeholders do not share 
the same interests and their positions are correspondingly influenced. It is evident from 
the results that stakeholders' positions are developed to be favorable to their underlying 
interests. However, optimal regulatory policy must be formulated to maximize the 
public health benefit. Thus, unhindered access to potent drug products and their safe use 
by consumers must be cautiously balanced to acheive effective self-medication. 
Results suggest that proposals to improve US regulatory structure for OTC 
medicines may include finalizing the pending OTC monographs and increasing 
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pharmacist intervention and/or prescriptive authority for OTC medicines. The latter 
proposal has been a controversial one for sometime and as discussed earlier has been 
vigorously opposed by the CHPA and the AMA. However, views from respondents in 
countries that have a pharmacist class of OTC medicines show that such a class can be 
enormously beneficial in ensuring safe and effective use of OTC drug products. Results 
from the earlier part of this study also evidenced very strong support for a pharmacist 
class of OTC medicines. Additionally, as the OTC arena in the US evolves and more 
potent prescription drug products are considered for OTC status, the pharmacist 
intervention can be employed as an effective tool in increasing the public health benefit 
and decreasing the public health risk. 
Evidence shows support for regulatory agencies to be able to unilaterally switch 
drug products and that such decisions must be based only on the overall public health 
benefit considerations. Study observations indicate that regulatory agencies must pursue 
a collaborative approach with manufacturers in switching drug products to OTC status. 
Based on the Australian system, it may be helpful to include "judicious use of 
medicines" to the current OTCness criterion as applied by the FDA in evaluating drug 
products for OTC status. Judicious use is defined as "the use of medicines only when 
appropriate with non-medicinal alternatives considered as needed" as per the Australian 
system. The urgency to correct the current non data-driven regulatory process for 
marketing of dietary supplements as per DSHEA is strongly supported by the study 
results. The importance of addressing safety of products marketed through DSHEA 
process cannot be overemphasized, as dietary supplements are rapidly becoming a 
substantial part of the OTC armamentarium. 
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Observations suggest that the suitability of disease conditions for self-treatment 
and drugs for OTC use must be evaluated without any presumption or bias in a case 
specific manner based on a data-driven approach with overall public health benefit as 
the paramount objective. Respondents stated that consumers are inherently intelligent 
and if educated adequately can make the decisions resulting in the responsible use of 
OTC medicines. In this regard, the onus of consumer education must be shared 
between the manufacturer and the regulatory authority to ensure that consumers have 
complete and truthful information that will enable them to use OTC medicines safely 
and effectively. Again, the utility of a pharmacist as a learned intermediary is invaluable 
in this regard and efforts to bridge the gap between the physician and the pharmacist to 
enhance the quality of healthcare delivery must be seriously considered. Results also 
suggest that marketing status of medicines should not be affected by the availability of 
newer or better medicines as it would be desirable to have a variety of treatment options 
as individuals do not respond to pharmacological agents in a uniform manner. 
Conclusions 
This study explored the opinions of thirty six key opm10n leaders and 
stakeholders in the area of OTC medicines regulation from the United States, United 
Kingdom, Australia and Canada on issues such as the OTC regulatory environment, role 
of regulatory agency in Rx-to-OTC switches, criteria for OTC classification, suitability 
of drugs for OTC status and disease conditions for self-medication, consumer behavior 
and understanding of OTC medicines and the approval of new OTC medicines. Results 
suggest that potential improvements to the US regulatory framework can include 
creation of an intermediate, pharmacist-controlled class of OTC medicines, delineation 
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of data requirements in a guidance document to support a switch petition, regulation of 
nontraditional medicines (dietary supplements and nutraceuticals) also as per current 
OTC standards of pre-market demonstration of safety and efficacy, and, the 
development of global OTC monographs. 
Responses showed support for regulatory agencies to unilaterally switch drug 
products and such decisions to be based only on the overall public health benefit 
considerations. A substantial majority of all respondents believed that consumers are 
inherently intelligent and if educated adequately can make the decisions resulting in the 
responsible use of OTC medicines. 
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Appendix 
List of statements in the interview questionnaire 
1. Current regulatory environment for marketing nonprescription medicines (NPM) in 
your country is adequate. 
2. Your country can learn from different nonprescription medicine regulatory 
environments and marketing systems within other developed nations. 
3. US should adopt a regulatory framework that includes an intermediate, pharmacist-
controlled class of nonprescription medicines (i.e. behind-the-counter medicines). 
(US ONLY) 
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4. The relevant regulatory Agency in your country should actively propose 
nonprescription marketing of a prescription drug in the absence of support from the 
drug manufacturer (sponsor). 
5. The relevant regulatory Agency in your country should be more active m 
unilaterally initiating switches of prescription medicines to nonprescription use. 
6. Current criteria used by the relevant regulatory Agency in your country in rendering 
decisions on availability of nonprescription drug products is adequate. 
7. The following types of diseases/illnesses are suitable for treatment with 
nonprescription drug products: 
a. Chronic illnesses (such as asthma) 
b. Diseases that require initial diagnosis by a physician (such as 
hypercholesterolemia, i.e. high cholesterol) 
c. Diseases (such as hypertension) that, if left untreated or are 
inadequately treated can lead to serious morbidity or mortality 
8. The following are specific classes of medicines that are not currently marketed as 
nonprescription medicines that should be available without a prescription: 
a. Diuretics 
b. Antihypertensive drugs 
c. Cholesterol lowering drugs 
d. Oral antidiabetic drugs 
e. Treatments for osteoporosis (including its prevention) 
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f. Antimicrobials 
g. Oral contraceptives 
9. Rational selection of treatment regimens by consumers may be ensured when there 
are coexisting prescription and nonprescription therapies for a certain disease. 
10. Patients know the best ways to treat their illnesses in an environment with 
coexisting prescription and nonprescription therapies for a certain disease. 
11. The risks and benefits to individuals and public health should be assessed and 
weighed in any decision on nonprescription marketing of drug products (for 
example, the potential benefits of nonprescription antimicrobial agents with the 
potential risks to society at large of the development of resistant organisms). 
12. Prevention claims for nonprescription medicines encourage ill-advised behavior (for 
example, use of an nonprescription cholesterol lowering drug would allow patients 
to ignore other needed interventions such as smoking cessation, dietary discretion 
and management of other risk factors). 
13. Within a therapeutic class, the first drug to enter the nonprescription market should 
be the "best" drug in terms of the benefit-to-risk ratio. 
14. Within a therapeutic class, the availability of a "better" nonprescription product in 
terms of efficacy or safety should affect the status of products already on the 
nonprescription market for treatment of the same condition. 
15. When newer nonprescription products become available within a therapeutic class, 
older therapies that may provide less benefit or more risk should be either removed 
from the market or their labeling should be revised. 
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16. Initiatives to market at least some nontraditional medicines (dietary supplements, 
vitamins, nutraceuticals and other traditional medicines) as regular OTC drug 
products by subjecting them to the same rigorous premarketing scientific evaluation 
and clinical review criteria should be promoted. (US ONLY) 
17. Direct-to-consumer marketing of prescription drug products adversely influences 
reclassification to OTC status and availability of new OTC drug products. (US 
ONLY) 
18. Initiatives to develop and establish globally acceptable monographs for 
nonprescription drug products, at least, within the developed world should be 
promoted. 
19. The US FDA should issue a "Guidance for Industry" document on the 
reclassification of prescription products to OTC status describing the nature of 
evidence required to substantiate such applications. (US ONLY) 
20. Assuming a new chemical entity meets all regulatory requirements necessary for 
nonprescription classification, it should still be marketed as prescription medicine 
for a specified duration before reclassification to nonprescription status may be 
considered. 
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Table 1: Description of participants interviewed for this study 
Participant Description 
Australia 
Participant # 1 Community pharmacist affiliated with the group of independent retail 
pharmacists 
Participant #2 Community pharmacist and Self-care specialist affiliated with the group 
of practicing pharmacists 
United Kingdom 
Participant #3 Community pharmacist, lawyer and professor affiliated with the 
University of Nottingham 
Participant #4 Health care economist and professor affiliated with the University of 
London 
Participant #5 Regulatory specialist affiliated with the industry group of manufacturers 
of nonprescription medicines 
Canada 
Participant #6 Regulatory specialist affiliated with the industry group of manufacturers 
of nonprescription medicines 
Participant #7 Community pharmacist affiliated with the group of practicing 
pharmacists 
Participant #8 Pharmacy regulatory professional affiliated with the group of 
pharmaceutical regulatory authorities 
Participant #9 Professor and researcher in OTC medicines affiliated with University of 
Saskatchewan 
United States of America 
Participant # 10 Physician, professor and researcher in OTC medicines affiliated with 
Northwestern University 
Participant #11 Community pharmacist and lawyer affiliated with the group of 
practicing pharmacists 
Participant # 12 Community pharmacist, clinical researcher and professor affiliated with 
Drake University 
Participant #13 Physician, professor and expert advisor to US FDA on OTC medicines 
affiliated with University of Pennsylvania 
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Table I: Description of participants interviewed for this study 
Participant Description 
Participant #14 Community pharmacist, self-care researcher and professor affiliated 
with University of Florida 
Participant # 15 Pharmacist, Ex-FDA and Ex-Industry leader affiliated with a food and 
drug law think tank 
Participant # 16 Community pharmacist, self-care researcher, author and professor 
affiliated with Southwest Oklahoma State University 
Participant #17 Representative of a women's health consumer activist group 
Participant # 18 Pharmacoeconomic policy expert, researcher and professor affiliated 
with the University of Minnesota 
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Table 2: Description of participants whose written statements were used 
for this study 
Participant Description/Affiliation Country 
Dr. Michael Maves, Dr. Bill Consumer Health Products Association USA 
Soller and Ms. Eve Bachrach 
Mr. DougHo~ National Communi.!.}'._ Pharmacist's Association USA 
Dr. Ratcliffe Anderson Jr. American Medical Association USA 
Dr. Sidney Wolfe Physician and consumer activist affiliated with USA 
Public Citizen 
Mr. Antho~Baruetta L~er and executive with Kaiser Permanante USA 
Ms. Linda Golodner National Consumer's League USA 
Mr. Steve Francesco Head of Rx-to-OTC Switch Consulting firm USA 
Francesco International 
Mr. Peter Barton Hutt Food & Drug lawyer and Ex-FDA staff member USA 
associated with the OTC Dru_g_ Review _]>focess 
Mr. Russell Bantham Pharmaceutical Research and Manufacturers USA 
Association{PhRMA) 
Ms. Judie Brown American Life Leagti_e USA 
Ms. Tara Shochet American Soci~ for Emerg_en~ Contracc:E_tion USA 
Ms. Suzanne Hughes Registered Nurse and President Lipid Nurse Task USA 
Force 
Mr. Robert Seidman Chief Pharmac:.t Officer, Wel~oint Health Network USA 
Dr. Randy Juhl Ex-FDA Advisory Committee chairman, USA 
Pharmacist, CHP A associate and Dean, Unversity 
of Pittsburg_h, School of Pharma~ 
Dr. David Bradford Clinical researcher specializing in Rx-to-OTC USA 
switches with P~s Research 
Mr. Robert G Pineo Food & Drug lawyer and Ex-FDA staff member USA 
associated with the OTC Dru_g_ Review J>fOCess 
Mr. David Steinberg_ Food & Dru_g_l~er USA 
British Medical Association United 
Ki!_!g__dom 
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SECTION III 
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APPENDIX A 
LIST OF PUBLICATIONS 
The following is a list of the journals in which manuscripts from this dissertation 
have been or will be published: 
I. Achanta A.S. , Willey-Temkin C. , and Rhodes C.T., "Attitudes and Opinions 
Towards Regulatory Aspects of Nonprescription Medicines", accepted for 
publication in Regulatory Affairs Journal. (Manuscript VII) 
2. Achanta A.S. and Rhodes C.T. , "Examination of Proposed OTC status for 
Nonsedating Antihistamines", Clinical Research & Regulatory Affairs, 19(1 ): 1-12 
(2002). (Manuscript VI) 
3. Achanta A.S. and Rhodes C.T. , "Evaluation of Proposed OTC Switch for 
Lovastatin", Clinical Research & Regulatory Affairs, 18(1 &2): 83-104 (2001 ). 
(Manuscript V) 
4. Achanta A.S. and Rhodes C.T. , "The Metaproterenol OTC Switch in the USA", 
Regulatory Affairs Journal, 12(8): 641-644 (2001). (Manuscript IV) 
224 
APPENDIXB 
Appendix B collates a variety of supporting information that would aid clearer 
understanding of the methodological details, discussion and inferences presented in the 
earlier manuscripts. The data included here are the appropriate transcripts, briefing 
material used at the FDA advisory committee meetings discussed in this dissertation, 
electronic files pertaining to the electronic survey administered and the database of the 
results collected from the survey. Due to the voluminous and digital nature of this 
supporting data, the information is presented in electronic format on a compact disk. 
The compact disk is attached to the dissertation. 
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APPENDIXC 
This appendix presents a brief chronological list of some key milestones in the 
history of food and drug regulation in the United States that are relevant to this 
dissertation. This information is presented to help the reader provide a historical 
perspective on developments related to drug regulation and obtain a detailed 
understanding of some discussions presented in the dissertation. The list provided below 
is an abridged version of "Milestones in U.S. Food and Drug Law History" published by 
the US FDA. The complete list may be accessed at 
http://www. fda. gov I opacom/backgrounders/miles.html 
1820 
Eleven physicians meet in Washington, D.C. , to establish the U.S. PHARMACOPEIA, 
the first compendium of standard drugs for the United States. 
1862 
PRESIDENT LINCOLN appoints a chemist, Charles M. Wetherill, to serve in the new 
Department of Agriculture. This was the beginning of the Bureau of Chemistry, the 
predecessor of the Food and Drug Administration. 
1880 
PETER COLLIER, chief chemist, U.S. Department of Agriculture, recommends 
passage of a national food and drug law, following his own food adulteration 
investigations. The bill was defeated, but during the next 25 years more than 100 food 
and drug bills were introduced in Congress. 
1883 
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DR. HARVEY W. WILEY becomes chief chemist, expanding the Bureau of 
Chemistry's food adulteration studies. Campaigning for a federal law, Dr. Wiley is 
called the "Crusading Chemist" and "Father of the Pure Food and Drugs Act". 
1898 
Association of Official Agricultural Chemists (now AOAC International) establishes a 
COMMITTEE ON FOOD ST AND ARDS headed by Dr. Wiley. States begin 
incorporating these standards into their food statutes. 
1902 
The BIOLOGICS CONTROL ACT is passed to ensure purity and safety of serums, 
vaccines, and similar products used to prevent or treat diseases in humans. 
Congress appropriates $5,000 to the Bureau of Chemistry to study CHEMICAL 
PRESERVATIVES AND COLORS and their effects on digestion and health. Dr. 
Wiley's studies draw widespread attention to the problem of food adulteration. Public 
support for passage of a federal food and drug law grows. 
1906 
The original FOOD AND DRUGS ACT is passed by Congress on June 30 and signed 
by President Theodore Roosevelt. It prohibits interstate commerce in misbranded and 
adulterated foods, drinks and drugs. The MEAT INSPECTION ACT is passed the same 
day. Shocking disclosures of unsanitary conditions in meat-packing plants, the use of 
poisonous preservatives and dyes in foods, and cure-all claims for worthless and 
dangerous patent medicines were the major problems leading to the enactment of these 
laws. 
1911 
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In U.S. v. JOHNSON, the Supreme Court rules that the 1906 Food and Drugs Act does 
not prohibit false therapeutic claims but only false and misleading statements about the 
ingredients or identity of a drug. 
1912 
Congress enacts the SHERLEY AMENDMENT to overcome the ruling in U.S. v. 
Johnson. It prohibits labeling medicines with false therapeutic claims intended to 
defraud the purchaser, a standard difficult to prove. 
1913 
GOULD AMENDMENT requires that food package contents be "plainly and 
conspicuously marked on the outside of the package in terms of weight, measure, or 
numerical count." 
1927 
The Bureau of Chemistry is reorganized into two separate entities. Regulatory functions 
are located in the FOOD, DRUG, AND INSECTICIDE ADMINISTRATION, and 
nonregulatory research is located in the BUREAU OF CHEMISTRY AND SOILS. 
1930 
The name of the Food, Drug, and Insecticide Administration is shortened to FOOD 
AND DRUG ADMINISTRATION (FDA) under an agricultural appropriations act. 
1933 
FDA recommends a complete revision of the obsolete 1906 FOOD AND DRUGS ACT. 
The first bill is introduced into the Senate, launching a five-year legislative battle. 
1937 
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ELIXIR OF SULF ANILAMIDE, containing the poisonous solvent diethylene glycol, 
kills 107 persons, many of whom are children, dramatizing the need to establish drug 
safety before marketing and to enact the pending food and drug law. 
1938 
THE FEDERAL FOOD, DRUG, AND COSMETIC (FDC) ACT of 1938 is passed by 
Congress, containing new provisions: 
0 Extending control to cosmetics and therapeutic devices. 
0 Requiring new drugs to be shown safe before marketing-starting a new system of 
drug regulation. 
0 Eliminating the Sherley Amendment requirement to prove intent to defraud in drug 
misbranding cases. 
0 Providing that safe tolerances be set for unavoidable poisonous substances. 
0 Authorizing standards of identity, quality, and fill-of-container for foods. 
0 Authorizing factory inspections. 
0 Adding the remedy of court injunctions to the previous penalties of seizures and 
prosecutions. 
Under the WHEELER-LEA ACT, the Federal Trade Commission is charged with 
overseeing advertising associated with products otherwise regulated by FDA, with the 
exception of prescription drugs. 
1940 
FDA TRANSFERRED from the Department of Agriculture to the Federal Security 
Agency, with Walter G. Campbell appointed as the first Commissioner of Food and 
Drugs. 
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1941 
INSULIN AMENDMENT requires FDA to test and certify purity and potency of this 
life-saving drug for diabetes. 
1943 
In U.S. v. DOTTERWEICH, the Supreme Court rules that the responsible officials of a 
corporation, as well as the corporation itself, may be prosecuted for violations. It need 
not be proven that the officials intended, or even knew of, the violations. 
1944 
PUBLIC HEALTH SERVICE ACT is passed, covering a broad spectrum of health 
concerns, including regulation of biological products and control of communicable 
diseases. 
1945 
PENICILLIN AMENDMENT requires FDA testing and certification of safety and 
effectiveness of all penicillin products. Later amendments extended this requirement to 
all antibiotics. In 1983 such control was found no longer needed and was abolished. 
1949 
FDA publishes GUIDANCE TO INDUSTRY for the first time. This guidance, 
"Procedures for the Appraisal of the Toxicity of Chemicals in Food," came to be known 
as the "black book." 
1950 
In ALBERTY FOOD PRODUCTS CO. v. U.S. , a court of appeals rules that the 
directions for use on a drug label must include the purpose for which the drug is 
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offered. Therefore, a worthless remedy cannot escape the law by not stating the 
condition it is supposed to treat. 
1951 
DURHAM-HUMPHREY AMENDMENT defines the kinds of drugs that cannot be 
safely used without medical supervision and restricts their sale to prescription by a 
licensed practitioner. 
1952 
In U.S. v. CARDIFF, the Supreme Court rules that the factory inspection provision of 
the 1938 FDC Act is too vague to be enforced as criminal law. 
FDA CONSUMER CONSULTANTS are appointed in each field district to maintain 
communications with consumers and ensure that FDA considers their needs and 
problems. 
1953 
FEDERAL SECURITY AGENCY becomes the Department of Health, Education, and 
Welfare (HEW). 
FACTORY INSPECTION AMENDMENT clarifies previous law and requires FDA to 
give manufacturers written reports of conditions observed during inspections and 
analyses of factory samples. 
1955 
HEW SECRETARY OVETA CULP HOBBY appoints a committee of 14 citizens to 
study the adequacy of FDA's facilities and programs. The committee recommends a 
substantial expansion of FDA staff and facilities, a new headquarters building, and more 
use of educational and informational programs. 
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The DIVISION OF BIOLOGICS CONTROL became an independent entity within the 
National Institutes of Health, after polio vaccine thought to have been inactivated is 
associated with about 260 cases of polio. 
1958 
FDA publishes in the Federal Register the first list of SUBSTANCES GENERALLY 
RECOGNIZED AS SAFE (GRAS). The list contains nearly 200 substances. 
1962 
THALIDOMIDE, a new sleeping pill, is found to have caused birth defects in 
thousands of babies born in western Europe. News reports on the role of Dr. Frances 
Kelsey, FDA medical officer, in keeping the drug off the U.S. market, arouse public 
support for stronger drug regulation. 
KEFAUVER-HARRIS DRUG AMENDMENTS passed to ensure drug efficacy and 
greater drug safety. For the first time, drug manufacturers are required to prove to FDA 
the effectiveness of their products before marketing them. 
1965 
DRUG ABUSE CONTROL AMENDMENTS are enacted to deal with problems caused 
by abuse of depressants, stimulants and hallucinogens. 
1966 
FDA contracts with the National Academy of Sciences/National Research Council to 
evaluate the EFFECTIVENESS OF 4,000 DRUGS approved on the basis of safety 
alone between 1938 and 1962. 
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FAIR PACKAGING AND LABELING ACT requires all consumer products in 
interstate commerce to be honestly and informatively labeled, with FDA enforcing 
provisions on foods, drugs, cosmetics, and medical devices. 
1968 
FDA forms the DRUG EFFICACY STUDY IMPLEMENT A TI ON (DESI) to 
implement recommendations of the National Academy of Sciences investigation of 
effectiveness of drugs first marketed between 1938 and 1962. 
1970 
In UPJOHN v. FINCH the Court of Appeals upholds enforcement of the 1962 drug 
effectiveness amendments by ruling that commercial success alone does not constitute 
substantial evidence of drug safety and efficacy. 
FDA requires the first PATIENT PACKAGE INSERT: oral contraceptives must 
contain information for the patient about specific risks and benefits. 
The COMPREHENSIVE DRUG ABUSE PREVENTION AND CONTROL ACT 
replaces previous laws and categorizes drugs based on abuse and addiction potential 
compared to their therapeutic value. 
1972 
OVER-THE-COUNTER DRUG REVIEW begun to enhance the safety, effectiveness 
and appropriate labeling of drugs sold without prescription. 
REGULATION OF BIOLOGICS-including serums, vaccmes, and blood products-is 
transferred from NIH to FDA. 
1973 
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THE U.S. SUPREME COURT upholds the 1962 drug effectiveness law and endorses 
FDA action to control entire classes of products by regulations rather than to rely only 
on time-consuming litigation. 
CONSUMER PRODUCT SAFETY COMMISSION created by Congress; takes over 
programs pioneered by FDA under 1927 Caustic Poison Act, 1960 Federal Hazardous 
Substances Labeling Act, 1966 Child Protection Act, and PHS accident prevention 
activities for safety of toys, home appliances, etc. 
1976 
VITAMINS AND MINERALS AMENDMENTS ("Proxmire Amendments") stop FDA 
from establishing standards limiting potency of vitamins and minerals in food 
supplements or regulating them as drugs based solely on potency. 
1982 
TAMPER-RESISTANT PACKAGING REGULATIONS issued by FDA to prevent 
poisonings such as deaths from cyanide placed in Tylenol capsules. The Federal Anti-
Tampering Act passed in 1983 makes it a crime to tamper with packaged consumer 
products. 
FDA publishes first RED BOOK (successor to 1949 "black book"), officially known as 
Toxicological Principles for the Safety Assessment of Direct Food Additives and Color 
Additives Used in Food. 
1983 
ORPHAN DRUG ACT passed, enabling FDA to promote research and marketing of 
drugs needed for treating rare diseases. 
1984 
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DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT 
expedites the availability of less costly generic drugs by permitting FDA to approve 
applications to market generic versions of brand-name drugs without repeating the 
research done to prove them safe and effective. At the same time, the brand-name 
companies can apply for up to five years additional patent protection for the new 
medicines they developed to make up for time lost while their products were going 
through FDA's approval process. 
1985 
AIDS TEST FOR BLOOD approved by FDA in its first major action to protect patients 
from infected donors. 
1987 
INVESTIGATIONAL DRUG REGULATIONS REVISED to expand access to 
experimental drugs for patients with serious diseases with no alternative therapies. 
1988 
FOOD AND DRUG ADMINISTRATION ACT of 1988 officially establishes FDA as 
an Agency of the Department of Health and Human Services with a Commissioner of 
Food and Drugs appointed by the President with the advice and consent of the Senate, 
and broadly spells out the responsibilities of the Secretary and the Commissioner for 
research, enforcement, education, and information. 
1991 
Regulations published to ACCELERATE THE REVIEW OF DRUGS for life-
threatening diseases. 
1992 
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GENERIC DRUG ENFORCEMENT ACT imposes debarment and other penalties for 
illegal acts involving abbreviated drug applications. 
PRESCRIPTION DRUG USER FEE ACT requires drug and biologics manufacturers to 
pay fees for product applications and supplements, and other services. The act also 
requires FDA to use these funds to hire more reviewers to assess applications. 
1994 
DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT establishes specific 
labeling requirements, provides a regulatory framework, and authorizes FDA to 
promulgate good manufacturing practice regulations for dietary supplements. This act 
defines "dietary supplements" and "dietary ingredients" and classifies them as food. The 
act also establishes a commission to recommend how to regulate claims. 
FDA announces it could consider REGULATING NICOTINE in cigarettes as a drug, in 
response to a Citizen's Petition by the Coalition on Smoking or Health. 
1995 
FDA declares CIGARETTES to be "drug delivery devices." Restrictions are proposed 
on marketing and sales to reduce smoking by young people. 
1997 
FOOD AND DRUG ADMINISTRATION MODERNIZATION ACT reauthorizes the 
Prescription Drug User Fee Act of 1992 and mandates the most wide-ranging reforms in 
Agency practices since 1938. Provisions include measures to accelerate review of 
devices, regulate advertising of unapproved uses of approved drugs and devices, and 
regulate health claims for foods. 
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SUMMARY OF CONCLUSIONS 
Synopsis 
The use of over-the-counter (OTC) medicines and interest in self-care is rapidly 
increasing worldwide. This dissertation presents the first and, perhaps, the most 
comprehensive analysis of the classification of nonprescription medicines and Rx-to-
OTC switch criteria in the United States, United Kingdom, Canada, Japan and 
Australia. The US FDA's overall switch regulatory policies were investigated through 
the application of case-history evaluations. An innovative investigational method that 
utilized a combination of web-based global electronic survey instrument and a 
telephone interview survey instrument has been applied to measure and study the 
attitudes and opinions of important stakeholders on global issues of vital interest to 
regulation of nonprescription medicines. The data collected has been used to provide 
answers to some questions posed by the US FDA as part of its overall review of 
regulation of OTC products in the US. 
This study demonstrates the utility of electronic communication in the rapid and 
effective completion of a global survey. Also, the electronic survey instrument is 
presented as an efficient alternative to traditional questionnaire-by-mail survey 
technique. Data shows that the OTC regulatory model in the United States may be 
improved. Evidence indicates that principles upon which approaches for improvements 
must be based are: an objective evaluation of pharmacist class of OTC medicines, 
development of effective consumer education tools, increase in regulation of non-
traditional OTC medicines, not all disease conditions and drug classes are suitable for 
self-treatment, a collaborative approach by FDA towards switching that includes all 
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stakeholders is more favored, decisions on switch petitions must be case-specific 
without a presumptive bias and public health benefit must be the paramount evaluation 
criterion. 
The significance of information presented in this dissertation is amplified as this 
area has received little academic attention and information is not readily available. It is 
proposed that an examination of the interactive effects between scientific, regulatory 
and economic principles affecting nonprescription medicines and their optimization to 
maximize public health benefit would be appropriate for subsequent research. 
List of conclusions 
Presented below in detail are some of the significant and original findings resulting 
from this study: 
1. Globally, healthcare systems are changing significantly to affect the use and 
attitudes toward over-the-counter (OTC) medicines and interest in self-care is 
rapidly increasing. In recent years, self-medication has undergone a dramatic change 
due to the advent of herbal medicines, dietary supplements, nutraceuticals and 
health foods in addition to traditional nonprescription medicines, and, increasing 
societal preferences towards greater individual control over the use of medicines. It 
is widely believed that responsible use of OTC medicines can lead to overall cost 
savings and public health benefit. Hence, the regulatory framework related to 
nonprescription medicines has become an important priority for regulatory 
authorities, academicians and the industry. 
2. This dissertation presents the first and, perhaps, the most comprehensive analysis of 
the classification of nonprescription medicines and Rx-to-OTC switch criteria in the 
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United States, United Kingdom, Canada, Japan and Australia. A new approach to 
investigating US FDA's overall switch regulatory policies through the application of 
case-history evaluations has been utilized. The significance of information elicited 
through this dissertation is amplified as this area has received little academic 
attention and only sparse data is available. 
3. A comparative examination of the OTC regulatory structures in the United States, 
United Kingdom, Canada and Australia shows universal recognition of OTC 
medicines as vital for public health care and remarkable differences in the 
classification of OTC medicines and criterion used for evaluation of Rx-to-OTC 
switch applications. A substantial majority of all survey respondents endorsed the 
development of globally acceptable monographs for OTC drug products within the 
developed world, so that scientific knowledge and best practices may be shared 
leading to efficiencies in regulation of nonprescription medicines and positive 
public health outcomes. 
4. An overwhelming majority of survey respondents stated that the paramount criterion 
for deciding OTC status must be overall public health benefit. Examination of 
FDA's application of switch regulatory policy in the case of nicotine replacement 
therapy, wherein nicotine, a recognized addictive drug, was made available without 
a prescription as a smoking cessation aid, demonstrates that FDA's action was in 
line with the survey finding. Post switch evidence showed that OTC reclassification 
of Nicorette® achieved the anticipated goal of balancing increased access with 
decreased control and led to public health benefit. This switch case also emphasizes 
the need to expand the use of innovative consumer education, communication tools 
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and behavioral support programs successfully pioneered and demonstrated by the 
sponsor. 
5. The case of metaproterenol OTC switch by the FDA upon its own initiative offers 
valuable information in the comprehension of FDA's application of OTC switch 
regulatory policy. The FDA is encouraged to initiate switch proposals that it 
considers to be safe and effective in an OTC environment and offer overall public 
health benefit. The learning from the failed metaproterenol switch emphasizes that a 
collaborative effort with the sponsor and all interested parties is more likely to result 
in a scientifically robust switch decision. Hence, the Agency must properly manage 
the consideration of switch proposals that it has initiated by ensuring active 
participation of all possible stakeholders that may be impacted by its rulemaking. 
6. It is possible to reason that for drugs such as lovastatin, used for chronic and 
asymptomatic conditions, where FDA maintains that the involvement of a learned 
intermediary is necessary, it may be feasible to favorably balance the benefit to risk 
by classifying them under an intermediate, pharmacist controlled class of drugs, 
where a physician's prescription is not required, but pharmacists may dispense 
medication based upon patient consultation and their professional judgment. 
7. An overwhelming majority (80%) of American respondents surveyed believed that 
the US should adopt a regulatory framework that includes an intermediate, 
pharmacist-controlled class of nonprescription medicines. Also, respondents from 
outside the United States endorsed the utility of a pharmacist-controlled class of 
nonprescription medicines. The physician and industry interest groups vigorously 
opposed such a class. Evidence collected strongly supports the consideration and 
240 
evaluation of a pharmacist-controlled class of nonprescription medicines in the 
United States. Efforts to bridge the gap between physicians, pharmacists and 
patients to enhance the quality of healthcare delivery must be seriously considered. 
8. An innovative investigational method that utilized a combination of web-based 
global electronic survey instrument and a telephone interview survey instrument has 
been applied to measure and study the attitudes and opinions of important 
stakeholders on global issues of vital interest to regulation of nonprescription 
medicines. This study demonstrates the utility of electronic communication in the 
rapid and effective completion of a global survey. Also, the electronic survey 
instrument is presented as an efficient alternative to traditional questionnaire-by-
mail survey technique. A total of 473 responses were received from United States, 
Australia, United Kingdom and Canada through the electronic survey instrument. 
Additionally, the opinions of thirty-six stakeholders (to include interest groups and 
key opinion leaders) in great detail from United States, Australia, United Kingdom 
and Canada were collected and examined. 
9. Some significant inferences based on the evidence presented in this dissertation on 
OTC issues of global interest and, in particular to the FDA, are: 
a. A majority of American respondents believed that the current regulatory 
environment for marketing OTC medicines in the US was inadequate 
b. Two thirds of the respondents believed that the US FDA could learn 
from different OTC regulatory environments and marketing systems 
within developed nations. 
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c. More than 8 in 10 Americans opined that US FDA should issue a 
"guidance for industry" document on the reclassification of prescription 
products to OTC status describing the nature of the evidence required to 
substantiate such applications. 
d. On the issue of a regulatory agency actively proposing OTC marketing 
of a drug in the absence of support from the sponsor, the response was 
varied. American opinion was evenly split with 40% disagreeing, 39% 
agreeing and 21 % being undecided. On the related question of a 
regulatory agency unilaterally initiating switches of prescription 
medicines to OTC use, American opinion was unclear with 43% 
agreeing, 42% disagreeing and 15% being undecided. Roughly 70% of 
Australians disagreed and 52% of Britains agreed with this idea. A 
majority of Canadians (45%) rejected this notion. Again, the industry 
interest groups vigorously opposed this proposal. This observation is 
most pertinent in the current context of proposed OTC status for second-
generation antihistamines. Also, if the FDA unilaterally switches the 
three antihistamines to OTC status, it will be setting a precedent and the 
procedural details of such an action are unknown. However, there was 
universal agreement that a collaborative switch process between the 
FDA and all stakeholders is most favored. 
e. The ambivalence of Americans on the adequacy of US FDA 
reclassification criteria reinforces the dissatisfaction of Americans with 
their OTC regulatory framework. 
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f. The respondents almost unanimously stated that the risks and benefits to 
individuals and public health should be assessed and weighed in any 
decision on OTC marketing of drug products. 9 in 10 Americans stated 
that initiatives to market at least some nontraditional medicines (dietary 
supplements and nutraceuticals) as regular OTC products by subjecting 
them to the same rigorous premarketing scientific evaluation and clinical 
review criteria should be promoted. Most respondents added that this is 
perhaps the most important public health issue that FDA should address 
in the area of OTC medicines regulation. 
g. Conditions like asthma, hypertension and medications like diuretics, 
antihypertensives, oral antidiabetics and antinfectives are unsuitable for 
self-treatment. The opinions over hypercholesterolemia and osteoporosis 
are complex and divided. Whereas complete lack of healthcare 
professional intervention does not have any support, support exists for 
nonprescription use with pharmacist or nurse intervention. Oral 
contraceptives could also be classified similarly, but some women's 
health interest groups opposed OTC status. 
h. Consumers may not always posses the knowledge and commitment to 
responsibly use OTC medicines without being assisted by a learned 
intermediary. It is important for consumers to responsibly use OTC 
medicines and the burden of effectively educating the general public and 
managing the consumer behavior lies on the industry, public and 
professional groups, regulatory authority and consumers themselves. 
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L The approval of new OTC medicines should not in any way affect the 
status of existing or already available OTC products. 
J. A drug's safety profile cannot be understood based solely on controlled 
clinical trials during development and surveillance during real-world 
clinical practice is necessary. 
10. At the time of this study, tremendous activity related to scientific and regulatory 
aspects of nonprescription medicines is underway globally. These aspects of OTC 
medicines are beginning to receive attention and scientific examination. The body of 
relevant reports currently available on this subject matter is not substantial. The 
author believes that this dissertation serves as an early and comprehensive 
exploration of this subject and contributes to filling the existing vacuum. It is not 
possible to have addressed all issues in this dissertation, and, numerous challenging 
questions in this area remain that present opportunities for subsequent research. 
Some findings, observations and proposals in this dissertation allow for the 
formulation of specific constructs suitable for further examination. This dissertation 
did not focus on economic aspects of global nonprescription medicines. An 
examination of the interactive effects between scientific, regulatory and economic 
principles affecting nonprescription medicines and their optimization to maximize 
public health benefit would be intellectually stimulating and invaluable. 
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